BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560-99. [PMID: 29405329 DOI: 10.1002/hep.29800] [Cited by in Crossref: 1550] [Cited by in F6Publishing: 1255] [Article Influence: 387.5] [Reference Citation Analysis]
Number Citing Articles
1 Prasidthrathsint K, Stapleton JT. Laboratory Diagnosis and Monitoring of Viral Hepatitis. Gastroenterol Clin North Am. 2019;48:259-279. [PMID: 31046974 DOI: 10.1016/j.gtc.2019.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Dai Y, Zhao Z, Liu C. Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. Front Pharmacol 2022;13:942841. [DOI: 10.3389/fphar.2022.942841] [Reference Citation Analysis]
3 Zhang Y, Hu X, Chang J, Chen J, Han X, Zhang T, Shen J, Shang N, Han J, Wang H, Kang W, Meng F. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol 2021;21:395. [PMID: 34686147 DOI: 10.1186/s12876-021-01974-4] [Reference Citation Analysis]
4 Ren H, Huang Y. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B. J Viral Hepat 2019;26 Suppl 1:5-31. [PMID: 31380584 DOI: 10.1111/jvh.13150] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
5 Spence AB, Levy ME, Monroe A, Castel A, Timpone J, Horberg M, Adams-Campbell L, Kumar P. Cancer Incidence and Cancer Screening Practices Among a Cohort of Persons Receiving HIV Care in Washington, DC. J Community Health 2021;46:75-85. [PMID: 32424501 DOI: 10.1007/s10900-020-00844-6] [Reference Citation Analysis]
6 Wang G, Tanaka A, Zhao H, Jia J, Ma X, Harada K, Wang FS, Wei L, Wang Q, Sun Y, Hong Y, Rao H, Efe C, Lau G, Payawal D, Gani R, Lindor K, Jafri W, Omata M, Sarin SK. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int 2021;15:223-57. [PMID: 33942203 DOI: 10.1007/s12072-021-10170-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
7 Yao K, Wang J, Wang L, Xia J, Yan X, Wu W, Liu J, Wang L, Yin S, Tong X, Ding W, Huang R, Wu C. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA. J Med Virol 2021. [PMID: 34499353 DOI: 10.1002/jmv.27327] [Reference Citation Analysis]
8 Smith AD, Porter KK, Elkassem AA, Sanyal R, Lockhart ME. Current Imaging Techniques for Noninvasive Staging of Hepatic Fibrosis. American Journal of Roentgenology 2019;213:77-89. [DOI: 10.2214/ajr.19.21144] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
9 Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. Clin Gastroenterol Hepatol 2019;17:2808-2810.e2. [PMID: 30639778 DOI: 10.1016/j.cgh.2019.01.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
10 Yin GQ, Li J, Zhong B, Yang YF, Wang MR. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. World J Gastroenterol 2021; 27(8): 666-676 [PMID: 33716446 DOI: 10.3748/wjg.v27.i8.666] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Chen S, Huang H. Clinical Non-invasive Model to Predict Liver Inflammation in Chronic Hepatitis B With Alanine Aminotransferase ≤ 2 Upper Limit of Normal. Front Med (Lausanne) 2021;8:661725. [PMID: 34150800 DOI: 10.3389/fmed.2021.661725] [Reference Citation Analysis]
13 Lanave G, Capozza P, Diakoudi G, Catella C, Catucci L, Ghergo P, Stasi F, Barrs V, Beatty J, Decaro N, Buonavoglia C, Martella V, Camero M. Identification of hepadnavirus in the sera of cats. Sci Rep 2019;9:10668. [PMID: 31337847 DOI: 10.1038/s41598-019-47175-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Lu F, Ni Y. Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience. Pediatr Gastroenterol Hepatol Nutr 2020;23:311. [DOI: 10.5223/pghn.2020.23.4.311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Itakura J, Kurosaki M, Setoyama H, Simakami T, Oza N, Korenaga M, Tanaka M, Torimura T, Sakamoto N, Enomoto N, Ueno Y, Kawada N, Kaneko S, Nishiguchi S, Chayama K, Tanaka J, Izumi N, Kanto T. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. J Gastroenterol 2021;56:470-8. [PMID: 33791882 DOI: 10.1007/s00535-021-01782-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
16 Martins TLS, Silva GRDCE, Silva CDA, Gomes DO, Diniz e Silva BV, Carneiro MADS, Pacheco LR, Araujo NMD, Zanchetta MS, Teles SA, Caetano KAA. Hepatitis B and C in Immigrants and Refugees in Central Brazil: Prevalence, Associated Factors, and Immunization. Viruses 2022;14:1534. [DOI: 10.3390/v14071534] [Reference Citation Analysis]
17 Lai CY, Yang SS, Lee SW, Tsai HJ, Lee TY. Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation. J Clin Med 2021;10:4883. [PMID: 34768403 DOI: 10.3390/jcm10214883] [Reference Citation Analysis]
18 Liu Y, Chen R, Liu W, Si L, Li L, Li X, Yao Z, Liao H, Wang J, Li Y, Zhao J, Xu D. Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs. Antiviral Res 2021;189:105058. [PMID: 33711338 DOI: 10.1016/j.antiviral.2021.105058] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wu IC, Liu WC, Chiu YC, Chiu HC, Cheng PN, Chang TT. Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss. Microorganisms 2021;9:1146. [PMID: 34073483 DOI: 10.3390/microorganisms9061146] [Reference Citation Analysis]
20 Zhao X, Bai X, Xi Y. Intrauterine Infection and Mother-to-Child Transmission of Hepatitis B Virus: Route and Molecular Mechanism. IDR 2022;Volume 15:1743-51. [DOI: 10.2147/idr.s359113] [Reference Citation Analysis]
21 Chen S, Zhou J, Wu X, Meng T, Wang B, Liu H, Wang T, Zhao X, Kong Y, Wu S, Ou X, Jia J, Sun Y, You H. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatol Int 2021;15:611-20. [PMID: 33677771 DOI: 10.1007/s12072-021-10162-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Yang H, Bae SH, Nam H, Lee HL, Lee SW, Yoo SH, Song MJ, Kwon JH, Nam SW, Choi JY, Yoon SK, Jang JW. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Remington TL, Osman M, Simmonds K, Charlton C, Doucette K. Baseline assessment of and linkage to care for newly diagnosed patients with chronic hepatitis B. CanLivJ 2020;3:263-75. [DOI: 10.3138/canlivj.2019-0024] [Reference Citation Analysis]
24 Papatheodoridis GV, Voulgaris T, Papatheodoridi M, Kim WR. Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine. Hepatology 2020;72:2197-205. [PMID: 32602980 DOI: 10.1002/hep.31440] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
25 Hu J, Wang Y, Jiang G, Zheng J, Chen T, Chen Z, Yang M, Zhang X, Zhao H, Li L. Predictors of inflammatory activity in treatment-naive hepatitis B e-antigen-negative patients with chronic hepatitis B infection. J Int Med Res 2020;48:300060520969582. [PMID: 33179557 DOI: 10.1177/0300060520969582] [Reference Citation Analysis]
26 Tsai YF, Yang CI, Du JS, Lin MH, Tang SH, Wang HC, Cho SF, Liu YC, Su YC, Dai CY, Hsiao HH. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study. PeerJ 2019;7:e7481. [PMID: 31565551 DOI: 10.7717/peerj.7481] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
27 Luo H, Tan N, Kang Q, Pan J, Chen H, Xi H, Yu M, Xu X. Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues. J Viral Hepat 2020;27:323-8. [PMID: 31667945 DOI: 10.1111/jvh.13227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
28 Zhu Z, Qin Y, Liang Q, Xia W, Zhang T, Wang W, Zhang M, Jiang T, Wu H, Tian Y. Increased HBV Coinfection and Decreased IFN-γ-Producing HBV-Specific CD8+ T Cell Numbers During HIV Disease Progression. Front Immunol 2022;13:861804. [PMID: 35432386 DOI: 10.3389/fimmu.2022.861804] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Xu B, Tang B, Wei J. Role of STAT1 in the resistance of HBV to IFN-α. Exp Ther Med 2021;21:550. [PMID: 33850522 DOI: 10.3892/etm.2021.9982] [Reference Citation Analysis]
30 Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Anderson M, Gersch J, Holzmayer V, Elsner C, Krawczyk A, Kuhns MC, Cloherty G, Dittmer U, Vaillant A. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection. Hepatol Commun 2021;5:189-202. [PMID: 33553968 DOI: 10.1002/hep4.1633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
31 Chen Y, Gao WK, Shu YY, Ye J. Clinical treatment of chronic hepatitis B virus infection in indeterminate phase: Current status and future prospects. Shijie Huaren Xiaohua Zazhi 2022; 30(10): 436-443 [DOI: 10.11569/wcjd.v30.i10.436] [Reference Citation Analysis]
32 Ma Z, Li S, He D, Wang Y, Jiang H, Zhou H, Jin J, Lin N. Rapid quantification of tenofovir in umbilical cord plasma and amniotic fluid in hepatitis B mono-infected pregnant women during labor by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2020;34:e8728. [PMID: 31960519 DOI: 10.1002/rcm.8728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Tang X, Huang W, Kang J, Ding K. Early dynamic changes of quasispecies in the reverse transcriptase region of hepatitis B virus in telbivudine treatment. Antiviral Res 2021;195:105178. [PMID: 34509461 DOI: 10.1016/j.antiviral.2021.105178] [Reference Citation Analysis]
34 Chu JN, Nguyen TT, Rivadeneira NA, Hiatt RA, Sarkar U. Exploring factors associated with hepatitis B screening in a multilingual and diverse population. BMC Health Serv Res 2022;22:479. [PMID: 35410249 DOI: 10.1186/s12913-022-07813-w] [Reference Citation Analysis]
35 Zhou J, Wang FD, Wang ML, Tao YC, Wu DB, Sheng YJ, Xiao GB, Chen XB, Chen X, Chen EQ. Antiviral Therapy for Chronic HBV Infection With Persistently Normal Alanine Aminotransferase: Controversy and Consensus. Front Med (Lausanne) 2021;8:717125. [PMID: 34527683 DOI: 10.3389/fmed.2021.717125] [Reference Citation Analysis]
36 Wong GL, Chan HL, Yuen BW, Tse YK, Luk HW, Yip TC, Hui VW, Liang LY, Lee HW, Lui GC, Wong VW. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. Liver Int 2020;40:549-57. [PMID: 31845462 DOI: 10.1111/liv.14330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Lee HA, Lee HW, Kim IH, Park SY, Sinn DH, Yu JH, Seo YS, Um SH, Lee JI, Lee KS, Lee CH, Tak WY, Kweon YO, Kang W, Paik YH, Lee JW, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther 2020;52:196-204. [PMID: 32452564 DOI: 10.1111/apt.15741] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
38 Kalisvaart M, Chadha R, De Martin E, Alconchel F, Goldaracena N, Keskin O, Liu J, Nasralla D, Mazzola A, Rammohan A, Spiro M, Tanaka T, Campos-Varela I, Victor D, Vinaixa C, Yoon U, Yoon YI, Hessheimer A, Kabacam G, Sapisochin G, Shaker T, Bhangui P, Chan A, Kirchner V. Proceedings of the 26th Annual Virtual Congress of the International Liver Transplantation Society. Transplantation 2022. [PMID: 35676871 DOI: 10.1097/TP.0000000000004183] [Reference Citation Analysis]
39 Lee TH, Schiano TD. Hepatology Clearance for Immunomodulation in Patients With Hepatitis B. Clin Liver Dis (Hoboken) 2019;14:78-85. [PMID: 31508226 DOI: 10.1002/cld.757] [Reference Citation Analysis]
40 Hui RW, Mak LY, Seto WK, Yuen MF. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: A spotlight on drugs at phase II clinical trials. Expert Opin Emerg Drugs 2022. [PMID: 35511483 DOI: 10.1080/14728214.2022.2074977] [Reference Citation Analysis]
41 Nishida T, Matsubara T, Yakushijin T, Inada M. Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers. Hepatol Int 2019;13:407-15. [PMID: 31290069 DOI: 10.1007/s12072-019-09966-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
42 Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, Choi BI, Wilson SR, Kudo M, Barr RG. Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. Ultrasound Med Biol. 2018;44:2419-2440. [PMID: 30209008 DOI: 10.1016/j.ultrasmedbio.2018.07.008] [Cited by in Crossref: 152] [Cited by in F6Publishing: 110] [Article Influence: 38.0] [Reference Citation Analysis]
43 Loureiro D, Mansouri A, Asselah T. Quantitative HBsAg: Not helpful to evaluate fibrosis in HBeAg-negative chronic hepatitis B patients. Saudi J Gastroenterol 2019;25:269-71. [PMID: 31552841 DOI: 10.4103/sjg.SJG_445_19] [Reference Citation Analysis]
44 Buonomo AR, Viceconte G, Scotto R, De Angelis M, Tozza S, Manganelli F, Lanza AG, Di Costanzo GG, Gentile I. Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy. Infectious Diseases 2020;52:216-8. [DOI: 10.1080/23744235.2019.1693624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
45 Quan Z, Zeng H, Yi X, Li C, Fang Z, Yang X. Psoas Major and Iliopsoas Hematomas without Anticoagulant Therapy as a Complication of Carbon Monoxide Poisoning: A Case Report. Am J Case Rep 2021;22:e933322. [PMID: 34556624 DOI: 10.12659/AJCR.933322] [Reference Citation Analysis]
46 Hsu HY, Chang MH. Hepatitis B Virus Infection and the Progress toward its Elimination. J Pediatr 2019;205:12-20. [PMID: 30244984 DOI: 10.1016/j.jpeds.2018.08.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Pol S. Withdrawal of Nucleos(t)ide Analogues in the Treatment of Chronic Hepatitis B: A Cornelian Choice. Gastroenterology 2021:S0016-5085(21)04075-0. [PMID: 34914942 DOI: 10.1053/j.gastro.2021.12.240] [Reference Citation Analysis]
48 Güzelbulut F, Gökçen P, Can G, Adalı G, Değirmenci Saltürk AG, Bahadır Ö, Özdil K, Doğanay HL. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. J Viral Hepat 2021;28:826-36. [PMID: 33586270 DOI: 10.1111/jvh.13485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Kouenkam JPI, Mbang J, Emvudu Y. Global dynamics of a model of hepatitis B virus infection in a sub-Saharan African rural area. Int J Biomath 2020;13:2050054. [DOI: 10.1142/s1793524520500540] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Van Hees S, Cuypers B, Bourgeois S, Groothuismink ZMA, Meysman P, Van der Vlies P, de Knegt R, Vonghia L, Michielsen P, Francque S, Laukens K, Boonstra A, Vanwolleghem T. Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Cell Immunol 2021;362:104283. [PMID: 33548734 DOI: 10.1016/j.cellimm.2021.104283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392:2313-2324. [PMID: 30496122 DOI: 10.1016/s0140-6736(18)31865-8] [Cited by in Crossref: 139] [Cited by in F6Publishing: 62] [Article Influence: 46.3] [Reference Citation Analysis]
52 Luo W, Wu S, Chen H, Wu Y, Peng J. Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with α-interferon. J Int Med Res 2021;49:3000605211025139. [PMID: 34182813 DOI: 10.1177/03000605211025139] [Reference Citation Analysis]
53 Sinn DH, Kim SE, Kim BK, Kim JH, Choi MS. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. J Viral Hepat 2019;26:1465-72. [PMID: 31332935 DOI: 10.1111/jvh.13185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
54 Liang LY, Lee HW, Wong VW, Yip TC, Tse YK, Hui VW, Lui GC, Chan HL, Wong GL. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clin Mol Hepatol 2021;27:499-509. [PMID: 33631920 DOI: 10.3350/cmh.2020.0333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Lee HY, Oh H, Park CH, Yeo YH, Nguyen MH, Jun DW. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis. World J Gastroenterol 2019; 25(23): 2961-2972 [PMID: 31249453 DOI: 10.3748/wjg.v25.i23.2961] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
56 Chen MH, Wu CS, Chen MH, Tsai CY, Lee FY, Huang YH. High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus. Int J Mol Sci 2021;22:9116. [PMID: 34502025 DOI: 10.3390/ijms22179116] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Pan CQ, Chang TT, Bae SH, Brunetto M, Seto WK, Coffin CS, Tan SK, Mo S, Flaherty JF, Gaggar A, Nguyen MH, Çelen MK, Thompson A, Gane EJ. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. PLoS One 2021;16:e0251552. [PMID: 33984038 DOI: 10.1371/journal.pone.0251552] [Reference Citation Analysis]
58 Li C, Li ZC, Ma L, Li LQ, Zhong JH, Xiang BD, Gong WF. Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:749-56. [PMID: 32552297 DOI: 10.1080/17474124.2020.1784727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol Commun. 2019;3:8-19. [PMID: 30619990 DOI: 10.1002/hep4.1281] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
60 Anteby R, Klang E, Horesh N, Nachmany I, Shimon O, Barash Y, Kopylov U, Soffer S. Deep learning for noninvasive liver fibrosis classification: A systematic review. Liver Int 2021. [PMID: 34008300 DOI: 10.1111/liv.14966] [Reference Citation Analysis]
61 Park S, Park ES, Koo JE, Park YK, Lee AR, Dezhbord M, Cho ES, Ahn SH, Kim DH, Lee JH, Lee HC, Kim KH. Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization. Liver Int 2020;40:1564-77. [PMID: 32216026 DOI: 10.1111/liv.14446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Zhou X, Li TM, Luo JZ, Lan CL, Wei ZL, Fu TH, Liao XW, Zhu GZ, Ye XP, Peng T. CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis. J Hepatocell Carcinoma 2021;8:1323-38. [PMID: 34765572 DOI: 10.2147/JHC.S335425] [Reference Citation Analysis]
63 Sripongpun P, Kim WR, Mannalithara A, Kwong A, Daugherty T, Goel A, Kwo PY. Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2020;. [PMID: 33285291 DOI: 10.1016/j.cgh.2020.11.047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
64 Ghazzawi M, James PB, Massaquoi SP, Yendewa SA, Salata RA, Yendewa GA. Factors Associated with HBsAg Seropositivity among Pregnant Women Receiving Antenatal Care at 10 Community Health Centers in Freetown, Sierra Leone: A Cross-Sectional Study. Pathogens 2022;11:243. [DOI: 10.3390/pathogens11020243] [Reference Citation Analysis]
65 Akyüz F, Çavuş B, Nizam N, Göktürk S, Baran B, Yazıcı H, Evirgen S, Akyüz Ü, Öbekli T, Karaca Ç, Demir K, Beşışık F, Kaymakoğlu S. Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data. Clin Exp Hepatol 2022;8:7-13. [PMID: 35415260 DOI: 10.5114/ceh.2022.114153] [Reference Citation Analysis]
66 Lee H, Kim BK, Jang S, Ahn SH. Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression. Clin Transl Gastroenterol 2021;12:e00299. [PMID: 33600103 DOI: 10.14309/ctg.0000000000000299] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Fadriquela A, Kim CS, Lee KJ, Kang SH, Kim MY, Lee JH. Soluble type immune checkpoint regulators using multiplex luminex immunoassay in chronic hepatitis B patients. J Clin Pathol 2021:jclinpath-2020-207125. [PMID: 34016716 DOI: 10.1136/jclinpath-2020-207125] [Reference Citation Analysis]
68 Yeh ML, Yu ML. Reply to "DAA and HBV/HCV co-infection: Glimmer of light and a few shades of grey". J Hepatol 2020;73:462. [PMID: 32327360 DOI: 10.1016/j.jhep.2020.03.041] [Reference Citation Analysis]
69 Wellhöner F, Döscher N, Woelfl F, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Pieper DH, Cornberg M, Wedemeyer H, Heidrich B. Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. Hepatology 2021;74:72-82. [PMID: 33411981 DOI: 10.1002/hep.31700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
70 Luo Y, Xiang K, Liu J, Song J, Feng J, Chen J, Dai Y, Hu Y, Zhuang H, Zhou Y. Inhibition of In Vitro Infection of Hepatitis B Virus by Human Breastmilk. Nutrients 2022;14:1561. [DOI: 10.3390/nu14081561] [Reference Citation Analysis]
71 Papatheodoridi M, Papatheodoridis G. Can we stop nucleoside analogues before HBsAg loss? J Viral Hepat. 2019;26:936-941. [PMID: 30803099 DOI: 10.1111/jvh.13091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
72 Wang X, Chen Y, Xu M, Cheng K, Duan X, Liao W, Wang Y, Lu Y, Duan Z, Wang L. Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir. Expert Rev Gastroenterol Hepatol 2021;:1-8. [PMID: 34511012 DOI: 10.1080/17474124.2021.1980385] [Reference Citation Analysis]
73 Berg T, Lampertico P. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol 2021;75:474-80. [PMID: 33957187 DOI: 10.1016/j.jhep.2021.04.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
74 Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, Miyoshi H, Kimura M, Maehara O, Yamada R, Kitagataya T, Yamamoto K, Shigesawa T, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N;  NORTE Study Group. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2021;56:168-180. [PMID: 33211179 DOI: 10.1007/s00535-020-01750-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
75 Lee SW, Kim SU. Editorial: tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment-still an open issue. Aliment Pharmacol Ther 2020;52:889-90. [PMID: 32852818 DOI: 10.1111/apt.15965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Burns EA, Muhsen IN, Anand K, Xu J, Umoru G, Arain AN, Abdelrahim M. Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors. J Immunother 2021;44:132-9. [PMID: 33480637 DOI: 10.1097/CJI.0000000000000358] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Özdemir E, Demirdal T, Emren SV, Tokaç M. Evaluation of early myocardial dysfunction with strain echocardiography in chronic hepatitis B patients. Echocardiography 2019;36:696-701. [PMID: 30868642 DOI: 10.1111/echo.14305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
78 Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: The promising paths forward. Hepatology 2022. [PMID: 34990029 DOI: 10.1002/hep.32314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
79 Jo AJ, Choi WM, Kim HJ, Choi SH, Han S, Ko MJ, Lim YS. A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study. J Viral Hepat 2021. [PMID: 34762757 DOI: 10.1111/jvh.13631] [Reference Citation Analysis]
80 O'Brien TR, Yang HI, Groover S, Jeng WJ. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology 2019;156:400-17. [PMID: 30287169 DOI: 10.1053/j.gastro.2018.09.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
81 Pisaturo M, Di Caprio G, Calò F, Portunato F, Martini S, Coppola N. Management of HBV reactivation in non-oncological patients. Expert Rev Anti Infect Ther 2018;16:611-24. [PMID: 30058401 DOI: 10.1080/14787210.2018.1505501] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
82 Zheng W, Guo W, Xiong M, Chen X, Gao L, Song Y, Cao D. Clinic-radiological features and radiomics signatures based on Gd-BOPTA-enhanced MRI for predicting advanced liver fibrosis. Eur Radiol. [DOI: 10.1007/s00330-022-08992-0] [Reference Citation Analysis]
83 Ciupe SM. Modeling the dynamics of hepatitis B infection, immunity, and drug therapy. Immunol Rev 2018;285:38-54. [PMID: 30129194 DOI: 10.1111/imr.12686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
84 Song Z, Ma Y, Jiang D, Zhao R, Dong F. Long-Term Safety of Rituximab in DLBCL Patients With Hepatitis B-Related Cirrhosis: A Retrospective Case Series. Front Med (Lausanne) 2022;9:890339. [PMID: 35712098 DOI: 10.3389/fmed.2022.890339] [Reference Citation Analysis]
85 Wong GL, Yuen BW, Chan HL, Tse YK, Yip TC, Lam KL, Lui GC, Wong VW. Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. Liver Int. 2019;39:271-279. [PMID: 30179316 DOI: 10.1111/liv.13953] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
86 Chularojanamontri L, Nimanong S, Wongpraparut C, Silpa-Archa N, Chaiyabutr C, Charoenpipatsin N. Impact of long-term systemic treatment for psoriasis on liver disease in psoriasis patients with coexisting hepatitis B virus infection. Dermatol Ther 2020;33:e14008. [PMID: 32654402 DOI: 10.1111/dth.14008] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Hou W, Huo Z, Du Y, Wang C, Syn WK. Characteristics of amino acid substitutions within the "a" determinant region of hepatitis B virus in chronically infected patients with coexisting HBsAg and anti-HBs. Clin Res Hepatol Gastroenterol 2020;44:923-31. [PMID: 31624004 DOI: 10.1016/j.clinre.2019.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
88 Liu C, Su T, Liu C, Hong C, Yang H, Tseng T, Chen P, Chen D, Kao J. Sofosbuvir‐based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. Journal of Gastroenterology and Hepatology 2019;34:1620-5. [DOI: 10.1111/jgh.14615] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
89 Mak LY, Hoang J, Jun DW, Chen CH, Peng CY, Yeh ML, Kim SE, Huang DQ, Jeong JY, Yoon E, Oh H, Tsai PC, Huang CF, Ahn SB, Trinh H, Xie Q, Wong GLH, Enomoto M, Shim JJ, Lee DH, Liu L, Kozuka R, Cho YK, Jeong SW, Kim HS, Trinh L, Dao A, Huang R, Hui RW, Tsui V, Quek S, Khine HHTW, Ogawa E, Dai CY, Huang JF, Cheung R, Wu C, Chuang WL, Lim SG, Yu ML, Yuen MF, Nguyen MH. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Hepatol Int 2021. [PMID: 34822056 DOI: 10.1007/s12072-021-10271-x] [Reference Citation Analysis]
90 Chang TS, Yang YH, Chen WM, Shen CH, Tung SY, Yen CW, Hsieh YY, Lee CP, Tsai ML, Hung CH, Lu SN. Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep. 2021;11:1365. [PMID: 33446835 DOI: 10.1038/s41598-020-80523-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
91 Jang TY, Wei YJ, Yeh ML, Liu SF, Hsu CT, Hsu PY, Liu TW, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. J Formos Med Assoc 2021;120:303-10. [PMID: 33109431 DOI: 10.1016/j.jfma.2020.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Jeng WJ, Lok AS. Should Treatment Indications for Chronic Hepatitis B Be Expanded? Clin Gastroenterol Hepatol. 2020;. [PMID: 32434068 DOI: 10.1016/j.cgh.2020.04.091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
93 Evon DM, Lin HS, Khalili M, Fontana RJ, Yim C, Wahed AS, Fried MW, Hoofnagle JH; Hepatitis B Research Network (HBRN). Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. Aliment Pharmacol Ther 2020;51:457-68. [PMID: 31943262 DOI: 10.1111/apt.15618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
94 Childs-Kean LM, Egelund EF, Jourjy J. Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection. Pharmacotherapy 2018;38:1051-7. [PMID: 30120841 DOI: 10.1002/phar.2174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
95 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Masetti C, Pugliese N, Aghemo A, Viganò M. Safety of current antiviral drugs for chronic hepatitis B. Expert Opin Drug Saf 2022. [PMID: 35209776 DOI: 10.1080/14740338.2022.2045271] [Reference Citation Analysis]
97 Kim HS, Yang JD, El-Serag HB, Kanwal F. Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. J Viral Hepat 2019;26:596-602. [PMID: 30629790 DOI: 10.1111/jvh.13060] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
98 Alsunaid SR, Ashraf H, Soubani AO. Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. Transpl Infect Dis 2018;20:e12960. [PMID: 29975806 DOI: 10.1111/tid.12960] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
99 Kaewdech A, Assawasuwannakit S, Sripongpun P, Chamroonkul N, Tangkijvanich P, Piratvisuth T. Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up. Front Med 2022;9:859430. [DOI: 10.3389/fmed.2022.859430] [Reference Citation Analysis]
100 Tan N, Luo H, Kang Q, Pan J, Cheng R, Xi H, Chen H, Han Y, Yang Y, Xu X. High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment. Virus Res 2021;309:198660. [PMID: 34929214 DOI: 10.1016/j.virusres.2021.198660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
102 Song A, Liu Y, Cao Z, Lu J, Ren S, Zheng S, Ma L, Hu Z, Lin X, Li H, Zheng Y, Chen X. Clinical Features and T Cell Immune Characteristics of Postpartum Hepatitis Flare in Pregnant Women With HBeAg-Positive Chronic HBV Infection. Front Immunol 2022;13:881321. [DOI: 10.3389/fimmu.2022.881321] [Reference Citation Analysis]
103 Hess L, Riesenberg K, Rolston KVI, Nesher L. Administering an additional hepatitis B vaccination dose after 18 years maintains adequate long-term protection levels in healthcare workers. Infect Dis (Lond) 2020;52:330-5. [PMID: 31983251 DOI: 10.1080/23744235.2020.1718201] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Li Q, Huang C, Xu W, Hu Q, Chen L. A simple algorithm for non-invasive diagnosis of significant liver histological changes in patients with CHB and normal or mildly elevated alanine transaminase levels. Medicine (Baltimore) 2019;98:e16429. [PMID: 31305465 DOI: 10.1097/MD.0000000000016429] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
105 Hardikar W. Viral hepatitis. J Paediatr Child Health 2019;55:1038-43. [DOI: 10.1111/jpc.14562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
106 Yamauchi R, Takeyama Y, Takata K, Fukunaga A, Sakurai K, Tanaka T, Fukuda H, Fukuda S, Kunimoto H, Umeda K, Morihara D, Yokoyama K, Irie M, Shakado S, Sakisaka S, Hirai F. Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate. Intern Med 2020;59:1163-6. [PMID: 31956202 DOI: 10.2169/internalmedicine.3805-19] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Chen Y, Kong Y, Shi L, Zhang X, Yang X, Liu X, Lin S, Ye F. Study of the distribution of hepatitis B immunoglobulin in pregnant mice using small-animal imaging technology. J Med Virol 2019;91:1811-7. [PMID: 31209906 DOI: 10.1002/jmv.25521] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
109 Nicastro E, Mangili B, Giacomet V, Benincaso AR, Di Giorgio A, Sansotta N, Callegaro A, D’antiga L. Longitudinal Immune Phenotype Assessment and Serological Outcome in Foreign-born Children With Chronic Hepatitis B. Journal of Pediatric Gastroenterology & Nutrition 2020;71:381-7. [DOI: 10.1097/mpg.0000000000002804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
110 Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology 2021;73:661-73. [PMID: 32324905 DOI: 10.1002/hep.31289] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 26.0] [Reference Citation Analysis]
111 Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Lin CH, Hoang J, Le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. J Infect Dis. 2020;221:389-399. [PMID: 31550363 DOI: 10.1093/infdis/jiz477] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
112 Xu H, Locarnini S, Wong D, Hammond R, Colledge D, Soppe S, Huynh T, Shaw T, Thompson AJ, Revill PA, Hogarth PM, Wines BD, Walsh R, Warner N. Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. J Hepatol 2021:S0168-8278(21)01959-0. [PMID: 34371070 DOI: 10.1016/j.jhep.2021.07.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
113 Garteiser P, Pagé G, d'Assignies G, Leitao HS, Vilgrain V, Sinkus R, Van Beers BE. Necro-inflammatory activity grading in chronic viral hepatitis with three-dimensional multifrequency MR elastography. Sci Rep 2021;11:19386. [PMID: 34588519 DOI: 10.1038/s41598-021-98726-x] [Reference Citation Analysis]
114 Yang Q, Wang Y, Guan X, Gu Y, Li LP, Dai WY, Bian L, Shang N. Evaluation of liver fibrosis by non-invasive diagnostic indexes in patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2020; 28(22): 1137-1144 [DOI: 10.11569/wcjd.v28.i22.1137] [Reference Citation Analysis]
115 Li Q, Lu Q, Zhu MQ, Huang C, Yu KK, Huang YX, Zhao X, Luo XG, Zheng JM. Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure. BMC Gastroenterol 2020;20:106. [PMID: 32293297 DOI: 10.1186/s12876-020-01258-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
116 Lei M, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Wu H, Xu MQ, Chen ZY, Wei YG. Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China. World J Gastroenterol 2018; 24(48): 5525-5536 [PMID: 30622380 DOI: 10.3748/wjg.v24.i48.5525] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
117 Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. Liver Int. 2019;39:1624-1630. [PMID: 31050379 DOI: 10.1111/liv.14129] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
118 Udompap P, Tanwandee T, Gani R. Affordability of Antiviral Therapy in Asia-Pacific Countries and Its Impact on Public Health Outcomes.Clin Liver Dis (Hoboken). 2020;16:249-253. [PMID: 33489097 DOI: 10.1002/cld.977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
119 Papatheodoridis GV, Mimidis K, Manolakopoulos S, Gatselis N, Goulis J, Kapatais A, Manesis E, Vasiliadis T, Triantos C, Samonakis D, Sevastianos V, Karatapanis S, Elefsiniotis I, Deutsch M, Mylopoulou T, Papatheodoridi M, Kranidioti H, Agorastou P, Karaoulani T, Kyriazidou A, Zisimopoulos K, Dalekos GN. HERACLIS-TAF: a multicentre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks. Aliment Pharmacol Ther 2022. [PMID: 35736010 DOI: 10.1111/apt.17093] [Reference Citation Analysis]
120 Hayashi T, Takeshita Y, Hutin YJ, Harmanci H, Easterbrook P, Hess S, van Holten J, Oru EO, Kaneko S, Yurdaydin C, Bulterys M. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response? Arch Public Health 2021;79:180. [PMID: 34663473 DOI: 10.1186/s13690-021-00693-2] [Reference Citation Analysis]
121 Zhang JH, Zhang X, Zhou ZH, Zhu XJ, Zheng C, Li M, Jin SG, Mao DW, Xue JD, Shi WB, Chi XL, Wang XB, Li XD, Li Y, Wang H, Li Q, Zhou DQ, Wang CB, Shi CH, Li CZ, Wu JH, Kong XN, Sun XH, Gao YQ. Bushen Jianpi Formula Combined with Entecavir for the Treatment of HBeAg-Negative Chronic Hepatitis B: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med 2022;2022:6097221. [PMID: 35368769 DOI: 10.1155/2022/6097221] [Reference Citation Analysis]
122 Nguyen VTT, Trang HTQ, Ishikawa N, Anh Nguyen L, Anh LAK, Minh TB, Lo YR, Kato M. Feasibility, benefits, and cost-effectiveness of adding universal hepatitis B and syphilis testing to routine antenatal care services in Thai Nguyen province, Vietnam. Int J STD AIDS 2021;32:135-43. [PMID: 33349143 DOI: 10.1177/0956462420953722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Seetharam A. Intensive Care Management of Acute Liver Failure: Considerations While Awaiting Liver Transplantation. J Clin Transl Hepatol 2019;7:384-91. [PMID: 31915608 DOI: 10.14218/JCTH.2019.00032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
124 Goh MJ, Kang W, Kim KM, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. Scand J Gastroenterol 2021;:1-8. [PMID: 34731072 DOI: 10.1080/00365521.2021.1988700] [Reference Citation Analysis]
125 Sbarigia U, Vincken T, Wigfield P, Hashim M, Heeg B, Postma M. A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients. J Comp Eff Res 2020;9:1051-65. [PMID: 32945178 DOI: 10.2217/cer-2020-0068] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Akbar SMF, Al Mahtab M, Cesar Aguilar J, Uddin MH, Khan MSI, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical. Exploration of Medicine. [DOI: 10.37349/emed.2021.00058] [Reference Citation Analysis]
127 Cardoso AC, Figueiredo-Mendes C, Villela-Nogueira CA, Marcellin P. Staging Fibrosis in Chronic Viral Hepatitis. Viruses 2022;14:660. [PMID: 35458391 DOI: 10.3390/v14040660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Unal C, Tanacan A, Ziyadova G, Fadiloglu E, Beksac MS. Effect of viral load on pregnancy outcomes in chronic hepatitis B infection. J Obstet Gynaecol Res 2019;45:1837-42. [PMID: 31332897 DOI: 10.1111/jog.14065] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
129 Liu LZ, Sun J, Hou J, Chan HLY. Improvements in the management of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2018;12:1153-66. [DOI: 10.1080/17474124.2018.1530986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
130 Aretzweiler G, Leuchter S, García-Álvarez M, Simon C, Marins E, Paxinos E, Canchola J, Delgado R, Frontzek A. Analytical performance of four molecular platforms used for HIV-1, HBV and HCV viral load determinations. Expert Rev Mol Diagn 2019;19:941-9. [PMID: 31159598 DOI: 10.1080/14737159.2019.1624162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
131 Muthiah MD, Tan EY, Chua SHM, Huang DQY, Bonney GK, Kow AWC, Lim SG, Dan YY, Tan PS, Lee GH, Lim BL. Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficacious. Hepatol Int 2020;14:57-69. [PMID: 31919678 DOI: 10.1007/s12072-019-10011-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
132 Kordzadeh-Kermani E, Khalili H, Karimzadeh I, Salehi M. Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators. Infect Drug Resist 2020;13:513-32. [PMID: 32110062 DOI: 10.2147/IDR.S233137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
133 Suoh M, Tamori A, Amano-Teranishi Y, Nakai T, Enomoto M, Kawasaki Y, Kioka K, Kawada N. The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B. Intern Med 2020;59:205-10. [PMID: 31941870 DOI: 10.2169/internalmedicine.3504-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
135 Mo Z, Gan W, Zhao Q, Yin Y, Gao Z. Functional cure of chronic hepatitis B: Efforts and prospects. Liver Research 2020;4:1-4. [DOI: 10.1016/j.livres.2020.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
136 Yuen MF, Wong DK, Schluep T, Lai CL, Ferrari C, Locarnini S, Lo RC, Gish RG, Hamilton J, Wooddell CI, Mak LY, Given BD. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut 2022;71:789-97. [PMID: 33712437 DOI: 10.1136/gutjnl-2020-323445] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
137 Chen B, Huang H, Pan CQ. The role of gut microbiota in hepatitis B disease progression and treatment. J Viral Hepat 2021. [PMID: 34415656 DOI: 10.1111/jvh.13595] [Reference Citation Analysis]
138 Saunders IM, Tan M, Koura D, Young R. Long-term Follow-up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics. Pharmacotherapy 2020;40:808-41. [PMID: 32652612 DOI: 10.1002/phar.2443] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Tout I, Loureiro D, Asselah T. The Changing Demographics of Hepatitis B Virus Infection. Clin Liver Dis 2021;25:673-87. [PMID: 34593147 DOI: 10.1016/j.cld.2021.06.001] [Reference Citation Analysis]
140 Salyani A, Shah J, Adam R, Otieno G, Mbugua E, Shah R. Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults. PLoS One 2021;16:e0244947. [PMID: 33406137 DOI: 10.1371/journal.pone.0244947] [Reference Citation Analysis]
141 Zhang W, Xu C, Rui Y, Chen J, Chen T, Dai Y, Xu B, Hu Y, Chen J, Zhou Y. Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers. Journal of Virus Eradication 2022. [DOI: 10.1016/j.jve.2022.100076] [Reference Citation Analysis]
142 Lee HM, Banini BA. Updates on Chronic HBV: Current Challenges and Future Goals. Curr Treat Options Gastro 2019;17:271-91. [DOI: 10.1007/s11938-019-00236-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
143 Huang YS, Cheng CY, Liou BH, Lu PL, Cheng SH, Lee YT, Liu CE, Sun HY, Yang CJ, Tang HJ, Lin SP, Ho MW, Huang SH, Tsai HC, Lee CH, Hung CC; Taiwan HIV Study Group. Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. J Acquir Immune Defic Syndr 2021;86:473-81. [PMID: 33273214 DOI: 10.1097/QAI.0000000000002589] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
144 Zhou L, He Q, Liu X, Yang X, Ou X, Situ B, Li Y, Pan X, Xu Q. Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse. Med Sci Monit 2022;28:e934785. [PMID: 35351845 DOI: 10.12659/MSM.934785] [Reference Citation Analysis]
145 Chen R, Zou J, Long L, Huang H, Zhang M, Fan X, Huang Y. Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B. Front Med 2022;8:796901. [DOI: 10.3389/fmed.2021.796901] [Reference Citation Analysis]
146 Odenwald MA, Paul S. Viral hepatitis: Past, present, and future. World J Gastroenterol 2022; 28(14): 1405-1429 [DOI: 10.3748/wjg.v28.i14.1405] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Zang C, Zhao Y, Qin L, Liu G, Sun J, Li K, Zhao Y, Sheng S, Zhang H, He N, Zhao P, Wang Q, Li X, Peng Y, Dong T, Zhang Y. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages. BMC Cancer 2021;21:1007. [PMID: 34496797 DOI: 10.1186/s12885-021-08720-9] [Reference Citation Analysis]
148 Ortonne V, Lucas Q, Garrigou O, Soulier A, Challine D, Pawlotsky JM, Leroy V, Chevaliez S. Alinity m, a Random-Access System, for Hepatitis B Virus DNA Quantification in Plasma and Whole Blood Collected on Dried Blood Spots. mSphere 2022;:e0008222. [PMID: 35477312 DOI: 10.1128/msphere.00082-22] [Reference Citation Analysis]
149 Yang Y, Huang A, Zhao Y. Spontaneous loss of chronic HBV infection markers in treatment-naïve children: a systematic review and pooled meta-analyses. Expert Rev Anti Infect Ther 2021;19:649-60. [PMID: 33164585 DOI: 10.1080/14787210.2021.1845652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Zhang ZQ, Shi BS, Lu W, Liu DP, Huang D, Feng YL. Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection. Can J Infect Dis Med Microbiol 2019;2019:6545642. [PMID: 31949546 DOI: 10.1155/2019/6545642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
151 Wang M, Chen L, Dong M, Li J, Zhu B, Yang Z, Gong Q, Han Y, Yu D, Zhang D, Zoulim F, Zhang J, Zhang X. Viral quasispecies quantitative analysis: a novel approach for appraising the immune tolerant phase of chronic hepatitis B virus infection. Emerg Microbes Infect 2021;10:842-51. [PMID: 33870846 DOI: 10.1080/22221751.2021.1919033] [Reference Citation Analysis]
152 Hu Q, Wang Q, Zhang Y, Tao S, Zhang X, Liu X, Li X, Jiang X, Huang C, Xu W, Qi X, Chen L, Li Q, Huang Y. Baseline serum exosome-derived miRNAs predict HBeAg seroconversion in chronic hepatitis B patients treated with peginterferon. J Med Virol 2021;93:4939-48. [PMID: 33666247 DOI: 10.1002/jmv.26916] [Reference Citation Analysis]
153 Ling SC, Lin HS, Murray KF, Rosenthal P, Mogul D, Rodriguez-Baez N, Schwarzenberg SJ, Teckman J, Schwarz KB; Hepatitis B Research Network (HBRN). Chronic Hepatitis Is Common and Often Untreated Among Children with Hepatitis B Infection in the United States and Canada. J Pediatr 2021:S0022-3476(21)00458-3. [PMID: 34022250 DOI: 10.1016/j.jpeds.2021.05.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Koc ÖM, Robaeys G, Topal H, Bielen R, Busschots D, Fevery J, Koek GH, Nevens F. Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: A long-term observational cohort study. J Med Virol 2020. [PMID: 32343427 DOI: 10.1002/jmv.25950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
155 Wu Y, Huang H, Luo Y. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:610500. [PMID: 33613534 DOI: 10.3389/fimmu.2020.610500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Ge FL, Si LL, Yang Y, Li YH, Lv ZL, Liu WH, Liao H, Wang J, Zou J, Li L, Li H, Zhang ZL, Wang JB, Lu XC, Xu DP, Bai ZF, Liu Y, Xiao XH. Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model. Front Pharmacol 2021;12:756975. [PMID: 34776974 DOI: 10.3389/fphar.2021.756975] [Reference Citation Analysis]
157 Lee YT, Wang JJ, Luu M, Tseng HR, Rich NE, Lu SC, Nissen NN, Noureddin M, Singal AG, Yang JD. State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States. Hepatology 2021;74:1384-94. [PMID: 33728665 DOI: 10.1002/hep.31811] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
158 Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Xiao L, Li C, Wu Q, Sun C, Niu J, Hou J; TMF Study Group. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther 2021;54:1134-49. [PMID: 34587302 DOI: 10.1111/apt.16611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
159 Wong GL, Wong VW, Yuen BW, Tse YK, Luk HW, Yip TC, Hui VW, Liang LY, Lui GC, Chan HL. An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. Hepatology 2020;71:444-55. [PMID: 31237366 DOI: 10.1002/hep.30833] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
160 Akdemir Kalkan I, Karasahin O, Sarigul F, Altunisik Toplu S, Aladag M, Akgul F, Mete AO, Golbol A, Nazik S, Kömür S, Merve Oren M, Yildiz Y, Demir Y, Ayhan M, Tasova Y, Bayındır Y, Dal T, Celen MK. Comparison of Tenofovir Alafenamide and Entecavir Therapy in Patients with Chronic Hepatitis B Initially Treated with Tenofovir Disoproxil: A Retrospective Observational Survey. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.118721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Pan CQ, Li MH, Zeng HH, Zhang Y, Cao WH, Wang Y, Zhou MF, Hu YH, Wan G, Xie Y, Yi W. Developmental Consequences of Prenatal Telbivudine Exposure during the Third Trimester. Clin Gastroenterol Hepatol 2021;19:1061-3. [PMID: 32371166 DOI: 10.1016/j.cgh.2020.04.056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Li J, Le MH, Barakat MT, Cheung RC, Nguyen MH. The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. Am J Gastroenterol 2021. [PMID: 34328446 DOI: 10.14309/ajg.0000000000001386] [Reference Citation Analysis]
163 Muhammad H, Tehreem A, Hammami MB, Ting PS, Idilman R, Gurakar A. Hepatitis D virus and liver transplantation: Indications and outcomes. World J Hepatol 2021; 13(3): 291-299 [PMID: 33815673 DOI: 10.4254/wjh.v13.i3.291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
164 Cacoub P, Asselah T. Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease. Am J Gastroenterol 2021. [PMID: 34913875 DOI: 10.14309/ajg.0000000000001575] [Reference Citation Analysis]
165 Yao TT, Pan J, Qian JD, Cheng H, Wang Y, Wang GQ. Shear wave elastography may be sensitive and more precise than transient elastography in predicting significant fibrosis. World J Clin Cases 2020; 8(17): 3730-3742 [PMID: 32953849 DOI: 10.12998/wjcc.v8.i17.3730] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
166 Campbell C, Wang T, Smith DA, Freeman O, Noble T, Várnai KA, Harris S, Salih H, Roadknight G, Little S, Glampson B, Mercuri L, Papadimitriou D, Jones CR, Taylor V, Chaudhry A, Phan H, Borca F, Olza J, Warricker F, Romão L, Ramlakhan D, English L, Klenerman P, Andersson MI, Collier J, Nastouli E, Khakoo SI, Gelson W, Cooke GS, Woods K, Davies J, Barnes E, Matthews PC. Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. Wellcome Open Res 2022;7:51. [DOI: 10.12688/wellcomeopenres.17522.1] [Reference Citation Analysis]
167 Aomura D, Tachibana N, Komatsu M, Kobayashi M. Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B. Case Rep Nephrol Dial 2020;10:130-8. [PMID: 33251250 DOI: 10.1159/000508806] [Reference Citation Analysis]
168 Liu H, Hou J, Zhang X. Targeting cIAPs, a New Option for Functional Cure of Chronic Hepatitis B Infection? Virol Sin 2018;33:459-61. [PMID: 30374825 DOI: 10.1007/s12250-018-0062-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
169 Zhang C, Li JW, Wu Z, Zhao H, Wang GQ. Significant Histologic Changes Are Not Rare in Treatment-naive Hepatitis B Patients with Normal Alanine Aminotransferase Level: A Meta-analysis. J Clin Transl Hepatol 2021;9:615-25. [PMID: 34722176 DOI: 10.14218/JCTH.2020.00136] [Reference Citation Analysis]
170 Jacobson IM, Brown RS Jr, McMahon BJ, Perrillo RP, Gish R. An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus. J Clin Gastroenterol 2022. [PMID: 35389923 DOI: 10.1097/MCG.0000000000001695] [Reference Citation Analysis]
171 Gatta LA, Hughes BL. Premature Rupture of Membranes with Concurrent Viral Infection. Obstet Gynecol Clin North Am 2020;47:605-23. [PMID: 33121648 DOI: 10.1016/j.ogc.2020.08.006] [Reference Citation Analysis]
172 Wei H, Song B. Elastography for Longitudinal Assessment of Liver Fibrosis after Antiviral Therapy: A Review. J Clin Transl Hepatol 2020;8:445-53. [PMID: 33447528 DOI: 10.14218/JCTH.2020.00033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Tariq H, Kamal MU, Makker J, Azam S, Pirzada UA, Mehak V, Kumar K, Patel H. Hepatitis in slaughterhouse workers. World J Hepatol 2019; 11(1): 37-49 [PMID: 30705717 DOI: 10.4254/wjh.v11.i1.37] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
174 Mouna L, Rossignol E, Tateo M, Coilly A, Duclos-Vallée JC, Duvoux C, Durand F, Tran A, Radenne S, Canva-Delcambre V, Houssel-Debry P, Dumortier J, Conti F, de Ledinghen V, Leroy V, Kamar N, Di Martino V, Moreno C, Botta Fridlund D, d'Alteroche L, Lebray P, Perre P, Besch C, Silvain C, Habersetzer F, Debette-Gratien M, Abergel A, Diallo A, Samuel D, Roque-Afonso AM, Pageaux GP; ANRS CO23 CUPILT study group. Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference. J Hepatol 2019;70:1297-300. [PMID: 30967293 DOI: 10.1016/j.jhep.2019.02.019] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
175 Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of Hepatocellular Carcinoma in Patients Treated with Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study. JAMA Oncol. 2019;5:30-36. [PMID: 30267080 DOI: 10.1001/jamaoncol.2018.4070] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 36.0] [Reference Citation Analysis]
176 Agbim U, Asrani SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Review of Gastroenterology & Hepatology 2019;13:361-74. [DOI: 10.1080/17474124.2019.1579641] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
177 Watermeyer G, Awuku Y, Fredericks E, Epstein D, Setshedi M, Devani S, Mudombi W, Kassianides C, Katsidzira L. Challenges in the management of inflammatory bowel disease in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00048-6] [Reference Citation Analysis]
178 Li X, Xing Y, Zhou D, Xiao H, Zhou Z, Han Z, Sun X, Li S, Zhang L, Li Z, Zhang P, Zhang J, Zhang N, Cao X, Zao X, Du H, Tong G, Chi X, Gao Y, Ye Y. A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels. Front Med (Lausanne) 2021;8:688091. [PMID: 34150818 DOI: 10.3389/fmed.2021.688091] [Reference Citation Analysis]
179 Gulbay M, Ciliz DS, Celikbas AK, Ocalan DT, Sayin B, Ozbay BO, Alp E. Intravoxel incoherent motion parameters in the evaluation of chronic hepatitis B virus-induced hepatic injury: fibrosis and capillarity changes. Abdom Radiol (NY) 2020;45:2345-57. [PMID: 32162021 DOI: 10.1007/s00261-020-02430-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
180 Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Akbar SMF, Cohen D, Nayagam S, Jeng A, Ceesay A, Sanneh B, Baldeh I, Imaizumi M, Moriyama K, Aoyagi K, D'Alessandro U, Mishiro S, Chemin I, Mendy M, Thursz MR, Lemoine M. Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. Clin Infect Dis 2020;70:1442-52. [PMID: 31102406 DOI: 10.1093/cid/ciz412] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
181 Mak LY, Wong DK, Cheung KS, Seto WK, Fung J, Yuen MF. First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. BMC Gastroenterol 2021;21:123. [PMID: 33731023 DOI: 10.1186/s12876-021-01711-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Sagnelli C, Macera M, Camaioni C, Salvati A, Coppola N, Sagnelli E. SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis. Infection 2022. [PMID: 35316530 DOI: 10.1007/s15010-022-01804-z] [Reference Citation Analysis]
183 Huang RJ, Sharp N, Talamoa R, Kapphahn K, Sathye V, Lin B, Srinivasan M, Palaniappan LP. Disaggregated mortality from gastrointestinal cancers in Asian Americans: Analysis of United States death records. Int J Cancer 2021;148:2954-63. [PMID: 33527405 DOI: 10.1002/ijc.33490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Jia F, Deng F, Tong S, Li S, Ren H, Yin W. Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis. Hepatol Int 2020;14:338-46. [PMID: 32130674 DOI: 10.1007/s12072-020-10024-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
185 Nogami A, Saito S, Hasegawa H, Yoneda M, Harada K, Fujikawa H. Lymphoepithelioma-like cholangiocarcinoma with Epstein-Barr virus infection treated by radiofrequency ablation. Clin J Gastroenterol 2021;14:638-44. [PMID: 33400192 DOI: 10.1007/s12328-020-01303-4] [Reference Citation Analysis]
186 Peliganga LB, Horta MAP, Lewis-ximenez LL. Enduring Challenges despite Progress in Preventing Mother-to-Child Transmission of Hepatitis B Virus in Angola. Pathogens 2022;11:225. [DOI: 10.3390/pathogens11020225] [Reference Citation Analysis]
187 Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
188 Yang D, Hu H, Li R, Tang CL, Ma KS, Guo DY. The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B. Abdom Radiol (NY) 2022;47:630-9. [PMID: 34910237 DOI: 10.1007/s00261-021-03345-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Li T, Liang Y, Zhang M, Liu F, Zhang L, Yang B, Wang L. Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatol Res 2021;51:633-40. [PMID: 33772988 DOI: 10.1111/hepr.13641] [Reference Citation Analysis]
190 Bahardoust M, Mokhtare M, Barati M, Bagheri-Hosseinabadi Z, Karimi Behnagh A, Keyvani H, Agah S. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study. J Infect Chemother 2020;26:1265-71. [PMID: 32762882 DOI: 10.1016/j.jiac.2020.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Johansson ED, Nunez M. Acute Hepatitis B Surge: Opioid Epidemic Implication and Management Challenges. Open Forum Infect Dis 2020;7:ofaa190. [PMID: 32550238 DOI: 10.1093/ofid/ofaa190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Alhajeri H, Abutiban F, Al-Adsani W, Al-Awadhi A, Aldei A, AlEnizi A, Alhadhood N, Al-Herz A, Alkandari W, Dehrab A, Muhanna Ghanem AA, Hasan E, Hayat S, Saleh K, Tarakmeh H, Ali Y. Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis. Rheumatol Int 2019;39:1483-97. [PMID: 31309293 DOI: 10.1007/s00296-019-04372-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
193 Xun Z, Yao X, Zhu C, Ye Y, Wu S, Chen T, Zeng Y, Lin C, Yang B, Ou Q, Liu C. Proteomic characterization of the natural history of chronic HBV infection revealed by tandem mass tag-based quantitative proteomics approach. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100302] [Reference Citation Analysis]
194 Cai Y, Dai Z, Wen S, Bhandari R. Risk factors associated with infection of blood-borne virus among people who used methamphetamine. BMC Infect Dis 2020;20:742. [PMID: 33036558 DOI: 10.1186/s12879-020-05464-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
195 Hong YM, Yoon KT. [Definition and Management of the Immune Tolerance Phase in Chronic Hepatitis B]. Korean J Gastroenterol 2022;79:156-60. [PMID: 35473773 DOI: 10.4166/kjg.2022.049] [Reference Citation Analysis]
196 Erken R, Zaaijer HL, Willemse SB, Bakker E, Takkenberg BB, Reesink HW, Kootstra NA. Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy. Ann Hepatol 2021;26:100540. [PMID: 34583061 DOI: 10.1016/j.aohep.2021.100540] [Reference Citation Analysis]
197 Hu CY, Tsou Y, Chung M, Lin N, Chen C, Lee P, Liu C. Hepatitis B Virus Infection Flare Induced Acute-on-chronic Liver Failure After COVID-19 Vaccination: A Case Report. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon-126460] [Reference Citation Analysis]
198 Shi H, Xiao G, Liao M, Zheng L, Jie Y, Lin G, Chong Y. Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure. Biomed Pharmacother 2021;134:111118. [PMID: 33341047 DOI: 10.1016/j.biopha.2020.111118] [Reference Citation Analysis]
199 Wang J, Xia J, Yan X, Yang Y, Wei J, Xiong Y, Wu W, Liu Y, Chen Y, Jia B, Chen Z, Zhang Z, Ding W, Huang R, Wu C. The gamma-glutamyl transpeptidase to platelet ratio predicts liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase. Clin Res Hepatol Gastroenterol 2020;44:913-22. [PMID: 32147439 DOI: 10.1016/j.clinre.2020.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
200 Srisuwarn P, Sumethkul V. Kidney transplant from donors with hepatitis B: A challenging treatment option. World J Hepatol 2021; 13(8): 853-867 [PMID: 34552692 DOI: 10.4254/wjh.v13.i8.853] [Reference Citation Analysis]
201 Liu TW, Huang CF, Yeh ML, Tsai PC, Jang TY, Huang JF, Dai CY, Chuang WL, Yu ML. Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index. BMJ Open Gastroenterol 2020;7:e000543. [PMID: 33323472 DOI: 10.1136/bmjgast-2020-000543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
202 Boucheron P, Lu Y, Yoshida K, Zhao T, Funk AL, Lunel-Fabiani F, Guingané A, Tuaillon E, van Holten J, Chou R, Bulterys M, Shimakawa Y. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis. Lancet Infect Dis 2021;21:85-96. [PMID: 32805201 DOI: 10.1016/S1473-3099(20)30593-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
203 Hammond SP, Ho VT, Marty FM. Hepatitis B virus vaccination after allogeneic hematopoietic cell transplantation prevents post-transplant HBV reactivation. Transplant Cell Ther 2022:S2666-6367(22)01197-6. [PMID: 35413458 DOI: 10.1016/j.jtct.2022.04.004] [Reference Citation Analysis]
204 Liu H, Shi Y, Hayden JC, Ryan PM, Rahmani J, Yu G. Tenofovir Treatment Has Lower Risk of Hepatocellular Carcinoma than Entecavir Treatment in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Liver Cancer 2020;9:468-76. [PMID: 32999872 DOI: 10.1159/000507253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
205 Wang M, Qian M, Fu R, Zhang Y, Shen X, Yue D, Wang N, Yang L. The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Front Public Health 2021;9:709220. [PMID: 34568257 DOI: 10.3389/fpubh.2021.709220] [Reference Citation Analysis]
206 Duan Y, Chen Z, Li H, Shen W, Zeng Y, Peng M, Hu P. Potential Molecular Targets of Tenofovir Disoproxil Fumarate for Alleviating Chronic Liver Diseases via a Non-Antiviral Effect in a Normal Mouse Model. Front Mol Biosci 2021;8:763150. [PMID: 34869594 DOI: 10.3389/fmolb.2021.763150] [Reference Citation Analysis]
207 Hui VW, Yip TC, Wong VW, Tse YK, Chan HL, Lui GC, Wong GL. Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. Clin Transl Gastroenterol 2021;12:e00324. [PMID: 33750746 DOI: 10.14309/ctg.0000000000000324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
208 Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, Tang H. Hepatitis B Virus Infection: Overview. Adv Exp Med Biol 2020;1179:1-16. [PMID: 31741331 DOI: 10.1007/978-981-13-9151-4_1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
209 Jang H, Yoon JS, Park SY, Lee HA, Jang MJ, Kim SU, Sinn DH, Seo YS, Kim HY, Kim SE, Jun DW, Yoon EL, Sohn JH, Ahn SB, Shim JJ, Jeong SW, Cho YK, Kim HS, Nam JY, Lee YB, Kim YJ, Yoon JH, Zoulim F, Lampertico P, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Papatheodoridis GV, Lee JH. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00935-6. [PMID: 34500103 DOI: 10.1016/j.cgh.2021.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
210 Wübbolding M, Cornberg M, Höner zu Siederdissen C. Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV. Curr Hepatology Rep 2019;18:512-21. [DOI: 10.1007/s11901-019-00502-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
211 Zeng QL, Zhang HX, Zhang JY, Huang S, Li WZ, Li GM, Pan YJ, Feng YH, Li ZQ, Zhang GF, Xu JH, Lin WB, Xu GH, Liu N, Zhang GQ, Li GT, Li W, Zeng YL, Song N, Wang M, Zhang DW, Chen ZM, Cui GL, Li J, Lv J, Liu YM, Liang HX, Sun CY, Zhou YH, Yu ZJ, Wang FS. Tenofovir Alafenamide for Pregnant Chinese Women with Active Chronic Hepatitis B: A Multicenter Prospective Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01306-9. [PMID: 34902570 DOI: 10.1016/j.cgh.2021.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
212 Tseng CW, Wu SF, Chen CY, Ho YC, He YT, Tseng KC. Characteristics of regulatory T-cell function in patients with chronic hepatitis B and C coinfection. J Viral Hepat 2020;27:800-9. [PMID: 32243022 DOI: 10.1111/jvh.13298] [Reference Citation Analysis]
213 Enomoto H, Aizawa N, Hasegawa K, Ikeda N, Sakai Y, Yoh K, Takata R, Yuri Y, Kishino K, Shimono Y, Ishii N, Takashima T, Nishimura T, Nishikawa H, Iwata Y, Iijima H, Nishiguchi S. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients. Int J Mol Sci 2020;21:E3089. [PMID: 32349377 DOI: 10.3390/ijms21093089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
214 Ma Z, Lu S, Sun D, Bai M, Jiang T, Lin N, Zhou H, Zeng S, Jiang H. Roles of organic anion transporter 2 and equilibrative nucleoside transporter 1 in hepatic disposition and antiviral activity of entecavir during non-pregnancy and pregnancy. Br J Pharmacol 2019;176:3236-49. [PMID: 31166004 DOI: 10.1111/bph.14756] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
215 Gao F, Zhang WT, Lin YY, Wang WM, Xu N, Bai GQ. Early Start Of Tenofovir Treatment Achieves Better Viral Suppression In Pregnant Women With A High HBV Viral Load: A Real-World Prospective Study. Infect Drug Resist 2019;12:3475-84. [PMID: 31807036 DOI: 10.2147/IDR.S228982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
216 Kumar P, Freeland C, Bodor S, Farrell S, Cohen C, Frasso R. Needs of Individuals Living With Hepatitis Delta Virus and Their Caregivers, 2016-2019. Prev Chronic Dis 2020;17:E159. [PMID: 33337297 DOI: 10.5888/pcd17.200324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
217 Yip TC, Chan HL, Tse Y, Lam KL, Lui GC, Wong VW, Wong GL. On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. American Journal of Gastroenterology 2018;113:1629-38. [DOI: 10.1038/s41395-018-0247-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
218 Reddy KR. SARS-CoV-2 and the Liver: Considerations in Hepatitis B and Hepatitis C Infections. Clin Liver Dis (Hoboken) 2020;15:191-4. [PMID: 32489654 DOI: 10.1002/cld.970] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
219 Lee TH, Hunt CM, Maier MM, Lowy E, Beste LA. Hepatitis B Virus-Related Care Quality In Patients With Hepatitis B/Hiv Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study. Clin Infect Dis 2022:ciac227. [PMID: 35349635 DOI: 10.1093/cid/ciac227] [Reference Citation Analysis]
220 Gish RG, Basit SA, Ryan J, Dawood A, Protzer U. Hepatitis B Core Antibody: Role in Clinical Practice in 2020. Curr Hepatology Rep 2020;19:254-65. [DOI: 10.1007/s11901-020-00522-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
221 Zhang M, Zhang Z, Imamura M, Osawa M, Teraoka Y, Piotrowski J, Ishida Y, Sozzi V, Revill PA, Saito T, Chayama K, Liang TJ. Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models. J Hepatol 2021:S0168-8278(21)01960-7. [PMID: 34363922 DOI: 10.1016/j.jhep.2021.07.030] [Reference Citation Analysis]
222 Pauley MP. Reply. Clin Gastroenterol Hepatol 2019;17:210-1. [PMID: 30558891 DOI: 10.1016/j.cgh.2018.08.046] [Reference Citation Analysis]
223 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
224 Ogawa E, Yeo YH, Dang N, Le MH, Jeong D, Tran S, Henry L, Cheung R, Nguyen MH. Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States. JAMA Netw Open 2020;3:e201844. [PMID: 32271388 DOI: 10.1001/jamanetworkopen.2020.1844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
225 Papatheodoridi M, Papatheodoridis G. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. Cells. 2020;9. [PMID: 32093411 DOI: 10.3390/cells9020493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
226 Liu J, Wang J, Yan X, Xue R, Zhan J, Jiang S, Geng Y, Liu Y, Mao M, Xia J, Yin S, Tong X, Chen Y, Ding W, Huang R, Wu C. Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis. Hepatol Commun 2021. [PMID: 34783181 DOI: 10.1002/hep4.1859] [Reference Citation Analysis]
227 Patel NH, Joshi SS, Lau KCK, Castillo E, Coffin CS. Analysis of serum hepatitis B virus RNA levels in a multiethnic cohort of pregnant chronic hepatitis B carriers. J Clin Virol 2019;111:42-7. [PMID: 30639847 DOI: 10.1016/j.jcv.2019.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
228 Lee JJ, Chang JM, Yang LJ, Hsu CC, Lin MH, Lin MY. Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: A nationwide survey in 2010-2018. J Formos Med Assoc 2022:S0929-6646(21)00584-2. [PMID: 34996670 DOI: 10.1016/j.jfma.2021.12.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
229 Yim HJ, Kim W, Ahn SH, Jung YK, Um SH, Sohn JH, Jang JY, Kim DJ, Park ES, Jin SY, Kim KH. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. J Gastroenterol Hepatol 2021. [PMID: 34653281 DOI: 10.1111/jgh.15710] [Reference Citation Analysis]
230 Wang G, Guan J, Khan NU, Li G, Shao J, Zhou Q, Xu L, Huang C, Deng J, Zhu H, Chen Z. Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus. Gut Pathog 2021;13:22. [PMID: 33845868 DOI: 10.1186/s13099-021-00421-9] [Reference Citation Analysis]
231 Sung PS, Park DJ, Kim JH, Han JW, Lee EB, Lee GW, Nam HC, Jang JW, Bae SH, Choi JY, Shin EC, Park SH, Yoon SK. Ex vivo Detection and Characterization of Hepatitis B Virus-Specific CD8+ T Cells in Patients Considered Immune Tolerant. Front Immunol 2019;10:1319. [PMID: 31244857 DOI: 10.3389/fimmu.2019.01319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
232 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Reference Citation Analysis]
233 Yeh ML, Liang PC, Huang CI, Hsieh MH, Lin YH, Jang TY, Wei YJ, Hsu PY, Hsu CT, Wang CW, Hsieh MY, Lin ZY, Chen SC, Huang CF, Huang JF, Dai CY, Chuang WL, Yu ML. Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. J Gastroenterol Hepatol 2021. [PMID: 34318943 DOI: 10.1111/jgh.15640] [Reference Citation Analysis]
234 Buti M, Marcos-Fosch C, Esteban R. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide. Liver Int 2021;41 Suppl 1:9-14. [PMID: 34155802 DOI: 10.1111/liv.14848] [Reference Citation Analysis]
235 Luo X, Wang Y. Analysis of the Effect of Health Management of Chronic Diseases and Metabolic Disorders under the Guidance of B-Ultrasound. J Healthc Eng 2021;2021:6648611. [PMID: 33604009 DOI: 10.1155/2021/6648611] [Reference Citation Analysis]
236 Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Reference Citation Analysis]
237 Yonezawa H, Tanaka S, Furuya M, Yamada K, Asanuma K, Fujiya Y, Miyanishi K, Takahashi S, Kato J. Determination of reactivation rate and risk factors for Hepatitis B virus reactivation in low-positive cases: A retrospective cohort study. J Infect Chemother 2021;27:1454-8. [PMID: 34176717 DOI: 10.1016/j.jiac.2021.06.009] [Reference Citation Analysis]
238 Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res 2021. [PMID: 34687121 DOI: 10.1111/hepr.13726] [Reference Citation Analysis]
239 Koc ÖM, Verbeek J, Koek GH, Bielen R, Busschots D, Gamil M, Robaeys G, Nevens F. A long-term study of liver-related events in Caucasian hepatitis B patients with normal ALT values and high viremia. Acta Gastroenterol Belg 2022;85:56-61. [PMID: 35304994 DOI: 10.51821/85.1.9160] [Reference Citation Analysis]
240 Siddique SM, May FP. Race-Based Clinical Recommendations in Gastroenterology. Gastroenterology 2021:S0016-5085(21)04050-6. [PMID: 34890599 DOI: 10.1053/j.gastro.2021.12.234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
241 Yu HC, Tseng JC, Lu LY, Hu JC, Chen YH, Hsu CL, Wu PC, Mar GY, Lin KH. Monitoring by viral load and quantitative hepatitis B surface antigen in patients with hepatitis B virus infection receiving immunosuppressive therapy. Eur J Gastroenterol Hepatol 2021;33:107-13. [PMID: 32243344 DOI: 10.1097/MEG.0000000000001707] [Reference Citation Analysis]
242 Tan CJ, Kumar R, Koomanan N, Loo WS, Farid M, Tao M, Somasundaram N, Poon E, Chan JY, Yang VS, Chang E, Lim ST, Chow WC, Chan A, Tang T. Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. Pharmacotherapy 2021;41:332-41. [PMID: 33547823 DOI: 10.1002/phar.2508] [Reference Citation Analysis]
243 Lee HW, Park JY, Lee JW, Yoon KT, Kim CW, Park H, Kim YS, Paik SK, Lee JI, Kim BK, Han KH, Ahn SH. Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. Clin Gastroenterol Hepatol 2019;17:1348-1355.e2. [PMID: 30613003 DOI: 10.1016/j.cgh.2018.10.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
244 Attar BM. CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated. Clin Liver Dis (Hoboken). 2020;15:25-30. [PMID: 32104574 DOI: 10.1002/cld.893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Zeng DW, Huang ZX, Lin MX, Kang NL, Lin X, Li YN, Zhu YY, Liu YR. A novel HBsAg-based model for predicting significant liver fibrosis among Chinese patients with immune-tolerant phase chronic hepatitis B: a multicenter retrospective study. Therap Adv Gastroenterol 2021;14:17562848211010675. [PMID: 34104207 DOI: 10.1177/17562848211010675] [Reference Citation Analysis]
246 Lim TS, Lee JS, Kim BK, Lee HW, Jeon MY, Kim SU, Park JY, Kim DY, Han KH, Ahn SH. An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. J Viral Hepat 2020;27:316-22. [PMID: 31639240 DOI: 10.1111/jvh.13222] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
247 Zhang Z, Lu W, Zeng D, Huang D, Lin W, Yan L, Feng Y. Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection. J Clin Med 2021;10:5617. [PMID: 34884319 DOI: 10.3390/jcm10235617] [Reference Citation Analysis]
248 Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder SD, Zoulim F, Botros I, Flaherty JF, Jump B, Op den Brouw ML, van Troostenburg A, Ramroth H; ReCoRd (Retrospective, Cohort, Renal, Viread) Investigators' Group. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. Aliment Pharmacol Ther 2020;52:500-12. [PMID: 32583915 DOI: 10.1111/apt.15901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
249 Zhang M, Li G, Shang J, Pan C, Zhang M, Yin Z, Xie Q, Peng Y, Mao Q, Xiao X, Jiang Y, Luo K, Xu Y, Ding H, Fan W, Diego V, Pourkarim MR, De Clercq E, Wang G, Gong G. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int 2020;14:212-24. [PMID: 32100261 DOI: 10.1007/s12072-020-10015-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
250 Weissmann L, Picone CM, Gouvêa MSG, Ferreira PRA, Viana MSVB, Pinho JRR, Cassenote AJF, Segurado AC. Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy. Braz J Infect Dis 2019;23:441-50. [PMID: 31715124 DOI: 10.1016/j.bjid.2019.10.002] [Reference Citation Analysis]
251 Sonneveld MJ, van Oord GW, van Campenhout MJ, De Man RA, Janssen HLA, de Knegt RJ, Boonstra A, van der Eijk AA. Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues. J Viral Hepat 2019;26:828-34. [PMID: 30896057 DOI: 10.1111/jvh.13097] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
252 Ma Y, Yang L, Bao Y, Yang Y, Chen L, Zheng M. Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy. Front Immunol 2021;12:751754. [PMID: 34691067 DOI: 10.3389/fimmu.2021.751754] [Reference Citation Analysis]
253 Perrillo R, Lin HS, Schwarz KB, Rosenthal P, Lisker-Melman M, Chung RT, Prokunina-Olsson L, Coherty G, Feld J; Hepatitis B Research Network (HBRN). Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. Hepatology 2022. [PMID: 35188674 DOI: 10.1002/hep.32400] [Reference Citation Analysis]
254 Delobel D, Furutani Y, Nagoshi S, Tsubota A, Miyasaka A, Watashi K, Wakita T, Matsuura T, Usui K. SEB genotyping: SmartAmp-Eprimer binary code genotyping for complex, highly variable targets applied to HBV. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07458-4] [Reference Citation Analysis]
255 Xing YF, Wei CS, Zhou TR, Huang DP, Zhong WC, Chen B, Jin H, Hu XY, Yang ZY, He Q, Jiang KP, Jiang JM, Hu ZB, Deng X, Yang F, Li FY, Zhao G, Wang LC, Mi YQ, Gong ZJ, Guo P, Wu JH, Shi WQ, Yang HZ, Zhou DQ, Tong GD. Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients. World J Gastroenterol 2020; 26(30): 4501-4522 [PMID: 32874061 DOI: 10.3748/wjg.v26.i30.4501] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
256 Medas R, Liberal R, Macedo G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J Clin Cases 2021; 9(24): 6979-6986 [PMID: 34540953 DOI: 10.12998/wjcc.v9.i24.6979] [Reference Citation Analysis]
257 Cho HJ, Shin SK, Kwon OS, Kim JH, Kim YS. Seroreversion and Acute Decompensation in Chronic Hepatitis B after Discontinuation of Oral Nucleotide Analog in the Patients Achieving HBsAg Loss. Korean J Gastroenterol 2020;76:256-60. [PMID: 33234774 DOI: 10.4166/kjg.2020.111] [Reference Citation Analysis]
258 Rodríguez-Tajes S, Pocurull A, Lens S, Mariño Z, Olivas I, Soy G, Alonso A, Vilella A, Forns X. Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis. J Viral Hepat 2021;28:1019-24. [PMID: 33763966 DOI: 10.1111/jvh.13509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
259 Charlton MR, Alam A, Shukla A, Dashtseren B, Lesmana CRA, Duger D, Payawal DA, Duy Cuong D, Jargalsaikhan G, Cua IHY, Sollano JD, Singh KR, Madan K, Win KM, Kyi KP, Tun KS, Salih M, Rastogi M, Saraf N, Thuy PTT, Hien PTD, Gani RA, Mohamed R, Tanwandee T, Piratvisuth T, Sukeepaisarnjaroen W, Naing W, Hashmi ZY. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol 2020;55:811-23. [PMID: 32666200 DOI: 10.1007/s00535-020-01698-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
260 Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Hao S, Yang Y. Reply to Kumar and Kulkarni. Am J Gastroenterol 2021;116:424-5. [PMID: 33284185 DOI: 10.14309/ajg.0000000000001067] [Reference Citation Analysis]
262 Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
263 Flecken T, Meier MA, Skewes-Cox P, Barkan DT, Heim MH, Wieland SF, Holdorf MM. Mapping the Heterogeneity of Histone Modifications on Hepatitis B Virus DNA Using Liver Needle Biopsies Obtained from Chronically Infected Patients. J Virol 2019;93:e02036-18. [PMID: 30787147 DOI: 10.1128/JVI.02036-18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
264 Palom A, Rando-segura A, Vico J, Pacín B, Vargas E, Barreira-díaz A, Rodríguez-frías F, Riveiro-barciela M, Esteban R, Buti M. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100547] [Reference Citation Analysis]
265 Liu J, Xu B, Chen T, Chen J, Feng J, Xu C, Liu L, Hu Y, Zhou YH. Presence of hepatitis B virus markers in umbilical cord blood: Exposure to or infection with the virus? Dig Liver Dis 2019;51:864-9. [PMID: 30528568 DOI: 10.1016/j.dld.2018.11.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
266 Hammami MB, Kohli R, Woreta T, Sulkowski MS, Hamilton JP, Toman L, Saberi B, Laurin J, Wang JG, Philosophe B, Cameron AM, Gurakar A. Hepatitis B Virus/Hepatitis D Virus-Coinfected Liver Transplant Candidate Receiving Hepatitis B Virus-Deoxyribonucleic Acid-Positive Allograft and Treated With High-Dose Hepatitis B Immune Globulin. ACG Case Rep J 2021;8:e00582. [PMID: 34549060 DOI: 10.14309/crj.0000000000000582] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Wang JH, Hu TH, Chen CH, Hung CH, Yen YH, Chang KC, Lu SN. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. Kaohsiung J Med Sci. 2019;35:708-714. [PMID: 31430035 DOI: 10.1002/kjm2.12114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
268 Yang G, Zhuang L, Sun T, Yeo YH, Tao L, Zhang W, Ma W, Wu L, Yang Z, Yang Y, Xue D, Zhang J, Feng R, Matthias P. E, Dooley S, Seki E, Liu P, Liu C, Solimando AG. Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-9. [DOI: 10.1155/2022/1048104] [Reference Citation Analysis]
269 Mao D, Lau ESH, Wu H, Yang A, Fan B, Shi M, Tam CHT, Chow E, Kong APS, Ma RCW, Luk A, Chan JCN. Risk Associations of Glycemic Burden and Obesity With Liver Cancer-A 10-Year Analysis of 15,280 Patients With Type 2 Diabetes. Hepatol Commun 2022. [PMID: 35044101 DOI: 10.1002/hep4.1891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
270 Hu Z, Zeng H, Hou J, Wang J, Xu L, Zhang Y, Chen M, Zhou Z. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. Viruses 2022;14:656. [PMID: 35458386 DOI: 10.3390/v14040656] [Reference Citation Analysis]
271 Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, Corral O, Soriano V. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. Hepatol Int 2022. [PMID: 35666390 DOI: 10.1007/s12072-022-10365-0] [Reference Citation Analysis]
272 An J, Kim D, Oh B, Oh YJ, Song J, Park N, Kim HI, Kang HJ, Oh JH, Kim W, Lee E, Sung CO, Song GW, Kim DG, Yu E, Letouzé E, Zucman-Rossi J, Lee HC, Shim JH. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas. Hepatology 2022;75:997-1011. [PMID: 34478159 DOI: 10.1002/hep.32135] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
273 Huang BY, Tsai MR, Hsu JK, Lin CY, Lin CL, Hu JT, Huang YW, Liu CJ, Wu WJ, Wu CF, Sung FY, Chen PJ, Liang HJ, Lin SM, Yu MW. Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma. Mol Carcinog 2020;59:1269-79. [PMID: 32914490 DOI: 10.1002/mc.23255] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
274 Ghany MG, King WC, Lisker-Melman M, Lok ASF, Terrault N, Janssen HLA, Khalili M, Chung RT, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. Hepatology 2021;74:2395-409. [PMID: 34133774 DOI: 10.1002/hep.32018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
275 Lee HM, Ahn J, Kim WR, Lim JK, Nguyen M, Pan CQ, Kim D, Mannalithara A, Te H, Trinh H, Chu D, Tran T, Woog J, Lok AS. A Comparison Between Community and Academic Practices in the USA in the Management of Chronic Hepatitis B Patients Receiving Entecavir: Results of the ENUMERATE Study. Dig Dis Sci 2019;64:358-66. [PMID: 30238203 DOI: 10.1007/s10620-018-5281-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
276 Lee SK, Kwon JH, Lee SW, Jang JW, Nam H, Baik KW, Yoo SH, Nam SW, Sung PS, Bae SH, Choi JY, Yoon SK. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B. Liver Int 2021;41:288-94. [PMID: 33043567 DOI: 10.1111/liv.14701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
277 Hwang JP, Torres HA. Hepatitis B virus and hepatitis C virus infection in immunocompromised patients. Curr Opin Infect Dis 2018;31:535-41. [PMID: 30299355 DOI: 10.1097/QCO.0000000000000500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
278 Mohammed BS, Aidoo M. Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines? Int J Hepatol 2020;2020:9750194. [PMID: 32550025 DOI: 10.1155/2020/9750194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
279 Lee HW, Chon YE, Kim BK, Yip TC, Tse YK, Wong GL, Wong VW, Chan HL, Ahn SH. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. Eur J Intern Med 2021;84:68-73. [PMID: 33288393 DOI: 10.1016/j.ejim.2020.10.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
280 Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099 [PMID: 34497437 DOI: 10.3748/wjg.v27.i30.5088] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Lai M, Chang Y, Cheng P, Chueh H, Chang S, Yeh C. Absence of chronicity in infants born to immunized mothers with occult HBV infection in taiwan. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.030] [Reference Citation Analysis]
282 Wu S, Yi W, Gao Y, Deng W, Bi X, Lin Y, Yang L, Lu Y, Liu R, Chang M, Shen G, Hu L, Zhang L, Li M, Xie Y. Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection. Front Immunol 2022;13:893512. [PMID: 35634301 DOI: 10.3389/fimmu.2022.893512] [Reference Citation Analysis]
283 Wang YW, Tsai XC, Hou HA, Tien FM, Liu JH, Chou WC, Ko BS, Chen YW, Lin CC, Cheng CL, Lo MY, Lin YC, Lu LC, Wu SJ, Kuo SH, Hong RL, Huang TC, Yao M. Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. Ann Hematol 2021. [PMID: 34766217 DOI: 10.1007/s00277-021-04711-9] [Reference Citation Analysis]
284 Wang WT, Zhao XQ, Li GP, Chen YZ, Wang L, Han MF, Li WN, Chen T, Chen G, Xu D, Ning Q, Zhao XP. Immune response pattern varies with the natural history of chronic hepatitis B. World J Gastroenterol 2019; 25(16): 1950-1963 [PMID: 31086463 DOI: 10.3748/wjg.v25.i16.1950] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
285 Pritchard H, Hwang JP, Angelidakis G, Yibirin M, Wang L, Miller E, Torres HA. Hepatitis B virus reactivation in cancer patients receiving direct-acting antivirals for hepatitis C virus infection. J Viral Hepat 2021;28:844-8. [PMID: 33523503 DOI: 10.1111/jvh.13478] [Reference Citation Analysis]
286 Niu JX, Xu Y, Wu DP. [Progress in the research of HBV reactivation in patients undergoing hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2021;42:348-52. [PMID: 33979984 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.016] [Reference Citation Analysis]
287 Alawad AS, Auh S, Suarez D, Ghany MG. Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen. Clin Gastroenterol Hepatol 2020; 18: 700-709. e3. [PMID: 31323381 DOI: 10.1016/j.cgh.2019.07.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
288 Aguilera A, Trastoy R, Rodríguez-Frias F, Muñoz-Bellido JL, Melón S, Suárez A, Orduña A, Viciana I, Bernal S, García-Bujalance S, Montiel N, Molina JM, Basaras M, Fernández-Cuenca F, García-Arata I, Reina G, Ocete MD, Fuentes A, Navarro-de la Cruz D, Nieto L, Blazquez de Castro A, Buti M, Álvarez M, García F. GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000-2016). J Infect 2020;81:600-6. [PMID: 32711039 DOI: 10.1016/j.jinf.2020.07.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
289 Wang J, Geng X, Zhang X, Xiao Y, Wang W. Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database. Front Pharmacol 2022;13:921084. [DOI: 10.3389/fphar.2022.921084] [Reference Citation Analysis]
290 Lee HW, Kim SU, Park JY, Baatarkhuu O, Kim DY, Ahn SH, Han KH, Kim BK. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. Clin Transl Gastroenterol 2019;10:e00036. [PMID: 31107725 DOI: 10.14309/ctg.0000000000000036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
291 Jianfei L, Ling L, Yu Z, Jiming Z, Bin W. Tooth loss associated with the use of tenofovir disoproxil fumarate. J Clin Pharm Ther 2020;45:1478-82. [PMID: 32820829 DOI: 10.1111/jcpt.13219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
292 Wang L, Wang Y, Liu S, Zhai X, Zhou G, Lu F, Zhao J. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol 2019;54:1096-105. [PMID: 31134334 DOI: 10.1007/s00535-019-01594-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
293 Stockdale AJ, Silungwe NM, Shawa IT, Kreuels B, Gordon MA, Geretti AM. Diagnostic performance evaluation of hepatitis B e antigen rapid diagnostic tests in Malawi. BMC Infect Dis 2021;21:487. [PMID: 34044776 DOI: 10.1186/s12879-021-06134-3] [Reference Citation Analysis]
294 Kardani K, Bolhassani A, Kardani M, Agi E; Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran, Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran, Iranian Comprehensive Hemophilia Care Center, Tehran, Iran. Correlation of SARS-CoV-2 Infection with Hepatitis and Liver Disorders. JoMMID 2021;9:122-32. [DOI: 10.52547/jommid.9.3.122] [Reference Citation Analysis]
295 Huang DQ, Yeo YH, Tan E, Takahashi H, Yasuda S, Saruwatari J, Tanaka K, Oniki K, Kam LY, Muthiah MD, Hyogo H, Ono M, Barnett SD, Li J, Zou B, Fung J, Lee TY, Wong VW, Yuen MF, Dan YY, Lim SG, Cheung R, Toyoda H, Eguchi Y, Nguyen MH. ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. Hepatol Commun 2020;4:1624-36. [PMID: 33163833 DOI: 10.1002/hep4.1593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
296 Fernández I, Pascasio JM, Colmenero J; en nombre del grupo de trabajo para el VII consenso de la SETH., Autores participantes en el grupo de trabajo en representación de sus respectivos programas de trasplante hepático. Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation. Gastroenterol Hepatol 2020;43:169-77. [PMID: 32094045 DOI: 10.1016/j.gastrohep.2019.11.005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
297 Sandmann L, Wedemeyer H. New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. Clin Liver Dis 2021;25:831-9. [PMID: 34593156 DOI: 10.1016/j.cld.2021.06.011] [Reference Citation Analysis]
298 Sun X, Hu D, Yang Z, Liu Z, Wang J, Chen J, Xu L, Zhou Z, Chen M, Zhang Y. Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy. J Hepatocell Carcinoma 2020;7:337-45. [PMID: 33294424 DOI: 10.2147/JHC.S278527] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
299 Chen J, Wang Y, Wu J. Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues. J Viral Hepat 2020;27:1511. [PMID: 32852859 DOI: 10.1111/jvh.13383] [Reference Citation Analysis]
300 Yang S, Ma X, Cai C, Wang H, Xiao F, Yu C. Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study. Front Med (Lausanne) 2021;8:637126. [PMID: 33791326 DOI: 10.3389/fmed.2021.637126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
301 Aguirre A, Yazdany J. Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement. J Rheumatol 2022;49:1-4. [PMID: 34725177 DOI: 10.3899/jrheum.211000] [Reference Citation Analysis]
302 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
303 Koh C, Heller T, Glenn JS. Pathogenesis of and New Therapies for Hepatitis D. Gastroenterology. 2019;156:461-476.e1. [PMID: 30342879 DOI: 10.1053/j.gastro.2018.09.058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
304 Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: Immunological Response, Natural Course and Pregnancy Outcomes. J Clin Med 2021;10:2926. [PMID: 34210105 DOI: 10.3390/jcm10132926] [Reference Citation Analysis]
305 Liu Y, Li H, Yan X, Wei J. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B. J Viral Hepat 2019;26 Suppl 1:69-76. [PMID: 31380585 DOI: 10.1111/jvh.13154] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
306 Teh CP, Chook JB, Ngeow YF, Tong TYK, Tee KK, Bong JJ, Mohamed R. Primer and probe conservation issue in the quantification of hepatitis B virus DNA. Rev Med Virol 2021;31. [DOI: 10.1002/rmv.2182] [Reference Citation Analysis]
307 Hsu YC, Chen CY, Chang IW, Chang CY, Wu CY, Lee TY, Wu MS, Bair MJ, Chen JJ, Chen CC, Tseng CH, Tai CM, Huang YT, Ku WH, Mo LR, Lin JT. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. Lancet Infect Dis 2021;21:823-33. [PMID: 33524314 DOI: 10.1016/S1473-3099(20)30692-7] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
308 Koc ÖM, Hens N, Bielen R, Van Damme P, Robaeys G. Hepatitis B virus prevalence and risk factors in hard-to-reach Turkish population living in Belgium: A protocol for screening. Medicine (Baltimore) 2019;98:e15412. [PMID: 31045797 DOI: 10.1097/MD.0000000000015412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
309 Liu T, Huang C, Tsai P, Yeh M, Jang T, Huang J, Dai C, Yu M, Chuang W. The compound annual growth rate of the fibrosis‐4 index in chronic hepatitis B patients. The Kaohsiung J of Med Scie. [DOI: 10.1002/kjm2.12543] [Reference Citation Analysis]
310 Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev 2019;8:207. [PMID: 31426837 DOI: 10.1186/s13643-019-1126-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
311 van Bömmel F, Berg T. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatol Commun 2021;5:1632-48. [PMID: 34558833 DOI: 10.1002/hep4.1708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
312 Fabrizi F, Cerutti R, Ridruejo E. Hepatitis B virus infection as a risk factor for chronic kidney disease. Expert Rev Clin Pharmacol 2019;12:867-74. [PMID: 31456441 DOI: 10.1080/17512433.2019.1657828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
313 Jeon MY, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Han K, Ahn SH, Kim SU. Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma. J Viral Hepat 2020;27:932-40. [DOI: 10.1111/jvh.13313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
314 Yang L, Wang Q, Cui T, Huang J, Jin H. Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis. Can J Gastroenterol Hepatol 2021;2021:9996358. [PMID: 34513751 DOI: 10.1155/2021/9996358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
315 Li K, Qin L, Jiang S, Li A, Zhang C, Liu G, Sun J, Sun H, Zhao Y, Li N, Zhang Y. The signature of HBV-related liver disease in peripheral blood mononuclear cell DNA methylation. Clin Epigenetics 2020;12:81. [PMID: 32513305 DOI: 10.1186/s13148-020-00847-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
316 Rosenbohm JM, Klapperich CM, Cabodi M. Tunable Duplex Semiquantitative Detection of Nucleic Acids with a Visual Lateral Flow Immunoassay Readout. Anal Chem 2022. [PMID: 35199994 DOI: 10.1021/acs.analchem.1c05039] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Proulx J, Ghaly M, Park I, Borgmann K. HIV-1-Mediated Acceleration of Oncovirus-Related Non-AIDS-Defining Cancers. Biomedicines 2022;10:768. [DOI: 10.3390/biomedicines10040768] [Reference Citation Analysis]
318 Sun X, Wang C, Wang B, Yang X, Xu H, Shen M, Zhu K. Efficacy of Nucleotide/Nucleoside Analogues and Hepatitis B Immunoglobulin Therapy in Blocking Mother-to-Child Transmission of Hepatitis B in an Eastern Chinese Group. Infect Dis Obstet Gynecol 2020;2020:4305950. [PMID: 33380780 DOI: 10.1155/2020/4305950] [Reference Citation Analysis]
319 Lazarevic I, Banko A, Miljanovic D, Cupic M. Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression. Viruses 2019;11:E778. [PMID: 31450544 DOI: 10.3390/v11090778] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
320 Malek AE, Nieto Y, Szvalb AD, Siddiqui S, Shafi MA, Hwang JP, Raad II, Torres HA. Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib. Clin Lymphoma Myeloma Leuk 2020;20:e124-7. [PMID: 31932250 DOI: 10.1016/j.clml.2019.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
321 Anabire NG, Tetteh WJ, Obiri-Yaboah D, Annan I, Luuse AT, Aryee PA, Helegbe GK, Hagan OCK, Eliason S. Evaluation of hepatic and kidney dysfunction among newly diagnosed HIV patients with viral hepatitis infection in Cape Coast, Ghana. BMC Res Notes 2019;12:466. [PMID: 31366401 DOI: 10.1186/s13104-019-4513-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
322 Fan R, Zhou B, Xu M, Tan D, Niu J, Wang H, Ren H, Chen X, Wang M, Ning Q, Shi G, Sheng J, Tang H, Bai X, Liu S, Lu F, Peng J, Sun J, Xie Q, Hou J; Chronic Hepatitis B Study Consortium. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. Clin Gastroenterol Hepatol 2020;18:719-727.e7. [PMID: 31362119 DOI: 10.1016/j.cgh.2019.07.046] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 16.0] [Reference Citation Analysis]
323 Zhao M, Zou H, Chen Y, Duan Z. Mechanism and Antiviral Therapy in Preventing Mother-to-Child Transmission During Pregnancy with Hepatitis B Virus Infection. Hepat Mon 2019;19. [DOI: 10.5812/hepatmon.81903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
324 Sun SW, Liu QP, Xu X, Zhu FP, Zhang YD, Liu XS. Direct Comparison of Four Presurgical Stratifying Schemes for Prediction of Microvascular Invasion in Hepatocellular Carcinoma by Gadoxetic Acid-Enhanced MRI. J Magn Reson Imaging 2020;52:433-47. [PMID: 31943465 DOI: 10.1002/jmri.27043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
325 Wei H, Jiang HY, Li M, Zhang T, Song B. Two-dimensional shear wave elastography for significant liver fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis. Eur J Radiol 2020;124:108839. [PMID: 31981878 DOI: 10.1016/j.ejrad.2020.108839] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
326 Xiao HM, Shi MJ, Jiang JM, Cai GS, Xie YB, Tian GJ, Xue JD, Mao DW, Li Q, Yang HZ, Guo H, Lei CL, Lu W, Chen L, Liu HB, Wang J, Gao YQ, Chen JZ, Wu SD, Chen HJ, Zhao PT, Zhang CZ, Ou-Yang WW, Wen ZH, Chi XL. Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: A randomized controlled trial. J Ethnopharmacol 2022;293:115210. [PMID: 35398501 DOI: 10.1016/j.jep.2022.115210] [Reference Citation Analysis]
327 Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev 2020;33:e00035-19. [PMID: 32522746 DOI: 10.1128/CMR.00035-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
328 Feld JJ, Krassenburg LAP. What Comes First: Treatment of Viral Hepatitis or Liver Cancer? Dig Dis Sci 2019;64:1041-9. [PMID: 30874985 DOI: 10.1007/s10620-019-05518-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
329 Ekpanyapong S, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed? Clin Liver Dis. 2020;24:317-333. [PMID: 32620274 DOI: 10.1016/j.cld.2020.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
330 Niño-Sandoval TC, Rocha NS, Sarinho FW, Vasconcelos CFM, Vasconcelos AFM, Vasconcelos BC. Effect of autohemotherapy in the treatment of viral infections - a systematic review. Public Health 2021;201:78-88. [PMID: 34798327 DOI: 10.1016/j.puhe.2021.09.024] [Reference Citation Analysis]
331 Tovo CV, Ahlert M, Panke C, de Mattos ÂZ, de Mattos AA. Treatment of hepatitis B virus infection in chronic infection with HBeAg-positive adult patients (immunotolerant patients): a systematic review. Eur J Gastroenterol Hepatol 2021;33:605-9. [PMID: 32947420 DOI: 10.1097/MEG.0000000000001907] [Reference Citation Analysis]
332 Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, Wang B, Zhan S, Kong Y, Jia J, You H, Yang H. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.02.040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
333 Garcia-Garcia S, Cortese MF, Rodríguez-Algarra F, Tabernero D, Rando-Segura A, Quer J, Buti M, Rodríguez-Frías F. Next-generation sequencing for the diagnosis of hepatitis B: current status and future prospects. Expert Rev Mol Diagn 2021;21:381-96. [PMID: 33880971 DOI: 10.1080/14737159.2021.1913055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
334 Mokaya J, Burn EAO, Tamandjou CR, Goedhals D, Barnes EJ, Andersson M, Pinedo-Villanueva R, Matthews PC. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa. BMC Public Health 2019;19:829. [PMID: 31242901 DOI: 10.1186/s12889-019-7095-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
335 Li MH, Chen QQ, Zhang L, Lu HH, Sun FF, Zeng Z, Lu Y, Yi W, Xie Y. Association of cytokines with hepatitis B virus and its antigen. J Med Virol 2020. [PMID: 32662892 DOI: 10.1002/jmv.26301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
336 Mentha N, Clément S, Negro F, Alfaiate D. A review on hepatitis D: From virology to new therapies. J Adv Res 2019;17:3-15. [PMID: 31193285 DOI: 10.1016/j.jare.2019.03.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
337 Ohsaki E, Suwanmanee Y, Ueda K. Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy. Viruses 2021;13:1691. [PMID: 34578273 DOI: 10.3390/v13091691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Ogawa E, Wei MT, Nguyen MH. Hepatitis B Virus Reactivation Potentiated by Biologics. Infect Dis Clin North Am 2020;34:341-58. [PMID: 32334985 DOI: 10.1016/j.idc.2020.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
339 Lim CT, Goh GBB, Li H, Lim TK, Leow WQ, Wan WK, Azhar R, Chow WC, Kumar R. Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up. Microbiol Insights 2020;13:1178636120918878. [PMID: 32435130 DOI: 10.1177/1178636120918878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
340 Pan XB, Lu YQ, Lin SZ, Ye J, Wu N, Lou YY, Ni L, Han JC, Zheng XQ, Wei L. An Assessment of Upper Limits of Normal for ALT and the Impact on Evaluating Natural Course of Chronic Hepatitis B Virus Infection in Chinese Children. Am J Gastroenterol 2018;113:1660-8. [PMID: 30353056 DOI: 10.1038/s41395-018-0248-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
341 Haider M, Flocco G, Lopez R, Carey W. Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab. BMJ Open 2020;10:e043672. [PMID: 33323450 DOI: 10.1136/bmjopen-2020-043672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Zhang X, Zhou Y, Chen C, Fang W, Cai X, Zhang X, Zhao M, Zhang B, Jiang W, Lin Z, Ma Y, Yang Y, Huang Y, Zhao H, Xu R, Hong S, Zhang L. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer 2019;7:322. [PMID: 31753012 DOI: 10.1186/s40425-019-0808-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 13.7] [Reference Citation Analysis]
343 Yuen MF, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, Thompson AJ, Given BD, Schluep T, Hamilton J, Biermer M, Kalmeijer R, Beumont M, Lenz O, De Ridder F, Cloherty G, Wong DK, Schwabe C, Jackson K, Lai CL, Gish RG, Gane E. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol 2022:S0168-8278(22)02941-5. [PMID: 35870702 DOI: 10.1016/j.jhep.2022.07.010] [Reference Citation Analysis]
344 Suliman I, Abdelgelil N, Kassamali F, Hassanein TI. The Effects of Hepatic Steatosis on the Natural History of HBV Infection. Clin Liver Dis. 2019;23:433-450. [PMID: 31266618 DOI: 10.1016/j.cld.2019.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
345 Ma JL, He LL, Jiang Y, Yang JR, Li P, Zang Y, Wei HS. New model predicting gastroesophageal varices and variceal hemorrhage in patients with chronic liver disease. Ann Hepatol 2020;19:287-94. [PMID: 32197976 DOI: 10.1016/j.aohep.2019.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
346 Zhou K, Terrault NA. Gaps in Viral Hepatitis Awareness in the United States in a Population-based Study. Clin Gastroenterol Hepatol 2020;18:188-195.e4. [PMID: 31173892 DOI: 10.1016/j.cgh.2019.05.047] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
347 Yu JH, Suh YJ, Jin YJ, Heo NY, Jang JW, You CR, An HY, Lee JW. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir. Eur J Gastroenterol Hepatol. 2019;31:865-872. [PMID: 30694912 DOI: 10.1097/meg.0000000000001357] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
348 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
349 Wang C, Ma C, Gong L, Dai S, Li Y. Preventive and therapeutic role of betaine in liver disease: A review on molecular mechanisms. Eur J Pharmacol 2021;912:174604. [PMID: 34743980 DOI: 10.1016/j.ejphar.2021.174604] [Reference Citation Analysis]
350 Wang T, Smith DA, Campbell C, Mokaya J, Freeman O, Salih H, McNaughton AL, Cripps S, Várnai KA, Noble T, Woods K, Collier J, Jeffery K, Davies J, Barnes E, Matthews PC. Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study. BMC Infect Dis 2021;21:610. [PMID: 34174833 DOI: 10.1186/s12879-021-06226-0] [Reference Citation Analysis]
351 Koffas A, Petersen J, Kennedy PT. Reasons to consider early treatment in chronic hepatitis B patients. Antiviral Res 2020;177:104783. [PMID: 32217150 DOI: 10.1016/j.antiviral.2020.104783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
352 Kumar M, Abbas Z, Azami M, Belopolskaya M, Dokmeci AK, Ghazinyan H, Jia J, Jindal A, Lee HC, Lei W, Lim SG, Liu CJ, Li Q, Al Mahtab M, Muljono DH, Niriella MA, Omata M, Payawal DA, Sarin SK, Ségéral O, Tanwandee T, Trehanpati N, Visvanathan K, Yang JM, Yuen MF, Zheng Y, Zhou YH. Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy. Hepatol Int 2022. [PMID: 35113359 DOI: 10.1007/s12072-021-10285-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
353 Chi X, Jiang L, Yuan Y, Huang X, Yang X, Hochwald S, Liu J, Huang H. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02279-w] [Reference Citation Analysis]
354 Lan W, Wang Y, Zhou Z, Sun X, Zhang Y, Zhang F. Metabolic Regulation of Hepatitis B Virus Infection in HBV-Transgenic Mice. Metabolites 2022;12:287. [DOI: 10.3390/metabo12040287] [Reference Citation Analysis]
355 Kumada T, Toyoda H, Tada T, Yasuda S, Tanaka J. Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. Liver Cancer 2020;9:518-28. [PMID: 33083278 DOI: 10.1159/000507933] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
356 Bollinger RC, Thio CL, Sulkowski MS, McKenzie-White J, Thomas DL, Flexner C. Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. Lancet HIV 2020;7:e443-8. [PMID: 31870675 DOI: 10.1016/S2352-3018(19)30342-X] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
357 Liu CH, Shih YL, Yang SS, Lin CL, Fang YJ, Cheng PN, Chen CY, Peng CY, Hsieh TY, Chiu YC, Su TH, Liu CJ, Yang HC, Chen PJ, Chen DS, Kao JH. Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. J Gastroenterol Hepatol 2019;34:1977-83. [PMID: 30931537 DOI: 10.1111/jgh.14672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
358 Lin SR, Yang TY, Peng CY, Lin YY, Dai CY, Wang HY, Su TH, Tseng TC, Liu IJ, Cheng HR, Shen YC, Wu FY, Liu CJ, Chen DS, Chen PJ, Yang HC, Kao JH. Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. JHEP Rep 2021;3:100254. [PMID: 33870157 DOI: 10.1016/j.jhepr.2021.100254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
359 Bae SK, Arita J, Akamatsu N, Maki H, Nishioka Y, Kawahara T, Miyata A, Kokudo T, Nagata R, Mihara Y, Ichida A, Inagaki Y, Kawaguchi Y, Ishizawa T, Kaneko J, Tamura S, Tanaka Y, Moriya K, Hasegawa K. The impact of the covalently closed circular DNA level on recurrence of hepatocellular carcinoma after initial hepatectomy: An analysis of patients with resolved hepatitis B virus infection. HPB 2022. [DOI: 10.1016/j.hpb.2022.06.013] [Reference Citation Analysis]
360 Meier-Stephenson V, Badmalia MD, Mrozowich T, Lau KCK, Schultz SK, Gemmill DL, Osiowy C, van Marle G, Coffin CS, Patel TR. Identification and characterization of a G-quadruplex structure in the pre-core promoter region of hepatitis B virus covalently closed circular DNA. J Biol Chem 2021;296:100589. [PMID: 33774051 DOI: 10.1016/j.jbc.2021.100589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
361 Jo HS, Khan JF, Han JH, Yu YD, Kim DS. Efficacy and Safety of Hepatitis B Virus Vaccination Following Hepatitis B Immunoglobulin Withdrawal After Liver Transplantation. Transplant Proc 2021:S0041-1345(21)00736-3. [PMID: 34740450 DOI: 10.1016/j.transproceed.2021.09.038] [Reference Citation Analysis]
362 Henriquez-Camacho C, Serre N, Norman F, Sánchez-Montalvá A, Torrús D, Goikoetxea AJ, Herrero-Martínez JM, Ruiz-Giardín JM, Treviño B, Monge-Maillo B, Molina I, Rodríguez A, García M, López-Vélez R, Pérez-Molina JA; Redivi Study Group. Clinicoepidemiological characteristics of viral hepatitis in migrants and travellers of the +Redivi network. Travel Med Infect Dis 2019;29:51-7. [PMID: 30738196 DOI: 10.1016/j.tmaid.2019.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
363 Tao YC, Chen EQ. Rely to: 'Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues'. J Viral Hepat 2021;28:221-2. [PMID: 32853403 DOI: 10.1111/jvh.13390] [Reference Citation Analysis]
364 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Reference Citation Analysis]
365 Hecker C, Welponer T, Herold M, Trinka E, Broussalis E, Killer-Oberpfalzer M. Update on treatment strategies for vasculitis affecting the central nervous system. Drug Discov Today 2021:S1359-6446(21)00501-8. [PMID: 34838730 DOI: 10.1016/j.drudis.2021.11.020] [Reference Citation Analysis]
366 Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxf) 2019;7:231-45. [PMID: 32477569 DOI: 10.1093/gastro/goz023] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
367 Phung TTB, Chu SV, Vu ST, Pham HT, Nguyen HM, Nguyen HD, Le NT, Nguyen DV, Truong PT, Vu VTT, Nguyen ATV. COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B. Diagnostics (Basel) 2020;10:E491. [PMID: 32708399 DOI: 10.3390/diagnostics10070491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
368 Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol 2021; 27(19): 2312-2324 [PMID: 34040324 DOI: 10.3748/wjg.v27.i19.2312] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
369 Li J, Cheung RC, Nguyen MH. Letter to the Editor: Chronic Hepatitis B and Nonalcoholic Steatohepatitis: Is "Fat" All Bad? Hepatology 2020;71:768. [PMID: 31595532 DOI: 10.1002/hep.30983] [Reference Citation Analysis]
370 Lu J, Zhang C, He P, Ou M, Xia J, Huang M. Risk factors for very low-level viremia in patients with chronic hepatitis B virus infection: A single-center retrospective study. Liver Research 2022. [DOI: 10.1016/j.livres.2022.02.001] [Reference Citation Analysis]
371 Shen Z, Gao Z, Gu C, Wu J, Wang J, Zhang J, Xie Y, Liu J. Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence. Antiviral Res 2021;190:105076. [PMID: 33865876 DOI: 10.1016/j.antiviral.2021.105076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Chen Y, Li Y, Li N, Fan X, Li C, Zhang P, Han Q, Liu Z. A Noninvasive Score to Predict Liver Fibrosis in HBeAg-Positive Hepatitis B Patients with Normal or Minimally Elevated Alanine Aminotransferase Levels. Dis Markers 2018;2018:3924732. [PMID: 30405859 DOI: 10.1155/2018/3924732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
373 Liu R, Guo J, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Li M, Xie Y. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. Clin Exp Med 2019;19:309-20. [PMID: 31111345 DOI: 10.1007/s10238-019-00560-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
374 Shih YF, Liu CJ. Hepatitis C Virus and Hepatitis B Virus Co-Infection. Viruses 2020;12:E741. [PMID: 32664198 DOI: 10.3390/v12070741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
375 Sbarigia U, Kariburyo F, Sah J, Colasurdo J, Xie L, Katz EG, Sylvester S. Evaluating the Effect of Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the United States Veterans Population. Adv Ther 2020;37:1156-72. [PMID: 32009232 DOI: 10.1007/s12325-020-01240-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
376 Xu C, Yi Y, Xie Z, Zhu D, Abuduwaili D, Wang Z, Xi Y. Platelets, mean platelet volume, lymphocytes, leukocytes, and ratios of them altered in patients with hepatitis B virus‐related decompensated cirrhosis. Precision Medical Sciences. [DOI: 10.1002/prm2.12070] [Reference Citation Analysis]
377 Kwon JH. The Role of Serum HBV-RNA Levels as a Marker of Intrahepatic Viral and Histologic Activity. Korean J Gastroenterol 2018;71:297-9. [PMID: 29791991 DOI: 10.4166/kjg.2018.71.5.297] [Reference Citation Analysis]
378 Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. Sci Rep 2019;9:2508. [PMID: 30792468 DOI: 10.1038/s41598-019-39043-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
379 Zhou K, Dodge JL, Grab J, Poltavskiy E, Terrault NA. Mortality in adults with chronic hepatitis B infection in the United States: a population-based study. Aliment Pharmacol Ther 2020;52:382-9. [PMID: 32432816 DOI: 10.1111/apt.15803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
380 Wong T, Bloom RD. Management and treatment of the HCV-infected kidney transplant patient. Semin Dial 2019;32:169-78. [PMID: 30536995 DOI: 10.1111/sdi.12766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
381 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model. Eur J Gastroenterol Hepatol 2019;31:1452-9. [PMID: 31082998 DOI: 10.1097/MEG.0000000000001434] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
382 Kikuchi M, Sawabe M, Aoyagi H, Wakae K, Watashi K, Hattori S, Kawabe N, Yoshioka K, Tanaka J, Muramatsu M, Wakita T, Aizaki H. Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers. Hepatol Int 2021. [PMID: 34855104 DOI: 10.1007/s12072-021-10269-5] [Reference Citation Analysis]
383 Sasadeusz J, Grigg A, Hughes PD, Lim SL, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies. Clin Liver Dis 2019;23:511-9. [PMID: 31266624 DOI: 10.1016/j.cld.2019.04.011] [Reference Citation Analysis]
384 Liu Z, Zhang Y, Xu M, Li X, Zhang Z. Distribution of hepatitis B virus genotypes and subgenotypes: A meta-analysis. Medicine (Baltimore) 2021;100:e27941. [PMID: 34918643 DOI: 10.1097/MD.0000000000027941] [Reference Citation Analysis]
385 Jaroenlapnopparat A, Chayanupatkul M, Tangkijvanich P. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review. J Gastroenterol Hepatol 2021. [PMID: 33811375 DOI: 10.1111/jgh.15516] [Reference Citation Analysis]
386 Lee KC, Cheng JS, Chang ML, Chien RN, Liaw YF. Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study. Hepatol Int 2022. [PMID: 35699864 DOI: 10.1007/s12072-022-10357-0] [Reference Citation Analysis]
387 McGrath B, Broadhurst M, Roman C. Infectious disease considerations in immunocompromised patients. JAAPA 2020;33:16-25. [PMID: 32841972 DOI: 10.1097/01.JAA.0000694948.01963.f4] [Reference Citation Analysis]
388 Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol. 2019;16:631-641. [PMID: 31477873 DOI: 10.1038/s41575-019-0197-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
389 Buti M, Riveiro-Barciela M, Esteban R. Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. Clin Liver Dis 2021;25:725-40. [PMID: 34593150 DOI: 10.1016/j.cld.2021.06.003] [Reference Citation Analysis]
390 Calabrese C. Vaccinations in Patients with Rheumatic Disease: Consider Disease and Therapy. Med Clin North Am 2021;105:213-25. [PMID: 33589098 DOI: 10.1016/j.mcna.2020.09.008] [Reference Citation Analysis]
391 Cheung KW, Seto MTY, Lao TT. Prevention of perinatal hepatitis B virus transmission. Arch Gynecol Obstet 2019;300:251-9. [PMID: 31098821 DOI: 10.1007/s00404-019-05190-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
392 Zhang ZQ, Shi BS, Lu W, Huang D, Wang YB, Feng YL. Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection. J Virol Methods 2021;296:114226. [PMID: 34217779 DOI: 10.1016/j.jviromet.2021.114226] [Reference Citation Analysis]
393 Mubarak G, Ferstenberg R. The Efficacy of Tenofovir to Prevent Perinatal Transmission in Chronic Hepatitis B Mothers. A Clinical Perspective. Hepatology 2018;68:1658. [PMID: 30070723 DOI: 10.1002/hep.30138] [Reference Citation Analysis]
394 Coffin CS, Zhou K, Terrault NA. New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology 2019;156:355-368.e3. [PMID: 30472225 DOI: 10.1053/j.gastro.2018.11.037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
395 Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, Wu W, Liu Y, Chen Y, Zhang Z, Li J, Huang R, Wu C. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat 2021;28:1025-33. [PMID: 33797145 DOI: 10.1111/jvh.13511] [Reference Citation Analysis]
396 Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol 2021:S0168-8278(21)02087-0. [PMID: 34606915 DOI: 10.1016/j.jhep.2021.09.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
397 Shiffman ML. Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver Int 2020;40 Suppl 1:22-6. [PMID: 32077612 DOI: 10.1111/liv.14359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
398 Joshi SS, Coffin CS. Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics. Hepatol Commun. 2020;4:157-171. [PMID: 32025602 DOI: 10.1002/hep4.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
399 Yardeni D, Ghany MG. Review article: hepatitis B-current and emerging therapies. Aliment Pharmacol Ther 2022;55:805-19. [PMID: 35224760 DOI: 10.1111/apt.16828] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
400 Khadka S, Pandit R, Dhital S, Baniya JB, Tiwari S, Shrestha B, Pandit S, Sato F, Fujita M, Sharma M, Tsunoda I, Mishra SK. Evaluation of Five International HBV Treatment Guidelines: Recommendation for Resource-Limited Developing Countries Based on the National Study in Nepal. Pathophysiology 2020;27:3-13. [PMID: 34321716 DOI: 10.3390/pathophysiology27010002] [Reference Citation Analysis]
401 Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: An Update on Evidence-Based Management. Obstet Gynecol Surv. 2020;75:557-565. [PMID: 32997148 DOI: 10.1097/ogx.0000000000000831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
402 McMahon BJ, Nolen LD, Snowball M, Homan C, Negus S, Roik E, Spradling PR, Bruden D. HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study. Hepatology 2021;74:2965-73. [PMID: 34292609 DOI: 10.1002/hep.32065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
403 Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Rep 2021;3:100290. [PMID: 34041470 DOI: 10.1016/j.jhepr.2021.100290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Park JS, Gayam V, Pan CQ. Review article: preventing hepatitis B graft infection in hepatitis B patients after liver transplantation: immunoglobulin vs anti-virals. Aliment Pharmacol Ther. 2020;52:944-954. [PMID: 32743822 DOI: 10.1111/apt.15999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
405 Tu Y, Chen D, Pan T, Chen Z, Xu J, Jin L, Sheng L, Jin X, Wang X, Lan X, Ge Y, Sun H, Chen Y. Inhibition of miR-431-5p attenuated liver apoptosis through KLF15/p53 signal pathway in S100 induced autoimmune hepatitis mice. Life Sci 2021;280:119698. [PMID: 34111466 DOI: 10.1016/j.lfs.2021.119698] [Reference Citation Analysis]
406 Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS;  Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71:397-408. [PMID: 31004683 DOI: 10.1016/j.jhep.2019.03.034] [Cited by in Crossref: 113] [Cited by in F6Publishing: 107] [Article Influence: 37.7] [Reference Citation Analysis]
407 Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, Marcinak JF, Lewis JH, Anania FA, Seekins D, Shneider BL, Chalasani N. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther. 2020;51:90-109. [PMID: 31762074 DOI: 10.1111/apt.15579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
408 Charatcharoenwitthaya P, Kaewdech A, Piratvisuth T. Controversies in Treating Chronic HBV: The Role of PEG-interferon-alfa. Clin Liver Dis 2021;25:741-62. [PMID: 34593151 DOI: 10.1016/j.cld.2021.06.004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
409 Zhang WB, Hou SZ, Chen YL, Mao F, Dong Y, Chen JG, Wang WP. Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of α-Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients. Front Oncol 2022;12:862297. [PMID: 35720017 DOI: 10.3389/fonc.2022.862297] [Reference Citation Analysis]
410 Tseng TC, Choi J, Nguyen MH, Peng CY, Siakavellas S, Papatheodoridis G, Wang CC, Lim YS, Lai HC, Trinh HN, Wong C, Wong C, Zhang J, Li J, Kao JH. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hepatol Int 2021;15:105-13. [PMID: 33547557 DOI: 10.1007/s12072-020-10124-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
411 Lee AU, Lee C. Hepatitis D Review: Challenges for the Resource-Poor Setting. Viruses 2021;13:1912. [PMID: 34696341 DOI: 10.3390/v13101912] [Reference Citation Analysis]
412 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
413 Wübbolding M, Lopez Alfonso JC, Lin CY, Binder S, Falk C, Debarry J, Gineste P, Kraft ARM, Chien RN, Maasoumy B, Wedemeyer H, Jeng WJ, Meyer Hermann M, Cornberg M, Höner Zu Siederdissen C. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB. Hepatol Commun 2021;5:97-111. [PMID: 33437904 DOI: 10.1002/hep4.1626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
414 Wang JH. Application of Ultrasound Liver Elastography to the Diagnosis and Monitoring of Liver Disease. J Med Ultrasound 2019;27:1-2. [PMID: 31031528 DOI: 10.4103/JMU.JMU_108_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
415 Chang M, Fischler B, Blauvelt B, Ciocca M, Dhawan A, Ekong U, Ni Y, Porta G, Sibal A, Dagostino D, Wirth S, Morhan N, Schwarz KB. Survey of Impediments to Prevention of Mother-to-infant Transmission of Hepatitis B Virus by International Societies. Journal of Pediatric Gastroenterology & Nutrition 2019;69:648-54. [DOI: 10.1097/mpg.0000000000002483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
416 Jacob R, Danta M. Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection. Expert Opin Pharmacother 2021;:1-8. [PMID: 34937470 DOI: 10.1080/14656566.2021.2019708] [Reference Citation Analysis]
417 Li R, Lin X, Wang JY, Wang X, Lu J, Liu Y, Cao Z, Ren S, Ma L, Jin Y, Zheng S, Hu Z, Wang L, Chen X. Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. Ann Transl Med 2021;9:1365. [PMID: 34733917 DOI: 10.21037/atm-21-1666] [Reference Citation Analysis]
418 Su PY, Su WW, Hsu YC, Huang SP, Yen HH. Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study. PeerJ 2021;9:e12527. [PMID: 34820208 DOI: 10.7717/peerj.12527] [Reference Citation Analysis]
419 Schmitz JE, Stratton CW, Persing DH, Tang Y, Mcadam AJ. Forty Years of Molecular Diagnostics for Infectious Diseases. J Clin Microbiol. [DOI: 10.1128/jcm.02446-21] [Reference Citation Analysis]
420 Scavone D, Lauzi S, Stranieri A, Tramontano G, Ratti G, Paltrinieri S. Evaluating the presence of domestic cat hepadnavirus viraemia in cats with biochemical alterations suggestive of liver disease. Vet Rec 2022;:e1626. [PMID: 35393638 DOI: 10.1002/vetr.1626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
421 Barone M, Venerito V, Paolillo R, Emmi G, Fornaro M, Cacciapaglia F, Cantarini L, Di Leo A, Iannone F, Lopalco G. Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection. Intern Emerg Med 2021. [PMID: 34476737 DOI: 10.1007/s11739-021-02836-3] [Reference Citation Analysis]
422 Wang Z, Wen P, Hu B, Cao S, Shi X, Guo W, Zhang S. Dopamine and dopamine receptor D1 as a novel favourable biomarker for hepatocellular carcinoma. Cancer Cell Int 2021;21:586. [PMID: 34717619 DOI: 10.1186/s12935-021-02298-9] [Reference Citation Analysis]
423 Tufon KA, Anong DN, Meriki HD, Georges TD, Maurice M, Kouanou YS, Bolimo AF, Tony NJ, Kwenti TE, Wung NH, Nkuo-Akenji T. Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon. PLoS One 2018;13:e0203312. [PMID: 30183765 DOI: 10.1371/journal.pone.0203312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
424 Jourdain G, Ngo-Giang-Huong N, Khamduang W. Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications. Infect Drug Resist 2019;12:977-87. [PMID: 31118703 DOI: 10.2147/IDR.S171695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
425 Nagra N, Kozarek RA, Burman BE. Therapeutic Advances in Viral Hepatitis A-E. Adv Ther 2022;39:1524-52. [PMID: 35220557 DOI: 10.1007/s12325-022-02070-z] [Reference Citation Analysis]
426 Yin XR, Liu ZH, Liu J, Liu YY, Xie L, Tao LB, Jia JD, Cui FQ, Zhuang GH, Hou JL. First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China. Chin Med J (Engl) 2019;132:2315-24. [PMID: 31567376 DOI: 10.1097/CM9.0000000000000445] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
427 Yang X, Zhong X, Liao H, Lai Y. Efficacy of antiviral therapy during the second or the third trimester for preventing mother-to-child hepatitis B virus transmission: a systematic review and meta-analysis. Rev Inst Med Trop Sao Paulo 2020;62:e13. [PMID: 32074216 DOI: 10.1590/S1678-9946202062013] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
428 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
429 Li L, Li B, Zhang M. HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion. Medicine (Baltimore) 2019;98:e16308. [PMID: 31277172 DOI: 10.1097/MD.0000000000016308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
430 Tsuruoka M, Inoue J, Onishi Y, Ninomiya M, Kakazu E, Iwata T, Sano A, Sato K, Harigae H, Masamune A. Hepatitis B Virus Reactivation with Discontinuation of Nucleoside Analogue in Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation. Case Rep Gastroenterol 2021;15:178-87. [PMID: 33708067 DOI: 10.1159/000512397] [Reference Citation Analysis]
431 Zhang J, Venkat D. Frequent Offenders and Patterns of Injury. Clin Liver Dis 2020;24:37-48. [PMID: 31753249 DOI: 10.1016/j.cld.2019.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
432 Miao J, Yang X, Shang X, Gao Z, Li Q, Hong Y, Wu J, Meng T, Yuan H, Hu F. Hepatocyte-targeting and microenvironmentally responsive glycolipid-like polymer micelles for gene therapy of hepatitis B. Mol Ther Nucleic Acids 2021;24:127-39. [PMID: 33738144 DOI: 10.1016/j.omtn.2021.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
433 Shah P, Sundaram V, Björnsson E. Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review. Hepatol Commun 2020;4:172-84. [PMID: 32025603 DOI: 10.1002/hep4.1465] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
434 Yoshida K, Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. Int J Mol Sci 2021;22:1456. [PMID: 33535672 DOI: 10.3390/ijms22031456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
435 Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, Ooho A, Satoh T, Kawano A, Kajiwara E, Takahashi K, Azuma K, Kato M, Shimoda S, Hayashi J;  Kyushu University Liver Disease Study (KULDS) Group. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578-1589. [PMID: 32304611 DOI: 10.1111/liv.14482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
436 Poiteau L, Wlassow M, Hézode C, Pawlotsky JM, Chevaliez S. Evaluation of the Xpert HBV Viral Load for hepatitis B virus molecular testing. J Clin Virol 2020;129:104481. [PMID: 32512377 DOI: 10.1016/j.jcv.2020.104481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
437 Miao J, Gao P, Li Q, He K, Zhang L, Wang J, Huang L. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int J Mol Sci 2021;22:11227. [PMID: 34681886 DOI: 10.3390/ijms222011227] [Reference Citation Analysis]
438 Kuo MH, Tseng C, Lee C, Yang Y, Wu H, Lin H, Chu Y, Chen Y, Tseng K. Identification and management of contraindicated drug–drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy. Journal of the Formosan Medical Association 2021. [DOI: 10.1016/j.jfma.2021.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
439 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
440 Xu H, Li X, Wu Z, Zhao L, Shen J, Liu J, Qin J, Shen Y, Ke J, Wei Y, Li J, Gao Y. LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB. Front Mol Biosci 2021;8:749648. [PMID: 34631799 DOI: 10.3389/fmolb.2021.749648] [Reference Citation Analysis]
441 Wang J, Zhang Q, Ai J, Liu D, Liu C, Xiang H, Gu Y, Guo Y, Lv J, Huang Y, Liu Y, Xu D, Chen S, Li J, Li Q, Liang J, Bian L, Zhang Z, Guo X, Feng Y, Liu L, Zhang X, Zhang Y, Xie F, Jiang S, Qin W, Wang X, Rao W, Zhang Q, Tian Q, Zhu Y, Cong Q, Xu J, Hou Z, Zhang N, Zhang A, Zu H, Wang Y, Yan Z, Du X, Hou A, Yan Y, Qiu Y, Wu H, Hu S, Deng Y, Ji J, Yang J, Huang J, Zhao Z, Zou S, Ji H, Ge G, Zhong L, He S, Yan X, Yangzhen BB, Qu C, Zhang L, Yang S, Gao X, Lv M, Zhu Q, Xu X, Zeng Q, Qi X, Zhang W. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int. [DOI: 10.1007/s12072-022-10332-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Kim HN. Chronic Hepatitis B and HIV Coinfection: A Continuing Challenge in the Era of Antiretroviral Therapy. Curr Hepatol Rep 2020;19:345-53. [PMID: 33796434 DOI: 10.1007/s11901-020-00541-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Nhu QM, Pockros PJ. Editorial: chronic hepatitis B combination therapy-emerging success as proof-of-concept for future hepatitis B eradication? Aliment Pharmacol Ther 2018;47:1560-1. [PMID: 29878430 DOI: 10.1111/apt.14680] [Reference Citation Analysis]
444 Toka B, Eminler AT, Gönüllü E, Tozlu M, Uslan MI, Parlak E, Karabay O, Koksal AS. Rheumatologists’ awareness of hepatitis B reactivation before immunosuppressive therapy. Rheumatol Int 2019;39:2077-85. [DOI: 10.1007/s00296-019-04437-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
445 Hercun J, Koh C, Heller T. Hepatitis Delta. Gastroenterology Clinics of North America 2020;49:239-52. [DOI: 10.1016/j.gtc.2020.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
446 Kakuda TN, Yogaratnam JZ, Westland C, Gane EJ, Schwabe C, Vuong J, Patel M, Snoeys J, Talloen W, Lenz O, Fry J, Chanda S, van Remoortere P. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers. Antiviral Therapy 2021;26:13-24. [DOI: 10.1177/13596535211044331] [Reference Citation Analysis]
447 Wu CCH, Kumar R. Hepatitis B reactivation in patients with hepatitis B core antibody positive and surface antigen negative on immunosuppressants. World J Meta-Anal 2019; 7(5): 209-217 [DOI: 10.13105/wjma.v7.i5.209] [Reference Citation Analysis]
448 Ramírez Mena A, Tine JM, Fortes L, Ndiaye O, Ka D, Ngom NF, Ramette A, Bittel P, Seydi M, Wandeler G; for SEN-B. Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal. J Viral Hepat 2021. [PMID: 34610183 DOI: 10.1111/jvh.13615] [Reference Citation Analysis]
449 Li J, Zhang D, Zhang X. The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report. Infect Drug Resist 2021;14:1013-7. [PMID: 33758517 DOI: 10.2147/IDR.S295060] [Reference Citation Analysis]
450 Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
451 Lim YS, Gwak GY, Choi J, Lee YS, Byun KS, Kim YJ, Yoo BC, Kwon SY, Lee HC. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. J Hepatol 2019;71:35-44. [PMID: 30876946 DOI: 10.1016/j.jhep.2019.02.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
452 Ergen P, Yilmaz Karadağ F. Approach to women who become pregnant while on tenofovir disoproxil fumarate for chronic B hepatitis: A report of two cases. J Obstet Gynaecol Res 2020;46:779-83. [PMID: 32128941 DOI: 10.1111/jog.14224] [Reference Citation Analysis]
453 Huang C, Shen D, Sun S, Huang Y, Xin Y, Luo H, Chen Y, Zhou Z, Liu F, Chen X. Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies. Medicine (Baltimore) 2019;98:e15297. [PMID: 31027094 DOI: 10.1097/MD.0000000000015297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
454 Chen Y, Wang Y, Chen Y, Yu Z, Chi X, Hu KQ, Li Q, Tan L, Xiang D, Shang Q, Lei C, Chen L, Hu X, Wang J, Liu H, Lu W, Chi W, Dong Z, Wang X, Li Z, Xiao H, Chen D, Bai W, Zhang C, Xiao G, Qi X, Chen J, Zhou L, Sun H, Deng M, Qi X, Zhang Z, Qi X, Yang Y. A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B. Clin Transl Gastroenterol 2019;10:1-12. [PMID: 31033506 DOI: 10.14309/ctg.0000000000000033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
455 Wang W, Jia R, Gao Y, Liu J, Luan J, Qiao F, Liu L, Zhang X, Wang F, Fu J. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients. Front Immunol 2022;13:894410. [DOI: 10.3389/fimmu.2022.894410] [Reference Citation Analysis]
456 Lee J, Lee JG, Hwang S, Lee K, Kim JM, Ryu JH, Kim B, Choi DL, You YK, Kim D, Nah YW, Kang KJ, Cho JY, Yu HC, Hong G, Choi D, Moon JI, Kim MS. Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study. Hepatol Int. [DOI: 10.1007/s12072-022-10320-z] [Reference Citation Analysis]
457 Roger S, Lefeuvre C, Grison M, Ducancelle A, Lunel-Fabiani F, Pivert A, Le Guillou-Guillemette H. Evaluation of the Aptima™ HBV Quant Dx assay for semi-quantitative HBV viral load from dried blood spots. J Clin Virol 2020;129:104524. [PMID: 32629186 DOI: 10.1016/j.jcv.2020.104524] [Reference Citation Analysis]
458 Tran S, Jeong D, Henry L, Cheung RC, Nguyen MH. Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. Am J Gastroenterol 2021;116:1885-95. [PMID: 33927125 DOI: 10.14309/ajg.0000000000001271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
459 Pereira SL, Duro R, Sarmento A. Late Hepatitis B reactivation after treatment with rituximab. IDCases 2022;27:e01393. [DOI: 10.1016/j.idcr.2022.e01393] [Reference Citation Analysis]
460 Lee DH. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2020;35:243-59. [PMID: 32615709 DOI: 10.3803/EnM.2020.35.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
461 Zhang S, Sang X, Hou D, Chen J, Gu H, Zhang Y, Li J, Yang D, Zhu H, Yang X, Wang F, Zhang C, Chen X, Zen K, Zhang C, Hong Z. Plant-derived RNAi therapeutics: A strategic inhibitor of HBsAg. Biomaterials 2019;210:83-93. [DOI: 10.1016/j.biomaterials.2019.04.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
462 Fang Y, Xu X, Hou F, Jia W. A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients. Antiviral Therapy 2021;26:126-33. [DOI: 10.1177/13596535211059895] [Reference Citation Analysis]
463 Cheng CW, Feng CM, Chua CS. Help-Seeking Experiences of Hepatitis B Patients in Transnational Medical Care: The Solution to Health Inequality Is Social Mobility. Healthcare (Basel) 2019;7:E125. [PMID: 31683636 DOI: 10.3390/healthcare7040125] [Reference Citation Analysis]
464 Wani MA, Sodhi JS, Yatoo GN, Shah A, Geelani S, Zargar SA, Gulzar GM, Khan M, Aziz SA. Clinical Profile and Efficacy of Antivirals in Hepatitis B Virus Reactivation, in Patients With Cancer Receiving Chemotherapy. J Clin Exp Hepatol 2020;10:590-8. [PMID: 33311896 DOI: 10.1016/j.jceh.2020.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
465 Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Reply to Soriano, Gómez-Gallego, and Corral. Clin Infect Dis 2019;69:1834-5. [PMID: 30943282 DOI: 10.1093/cid/ciz274] [Reference Citation Analysis]
466 Zhong S, Zhang T, Tang L, Li Y. Cytokines and Chemokines in HBV Infection. Front Mol Biosci 2021;8:805625. [PMID: 34926586 DOI: 10.3389/fmolb.2021.805625] [Reference Citation Analysis]
467 Li EM, Xiao LX, Xu Z, Mo ZS, Li JQ, Mei YY, Lin CS. Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy. BMC Pregnancy Childbirth 2021;21:551. [PMID: 34384374 DOI: 10.1186/s12884-021-04020-z] [Reference Citation Analysis]
468 Toy M, Hutton D, McCulloch K, Romero N, Revill PA, Penicaud MC, So S, Cowie BC. The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia. Liver Int 2021. [PMID: 34328697 DOI: 10.1111/liv.15027] [Reference Citation Analysis]
469 Lee YS, Lee HS, Kim JH, Chang SW, Hyun MH, Bak H, Kim S, Lee MJ, Lee CU, Jung YK, Seo YS, Yim HJ, Yeon JE, Um SH, Byun KS. Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis. Korean J Intern Med 2021;36:76-85. [PMID: 31878771 DOI: 10.3904/kjim.2018.465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
470 Thompson KA, Blank G, Toy J, Moore DM, Lachowsky N, Bacani N, Zhang W, Sereda P, Lima VD, Barrios R, Montaner JSG, Hull MW. Chronic Hepatitis B Infection Among Preexposure Prophylaxis Users Enrolled in a Population-Based Program in British Columbia, Canada. Open Forum Infect Dis 2021;8:ofab492. [PMID: 34805433 DOI: 10.1093/ofid/ofab492] [Reference Citation Analysis]
471 Zhang M, Fu S, Ren D, Wu Y, Yao N, Ni T, Feng Y, Chen Y, Chen T, Zhao Y, Liu J. Maternal and Fetal Outcomes After Interferon Exposure During Pregnancy: A Systematic Review With Meta-Analysis. Front Reprod Health 2021;3:702929. [DOI: 10.3389/frph.2021.702929] [Reference Citation Analysis]
472 Dong XQ, Wu Z, Zhao H, Wang GQ; China HepB-Related Fibrosis Assessment Research Group. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients. J Viral Hepat 2019;26:297-307. [PMID: 30380170 DOI: 10.1111/jvh.13031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
473 Canzoni M, Marignani M, Sorgi ML, Begini P, Biondo MI, Caporuscio S, Colonna V, Casa FD, Conigliaro P, Marrese C, Celletti E, Modesto I, Peragallo MS, Laganà B, Picchianti-Diamanti A, Rosa RD, Ferlito C, Salemi S, D'Amelio R, Stroffolini T. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. Microorganisms 2020;8:E1792. [PMID: 33207663 DOI: 10.3390/microorganisms8111792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
474 Tout I, Loureiro D, Mansouri A, Soumelis V, Boyer N, Asselah T. Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development. J Hepatol. 2020;73:409-422. [PMID: 32333923 DOI: 10.1016/j.jhep.2020.04.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
475 Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis 2021;8:2049936120985954. [PMID: 33614029 DOI: 10.1177/2049936120985954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
476 Ziogas DC, Kostantinou F, Cholongitas E, Anastasopoulou A, Diamantopoulos P, Haanen J, Gogas H. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. J Immunother Cancer 2020;8:e000943. [PMID: 33067316 DOI: 10.1136/jitc-2020-000943] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
477 Diao Y, Hu D, Hu X, Wang P, Wang X, Luo X, Wang H, Ning Q. The Role of Metabolic Factors and Steatosis in Treatment-Naïve Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase. Infect Dis Ther. [DOI: 10.1007/s40121-022-00629-5] [Reference Citation Analysis]
478 Fontana RJ, Avigan MI, Janssen HLA, Regev A, Mishra P, Gaggar A, Brown N, Wat C, Mendez P, Anderson RT, Given B, Miller V, Beumont M. Liver safety assessment in clinical trials of new agents for chronic hepatitis B. J Viral Hepat 2020;27:96-109. [PMID: 31828894 DOI: 10.1111/jvh.13223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
479 Zhou Y, Li J, Gordon SC, Trudeau S, Rupp LB, Boscarino JA, Daida YG, Schmidt MA, Lu M. Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States. J Viral Hepat 2021. [PMID: 34905259 DOI: 10.1111/jvh.13639] [Reference Citation Analysis]
480 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Reference Citation Analysis]
481 Inoue J, Akahane T, Kobayashi T, Obara N, Umetsu T, Kakazu E, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Sato K, Masamune A. Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis B patients: A pilot randomized controlled study. Biomed Rep 2021;14:20. [PMID: 33335726 DOI: 10.3892/br.2020.1396] [Reference Citation Analysis]
482 Tziomalos K, Neokosmidis G, Mavromatidis G, Dinas K. Novel insights in the prevention of perinatal transmission of hepatitis B. World J Hepatol 2018; 10(11): 795-798 [PMID: 30533180 DOI: 10.4254/wjh.v10.i11.795] [Reference Citation Analysis]
483 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
484 Feng J, Tang YN, Zhou LX, Pan JS. Standardized Nursing Procedures for Fecal Microbiota Transplantation via Upper Endoscopy. Gastroenterol Nurs 2021;44:227-32. [PMID: 34176888 DOI: 10.1097/SGA.0000000000000577] [Reference Citation Analysis]
485 Kim MA, Kim SU, Sinn DH, Jang JW, Lim YS, Ahn SH, Shim JJ, Seo YS, Baek YH, Kim SG, Kim YS, Kim JH, Choe WH, Yim HJ, Lee HW, Kwon JH, Lee SW, Jang JY, Kim HY, Park Y, Kim GA, Yang H, Lee HA, Koh M, Lee YS, Kim M, Chang Y, Kim YJ, Yoon JH, Zoulim F, Lee JH. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut 2020;69:2214-22. [PMID: 32209606 DOI: 10.1136/gutjnl-2019-320015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
486 Wang J, Huang H, Liu Y, Chen R, Yan Y, Shi S, Xi J, Zou J, Yu G, Feng X, Lu F. HBV Genome and Life Cycle. Adv Exp Med Biol 2020;1179:17-37. [PMID: 31741332 DOI: 10.1007/978-981-13-9151-4_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
487 Lim TS, Kim JK. Is liver biopsy still useful in the era of non-invasive tests? Clin Mol Hepatol 2020;26:302-4. [PMID: 32646204 DOI: 10.3350/cmh.2020.0081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
488 Gilman C, Heller T, Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies. World J Gastroenterol 2019; 25(32): 4580-4597 [PMID: 31528088 DOI: 10.3748/wjg.v25.i32.4580] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
489 Sun H, Liu Y, Zhang Y, Jie Y, Wu Y, Li Z, Wei X, Li X, Niu B. Finite versus Indefinite Nucleos(t)ide Analogue Therapy of Patients with Chronic Hepatitis B Exhibiting Negative HBsAg Levels after Treatment. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/6069781] [Reference Citation Analysis]
490 Yeo YH, Le MH, Chang ET, Henry L, Nguyen MH. Prevalence of Undetectable Vaccine-Induced Immunity Against Hepatitis B Virus in US Adults at High Risk for Infection. Hepatology 2019;69:1385-97. [PMID: 30246260 DOI: 10.1002/hep.30285] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
491 Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int 2020;14:958-72. [PMID: 33185803 DOI: 10.1007/s12072-020-10099-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
492 Lin C, Lin Y, Liang K, Chen L, Chien C, Hu C, Huang T, Shyu Y, Yeh C, Chien R. Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan. Clinical Therapeutics 2022;44:403-417.e6. [DOI: 10.1016/j.clinthera.2022.01.010] [Reference Citation Analysis]
493 Blaney H, Thotakura D, Sisco L. Hemophagocytic Lymphohistiocytosis Associated With Hepatitis B and HIV Coinfection With Resultant Liver Failure. ACG Case Rep J 2021;8:e00532. [PMID: 33553464 DOI: 10.14309/crj.0000000000000532] [Reference Citation Analysis]
494 Mao QG, Liang HQ, Yin YL, Tang JM, Yang JE, Wu CC, Chen Y, Zhang MY, Liu YY, Zheng XT, Zhuang LY, Chen SD. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B. Clin Res Hepatol Gastroenterol 2021;:101758. [PMID: 34303003 DOI: 10.1016/j.clinre.2021.101758] [Reference Citation Analysis]
495 Lee J, Park JY, Yang SJ, Lee JY, Kim DG, Joo DJ, Kim MS, Kim SI, Lee JG. Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients. J Viral Hepat 2020;27:818-25. [PMID: 32302037 DOI: 10.1111/jvh.13291] [Reference Citation Analysis]
496 Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, Han MF, Wang Y, Zhang WH, Lu FM, Wang FS. Roadmap to functional cure of chronic hepatitis B: An expert consensus. J Viral Hepat 2019;26:1146-55. [PMID: 31087479 DOI: 10.1111/jvh.13126] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
497 Brady CW. Liver Disease in Pregnancy: What's New. Hepatol Commun 2020;4:145-56. [PMID: 32025601 DOI: 10.1002/hep4.1470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
498 Choi H, Seo GH. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea. J Korean Med Sci 2021;36:e89. [PMID: 33847080 DOI: 10.3346/jkms.2021.36.e89] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
499 Han Z, Zhang Y, Hou H. Response to the comment on “Mother‐to‐child transmission of hepatitis B virus after amniocentesis: A retrospective matched cohort study”. Prenatal Diagnosis 2019;39:1300-1. [DOI: 10.1002/pd.5574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
500 Rivera CG, Otto AO, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs. Curr Opin HIV AIDS 2021;16:279-85. [PMID: 34545037 DOI: 10.1097/COH.0000000000000706] [Reference Citation Analysis]
501 Westin J, Aleman S, Castedal M, Duberg A, Eilard A, Fischler B, Kampmann C, Lindahl K, Lindh M, Norkrans G, Stenmark S, Weiland O, Wejstål R. Management of hepatitis B virus infection, updated Swedish guidelines. Infectious Diseases 2020;52:1-22. [DOI: 10.1080/23744235.2019.1675903] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
502 Gherlan GS. Occult hepatitis B — the result of the host immune response interaction with different genomic expressions of the virus. World J Clin Cases 2022; 10(17): 5518-5530 [DOI: 10.12998/wjcc.v10.i17.5518] [Reference Citation Analysis]
503 Hou ZJ, Zhang JH, Zhang X, Ling QH, Zheng C, Zhu XJ, Zhou ZH, Li M, Kong XN, Sun XH, Gao YQ, Chen JJ. Long-Term Traditional Chinese Medicine Combined with NA Antiviral Therapy on Cirrhosis Incidence in Chronic Hepatitis B Patients in the Real-World Setting: A Retrospective Study. Evid Based Complement Alternat Med 2020;2020:3826857. [PMID: 32831863 DOI: 10.1155/2020/3826857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
504 Suzuki K, Suda G, Yamamoto Y, Abiko S, Kinoshita K, Miyamoto S, Sugiura R, Kimura M, Maehara O, Yamada R, Kitagataya T, Shigesawa T, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS One 2022;17:e0261760. [PMID: 35051189 DOI: 10.1371/journal.pone.0261760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
505 Li L, Zou H, Xu M, Li S, Zhu Y, Zheng S, Duan Z, Chen Y. Risk factors related to postpartum hepatic inflammation in pregnant women with chronic hepatitis B. J Int Med Res 2020;48:300060520966439. [PMID: 33208011 DOI: 10.1177/0300060520966439] [Reference Citation Analysis]
506 Yan Y, Chang L, Ji H, Han Y, Wang L. Evaluation of the Aptima HBV Quant Assay Compared to Abbott RealTime M2000 HBV Quant Assay and Procleix Ultrio Plus dHBV Assay in Plasma Samples. Microbiol Spectr 2022;:e0176122. [PMID: 35880868 DOI: 10.1128/spectrum.01761-22] [Reference Citation Analysis]
507 Lee H, Jang S, Ahn SH, Kim BK. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU/mL. Hepatol Int 2022. [PMID: 35322374 DOI: 10.1007/s12072-022-10310-1] [Reference Citation Analysis]
508 Zhao Q, Liu K, Zhu X, Yan L, Ding Y, Xu Y, Lou S, Zhao G, Xie Q, Gao Y, Bao S, Wang H. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase. Antiviral Res 2020;184:104953. [PMID: 33065138 DOI: 10.1016/j.antiviral.2020.104953] [Reference Citation Analysis]
509 De Pooter D, Van Gulck E, Chen A, Evans CF, Neefs JM, Horton H, Boden D. A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates. Vaccines (Basel) 2021;9:969. [PMID: 34579206 DOI: 10.3390/vaccines9090969] [Reference Citation Analysis]
510 Gane EJ, Schwabe C, Berliba E, Tangkijvanich P, Jucov A, Ghicavii N, Verbinnen T, Lenz O, Talloen W, Kakuda TN, Westland C, Patel M, Yogaratnam JZ, Dragone L, Van Remoortere P. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. J Antimicrob Chemother 2022:dkab491. [PMID: 35040959 DOI: 10.1093/jac/dkab491] [Reference Citation Analysis]
511 Lebray P, Delignat S, Frelicot A, Carrette M, Gautier A, Jamet N, Lecefel C, Houot M, Bourguignon S, Thabut D, Conti F, Liou A. Hepatitis B or Delta liver transplant patients at risk of recurrence: Long-term effectiveness and budget impact of low-dose subcutaneous anti-hepatitis B immunoglobulin plus patient education program. Journal of Liver Transplantation 2022. [DOI: 10.1016/j.liver.2022.100088] [Reference Citation Analysis]
512 Huang X, Zhuang J, Yang Y, Jian J, Ai W, Liu C, Tang W, Jiang C, He Y, Huang L, Peng S, Pan JS. Diagnostic Value of Serum Chitinase-3-Like Protein 1 for Liver Fibrosis: A Meta-analysis. BioMed Research International 2022;2022:1-13. [DOI: 10.1155/2022/3227957] [Reference Citation Analysis]
513 Argentiero A, Solimando AG, Ungaro V, Laforgia M, Strippoli S, Pinto D, Negri A, Ferraiuolo S, Zito A, Guida M. Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm. Front Oncol 2020;10:583781. [PMID: 33381454 DOI: 10.3389/fonc.2020.583781] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
514 Feng M, Liu K, Zhao G, Lou S, An B, Lin L, Ding Y, Bao S, Wang H. A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105315] [Reference Citation Analysis]
515 Liu CH, Liu CJ, Hung CC, Hsieh SM, Su TH, Sun HY, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. Liver Int 2020;40:758-68. [PMID: 31710759 DOI: 10.1111/liv.14295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
516 Ha Y, Chon YE, Kim MN, Lee JH, Hwang SG. Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate. Sci Rep 2020;10:13537. [PMID: 32782369 DOI: 10.1038/s41598-020-70433-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
517 Yendewa GA, Lakoh S, Jiba DF, Yendewa SA, Barrie U, Deen GF, Samai M, Jacobson JM, Sahr F, Salata RA. Hepatitis B Virus and Tuberculosis Are Associated with Increased Noncommunicable Disease Risk among Treatment-Naïve People with HIV: Opportunities for Prevention, Early Detection and Management of Comorbidities in Sierra Leone. J Clin Med 2022;11:3466. [PMID: 35743539 DOI: 10.3390/jcm11123466] [Reference Citation Analysis]
518 Atteya A, Ahmad A, Daghstani D, Mushtaq K, Yassin MA. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 2020;27:1073274820976594. [PMID: 33297765 DOI: 10.1177/1073274820976594] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
519 Mak LY, Yuen MF. Letter: serum HBcrAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infection-authors' reply. Aliment Pharmacol Ther 2018;47:1720-1. [PMID: 29878508 DOI: 10.1111/apt.14684] [Reference Citation Analysis]
520 Rajasekaran A, Franco RA, Overton ET, McGuire BM, Towns GC, Locke JE, Sawinski DL, Bell EK. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021;6:1788-98. [PMID: 34307975 DOI: 10.1016/j.ekir.2021.04.015] [Reference Citation Analysis]
521 Yeh ML, Huang CI, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Dai CY, Yu ML, Chuang WL. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. J Infect Dis 2019;219:1224-33. [PMID: 30452671 DOI: 10.1093/infdis/jiy648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
522 Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld JJ, Hansen BE, Janssen HLA. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut 2019;68:2206-13. [PMID: 31462554 DOI: 10.1136/gutjnl-2019-318981] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 22.3] [Reference Citation Analysis]
523 Levy MT, Kashuba A, Gane E. Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection-Authors' reply. Aliment Pharmacol Ther 2022;56:548-9. [PMID: 35804469 DOI: 10.1111/apt.17102] [Reference Citation Analysis]
524 Vyas AK, Jindal A. Muddle and Mechanism of Hepatitis B Surface Antigen Seroclearance. Clin Gastroenterol Hepatol 2019;17:2621. [PMID: 31653316 DOI: 10.1016/j.cgh.2019.04.049] [Reference Citation Analysis]
525 Yoo S, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Yoo C, Ryoo BY, Choi J. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00683-2. [PMID: 34182151 DOI: 10.1016/j.cgh.2021.06.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
526 Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study. Hepatol Int. [DOI: 10.1007/s12072-021-10295-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
527 Kiruthika S, Bhat R, Dash R, Rathore AS, Vivekanandan P, Jayaram B. A novel piperazine derivative that targets hepatitis B surface antigen effectively inhibits tenofovir resistant hepatitis B virus. Sci Rep 2021;11:11723. [PMID: 34083665 DOI: 10.1038/s41598-021-91196-1] [Reference Citation Analysis]
528 Chan GH, Gwee YX, Low JL, Huang Y, Chan ZY, Choo JR, Ngoi NY, LE Ang Y, Muthu V, Chong WQ, Wong A, Soo RA. Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre. Lung Cancer 2020;146:145-53. [PMID: 32540557 DOI: 10.1016/j.lungcan.2020.05.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
529 Park JH, Seo N, Chung YE, Kim SU, Park YN, Choi JY, Park MS, Kim MJ. Noninvasive evaluation of liver fibrosis: comparison of the stretched exponential diffusion-weighted model to other diffusion-weighted MRI models and transient elastography. Eur Radiol 2021;31:4813-23. [PMID: 33439321 DOI: 10.1007/s00330-020-07600-3] [Reference Citation Analysis]
530 Daniel K, Palavecino EL, Nunez M. Low Yield of Hepatitis B Virus DNA Testing in the Absence of Surface Antigen. Am J Med Qual 2021;36:68. [PMID: 32126795 DOI: 10.1177/1062860620908059] [Reference Citation Analysis]
531 Hou L, Zhang Y, Tang S, Tang X. The loss and return of self: An interpretative phenomenological analysis of coping and recovery from chronic hepatitis B in China. Nurs Health Sci 2022. [PMID: 35670524 DOI: 10.1111/nhs.12963] [Reference Citation Analysis]
532 Kim MP, Yang JK, Jun BG, Kim YD, Cheon GJ, Jung HJ, Yoo JJ, Kim SG, Kim YS, Jeong SW, Jang JY, Kim HS, Lee SH. Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma. J Viral Hepat 2021;28:1011-8. [PMID: 33759295 DOI: 10.1111/jvh.13508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
533 Yeh ML, Huang JF, Dai CY, Yu ML, Chuang WL. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. Expert Opin Drug Metab Toxicol. 2019;15:779-785. [PMID: 31593639 DOI: 10.1080/17425255.2019.1678584] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
534 Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C, Kendrick S. Health-related quality of life for adults living with hepatitis B in the United States: a qualitative assessment. J Patient Rep Outcomes 2021;5:121. [PMID: 34757456 DOI: 10.1186/s41687-021-00398-8] [Reference Citation Analysis]
535 Roy A, De A, Singh V. DAAs and HBV/HCV coinfection: Glimmer of light and a few shades of grey. J Hepatol 2020;73:461. [PMID: 32327362 DOI: 10.1016/j.jhep.2020.03.010] [Reference Citation Analysis]
536 Nasir M, Wu GY. HEV and HBV Dual Infection: A Review. J Clin Transl Hepatol 2020;8:313-21. [PMID: 33083255 DOI: 10.14218/JCTH.2020.00030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
537 Sun F, Liu Z, Wang B. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study. BMC Cancer 2021;21:1103. [PMID: 34649509 DOI: 10.1186/s12885-021-08483-3] [Reference Citation Analysis]
538 Cressey TR, Harrison L, Achalapong J, Kanjanavikai P, Patamasingh Na Ayudhaya O, Liampongsabuddhi P, Siriwachirachai T, Putiyanun C, Suriyachai P, Tierney C, Salvadori N, Chinwong D, Decker L, Tawon Y, Murphy TV, Ngo-Giang-Huong N, Siberry GK, Jourdain G;  iTAP Study Team. Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus. Antimicrob Agents Chemother. 2018;62. [PMID: 30275094 DOI: 10.1128/aac.01686-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
539 Fang HW, Yen YH, Hung CH, Wang JH, Hu TH, Lu SN, Chen CH. Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir. Dig Dis Sci 2021. [PMID: 34241753 DOI: 10.1007/s10620-021-07128-6] [Reference Citation Analysis]
540 Reynolds G, Haeusler G, Slavin MA, Teh B, Thursky K. Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach? Support Care Cancer 2021. [PMID: 33763725 DOI: 10.1007/s00520-021-06116-w] [Reference Citation Analysis]
541 Kamal H, Fornes R, Simin J, Stål P, Duberg AS, Brusselaers N, Aleman S. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. J Viral Hepat 2021. [PMID: 34291520 DOI: 10.1111/jvh.13577] [Reference Citation Analysis]
542 Chen W, Fu M, Zhang C, Xing Q, Zhou F, Lin M, Dong X, Huang J, Lin S, Hong M, Zheng Q, Pan J. Deep Learning-Based Universal Expert-Level Recognizing Pathological Images of Hepatocellular Carcinoma and Beyond. Front Med 2022;9:853261. [DOI: 10.3389/fmed.2022.853261] [Reference Citation Analysis]
543 Sinn DH. [Natural History and Treatment Indications of Chronic Hepatitis B]. Korean J Gastroenterol 2019;74:245-50. [PMID: 31765552 DOI: 10.4166/kjg.2019.74.5.245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
544 Lau KCK, Burak KW, Coffin CS. Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphotropism in Antiviral Treatment and Oncogenesis. Microorganisms 2020;8:E1470. [PMID: 32987867 DOI: 10.3390/microorganisms8101470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
545 Lee JGH, Carruthers M, Ko HH. Reactivation of hepatitis B virus associated with immunosuppression therapy. CMAJ 2018;190:E1284. [PMID: 30373742 DOI: 10.1503/cmaj.180389] [Reference Citation Analysis]
546 Wu Z, Dong X, Wang G, Zhao H; China HepB-Related Fibrosis Assessment Research Group. Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal. J Viral Hepat 2019;26:287-96. [PMID: 30380162 DOI: 10.1111/jvh.13030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
547 Cheah JT, Faragon JJ, Marks KM. Management of hepatitis B and C infections in rheumatologic disease. Best Pract Res Clin Rheumatol 2018;32:848-68. [PMID: 31427059 DOI: 10.1016/j.berh.2019.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
548 Dai Z, Wong IOL, Xie C, Xu W, Xiang Y, Peng L, Lau EHY. Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China. Clin Microbiol Infect 2021:S1198-743X(21)00344-X. [PMID: 34197929 DOI: 10.1016/j.cmi.2021.06.024] [Reference Citation Analysis]
549 Arnouk S, Whitsett M, Papadopoulos J, Stewart Lewis Z, Dagher NN, Feldman DM, Park JS. Successful Treatment of Tenofovir Alafenamide-Induced Lactic Acidosis: A Case Report. Journal of Pharmacy Practice. [DOI: 10.1177/08971900221105042] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
550 Zhang Y, Li W, Liu Z, Ye J, Zou G, Zhang Z, Li J. Combination therapy based on pegylated interferon alfa improves the therapeutic response of patients with chronic hepatitis B who exhibit high levels of hepatitis B e-antigen at 24 weeks: A retrospective observational study. Medicine (Baltimore) 2019;98:e17022. [PMID: 31490387 DOI: 10.1097/MD.0000000000017022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
551 Wang K, Huang G, Chen Y, Wang Y. Hepatitis B Surface Antigen (HBsAg) Kinetics in Chronic Hepatitis B Patients during Peginterferon Treatment. Med Sci Monit 2020;26:e921487. [PMID: 32587233 DOI: 10.12659/MSM.921487] [Reference Citation Analysis]
552 Mohareb AM, Larmarange J, Kim AY, Coffie PA, Kouamé MG, Boyd A, Freedberg KA, Hyle EP. Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. The Lancet HIV 2022;9:e585-94. [DOI: 10.1016/s2352-3018(22)00123-0] [Reference Citation Analysis]
553 Zhu YF, Wang J, Fang JZ, Yang Q, Lv FF. Interface Hepatitis over Grade 2 May Differentiate Chronic Inflammation Associated with CHB from NAFLD in the Early Stage. Gastroenterol Res Pract 2020;2020:3584568. [PMID: 32382264 DOI: 10.1155/2020/3584568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
554 Xu XL, Jiang LS, Wu CS, Pan LY, Lou ZQ, Peng CT, Dong Y, Ruan B. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool? J Formos Med Assoc 2021:S0929-6646(21)00344-2. [PMID: 34325952 DOI: 10.1016/j.jfma.2021.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
555 Guo H, Zhu B, Li S, Li J, Shen Z, Zheng Y, Zhao W, Tan D, Wu J, Zhang X, Jiang Q, Qi X, Mao R, Yu X, Su Z, Zhang J. Development and Validation of a Novel Model to Predict Liver Histopathology in Patients with Chronic Hepatitis B. Biomed Res Int 2019;2019:1621627. [PMID: 30937309 DOI: 10.1155/2019/1621627] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
556 Mustafayev K, Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.02.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
557 Gentile G, Antonelli G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019;11. [PMID: 31717647 DOI: 10.3390/v11111049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
558 Chang JW, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Seo YS, Lee HA, Kim MN, Lee YR, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Park SY, Kim SU. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. J Viral Hepat 2021;28:95-104. [DOI: 10.1111/jvh.13411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
559 Cheng HR, Yang HC, Lin SR, Yang TY, Lin YY, Su TH, Tseng TC, Liu CJ, Kao JH. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients. Hepatol Int 2021;15:582-92. [PMID: 33886088 DOI: 10.1007/s12072-021-10186-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
560 Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
561 Dong B, Chen Y, Lyu G, Qin R. Liver stiffness measurement as a quantitative method for liver fibrosis in children with non-alcoholic fatty liver disease: A meta-analysis. J Paediatr Child Health 2021. [PMID: 34554611 DOI: 10.1111/jpc.15751] [Reference Citation Analysis]
562 Khanam A, Kottilil S. Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management. Front Med (Lausanne) 2021;8:752875. [PMID: 34820395 DOI: 10.3389/fmed.2021.752875] [Reference Citation Analysis]
563 Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
564 Li LJ, Wu XY, Tan SW, Xie ZJ, Pan XM, Pan SW, Bai WR, Li HJ, Liu HL, Jiang J, Wu B. Lnc-TCL6 is a potential biomarker for early diagnosis and grade in liver-cirrhosis patients. Gastroenterol Rep (Oxf). 2019;7:434-443. [PMID: 31857905 DOI: 10.1093/gastro/goz050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
565 Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019; 25(19): 2327-2337 [PMID: 31148904 DOI: 10.3748/wjg.v25.i19.2327] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
566 Esmaeilzadeh A, Bahmaie N, Nouri E, Hajkazemi MJ, Zareh Rafie M. Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study. Int J Mol Sci 2021;22:12552. [PMID: 34830435 DOI: 10.3390/ijms222212552] [Reference Citation Analysis]
567 Malik GF, Zakaria N, Majeed MI, Ismail FW. Viral Hepatitis - The Road Traveled and the Journey Remaining. Hepat Med 2022;14:13-26. [PMID: 35300491 DOI: 10.2147/HMER.S352568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
568 Elsaid MI, Li Y, John T, Narayanan N, Catalano C, Rustgi VK. Economic and Health Care Burdens of Hepatitis Delta: A Study of Commercially Insured Adults in the United States. Hepatology 2020;72:399-411. [PMID: 31804707 DOI: 10.1002/hep.31055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
569 Furquim d'Almeida A, Ho E, Van Hees S, Vanwolleghem T. Clinical management of chronic hepatitis B: A concise overview. United European Gastroenterol J 2021. [PMID: 34846093 DOI: 10.1002/ueg2.12176] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
570 Zou X, Fang M, Li S, Wu L, Gao B, Gao H, Ran X, Bian Y, Li R, ShanshanYu, Ling J, Li D, Tian D, Huang J. Characteristics of Liver Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection. Clin Gastroenterol Hepatol. 2021;19:597-603. [PMID: 32553907 DOI: 10.1016/j.cgh.2020.06.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 17.0] [Reference Citation Analysis]
571 Liu J, Chen T, Chen Y, Ren H, Wang G, Zhang W, Zhao Y; Society of Infectious Diseases and Chinese Medical Association. 2019 Chinese Clinical Practice Guidelines for the Prevention of Mother-to-child Transmission of Hepatitis B Virus. J Clin Transl Hepatol 2020;8:397-406. [PMID: 33447523 DOI: 10.14218/JCTH.2020.00070] [Reference Citation Analysis]
572 Chang ML, Liaw YF. Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses. Int J Mol Sci 2022;23:1552. [PMID: 35163476 DOI: 10.3390/ijms23031552] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
573 Yuen MF, Heo J, Kumada H, Suzuki F, Suzuki Y, Xie Q, Jia J, Karino Y, Hou J, Chayama K, Imamura M, Lao-Tan JY, Lim SG, Tanaka Y, Xie W, Yoon JH, Duan Z, Kurosaki M, Park SJ, Labio ME, Kumar R, Kweon YO, Yim HJ, Tao Y, Cremer J, Elston R, Davies M, Baptiste-Brown S, Han K, Campbell FM, Paff M, Theodore D. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J Hepatol 2022:S0168-8278(22)00351-8. [PMID: 35714812 DOI: 10.1016/j.jhep.2022.05.031] [Reference Citation Analysis]
574 Lai P, Chen X, Qin L, Jiang Z, Luo C, Huang X, Wu S, Ling W, Wang Y, Wang J, Deng C, Huang L, Zeng L, Lu Z, Zhong L, Liao P, Li M, Chen D, Geng S, Wu P, Tang Z, Pei D, Du X, Li P, Weng J. The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection. Leukemia 2020;34:2790-3. [PMID: 32632097 DOI: 10.1038/s41375-020-0952-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
575 Jones JM, Gurbaxani BM, Asher A, Sansom S, Annambhotla P, Moorman AC, Kamili S, Brooks JT, Basavaraju SV. Quantifying the risk of undetected HIV, hepatitis B virus, or hepatitis C virus infection in Public Health Service increased risk donors. Am J Transplant 2019;19:2583-93. [PMID: 30980600 DOI: 10.1111/ajt.15393] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
576 Hamida ME, Raja SM, Seyoum Y, Elkhidir IM, Tekle F. Prevalence of chronic hepatitis B phases in Eritrean patients: a laboratory-based cross-sectional study. BMC Gastroenterol 2021;21:198. [PMID: 33933017 DOI: 10.1186/s12876-021-01789-3] [Reference Citation Analysis]
577 Wang CC, Tzeng IS, Su WC, Li CH, Lin HH, Yang CC, Kao JH. The association of vitamin D with hepatitis B virus replication: Bystander rather than offender. J Formos Med Assoc 2020;119:1634-41. [PMID: 31932201 DOI: 10.1016/j.jfma.2019.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
578 Kong H, Ju E, Yi K, Xu W, Lao YH, Cheng D, Zhang Q, Tao Y, Li M, Ding J. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. Adv Sci (Weinh) 2021;8:e2102051. [PMID: 34665528 DOI: 10.1002/advs.202102051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
579 Ha I, Chung JW, Jang ES, Jeong SH, Kim JW. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis. J Gastroenterol Hepatol 2020;35:1774-81. [PMID: 32154938 DOI: 10.1111/jgh.15031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
580 Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat 2021;28:493-507. [PMID: 33305479 DOI: 10.1111/jvh.13452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
581 Sandmann L, Petersen J, Cornberg M. Die wichtigsten Änderungen der S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion im Überblick. Z Gastroenterol 2021;59:641-3. [PMID: 34255314 DOI: 10.1055/a-1498-2680] [Reference Citation Analysis]
582 Fukutomi K, Hikita H, Murai K, Nakabori T, Shimoda A, Fukuoka M, Yamai T, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T. Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus-Infected Hepatocytes During Interferon Administration. Hepatol Commun 2021. [PMID: 34558845 DOI: 10.1002/hep4.1804] [Reference Citation Analysis]
583 Molagic V, Popescu C, Tiliscan C, Arama V, Arama SS. Rapid loss of HBs antigen in patients with HBV reactivation and high level of transaminases during immunosuppressive therapy - case series. Revista Romana de Medicina de Laborator 2021;29:105-13. [DOI: 10.2478/rrlm-2020-0039] [Reference Citation Analysis]
584 Martinez ARM, de Lima FD, Martins MP, Pereira IE, Miotto N, Mazo DFC, Vigani AG, da Costa LBE, Stucchi RSB, Almeida JRS, Nucci A, França MC Jr. Sensory neuronopathy is a specific and disabling neurological manifestation of autoimmune hepatitis. Eur J Neurol 2020;27:2072-8. [PMID: 32441838 DOI: 10.1111/ene.14355] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
585 Huang H, Xu C, Hu Y, Zhou YH. Reply to Pan. Clin Infect Dis 2021;73:166-7. [PMID: 32818227 DOI: 10.1093/cid/ciaa1227] [Reference Citation Analysis]
586 Loglio A, Lampertico P. How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals? Hepatol Commun. 2020;4:5-7. [PMID: 31909351 DOI: 10.1002/hep4.1476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
587 Li J, Hu C, Chen Y, Zhang R, Fu S, Zhou M, Gao Z, Fu M, Yan T, Yang Y, Li J, Liu J, Chen T, Zhao Y, He Y. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis 2021;21:567. [PMID: 34126939 DOI: 10.1186/s12879-021-06237-x] [Reference Citation Analysis]
588 Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol 2021;12:733364. [PMID: 34557195 DOI: 10.3389/fimmu.2021.733364] [Reference Citation Analysis]
589 Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
590 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 18.5] [Reference Citation Analysis]
591 Papatheodoridi A, Karakousis N, Lembessis P, Chatzigeorgiou A, Papatheodoridis GV. The Significance of Circulating Cell-Free DNA Markers in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. Pathogens 2021;10:1524. [PMID: 34832679 DOI: 10.3390/pathogens10111524] [Reference Citation Analysis]
592 Yamashige D, Hosaka T, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs. J Gastroenterol 2021;56:1008-21. [PMID: 34596753 DOI: 10.1007/s00535-021-01826-8] [Reference Citation Analysis]
593 Hara T, Oka K, Iwai N, Inada Y, Tsuji T, Okuda T, Nagata A, Komaki T, Kagawa K. Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma. Intern Med 2021;60:417-21. [PMID: 32963163 DOI: 10.2169/internalmedicine.5678-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
594 Jeong HM, Kim DJ. Bone Diseases in Patients with Chronic Liver Disease. Int J Mol Sci. 2019;20. [PMID: 31480433 DOI: 10.3390/ijms20174270] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
595 Riveiro-Barciela M. Outcome and risk of de novo Hepatitis B after liver transplantation: Are all anti-HBc-positive grafts the same? Clin Res Hepatol Gastroenterol 2020;44:791-3. [PMID: 32586783 DOI: 10.1016/j.clinre.2020.05.016] [Reference Citation Analysis]
596 Li M, Zhang L, Lu Y, Chen Q, Lu H, Sun F, Zeng Z, Wan G, Zhao L, Xie Y. Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a. Virol Sin 2021;36:311-20. [PMID: 32975731 DOI: 10.1007/s12250-020-00290-7] [Reference Citation Analysis]
597 Wang W, Xiong L, Wang P, Wang F, Ma Q. Major vault protein plays important roles in viral infection. IUBMB Life 2020;72:624-31. [PMID: 31769934 DOI: 10.1002/iub.2200] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
598 Liu R, Chen Y, Guo J, Li M, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Zhang H, Xie Y. The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients. BMC Infect Dis 2020;20:590. [PMID: 32778058 DOI: 10.1186/s12879-020-05320-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
599 Kim TH, Kim M, Yim HJ, Suh SJ, Jung YK, Seo YS, Um SH, Lee JI, Lee SH, Kim SG, Kim IH, Kim HS, Cho EY, Kim TY, Hwang SG. Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.121627] [Reference Citation Analysis]
600 Chang X, Wang J, Chen Y, Long Q, Song L, Li Q, Liu H, Shang Q, Yu Z, Jiang L, Xiao G, Li L, Chen L, Wang X, Li Z, Chen D, Dong Z, An L, Tan L, Chen Y, Yang Y. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection. EBioMedicine 2021;67:103389. [PMID: 34004423 DOI: 10.1016/j.ebiom.2021.103389] [Reference Citation Analysis]
601 Wong GL, Lampertico P. Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB – Is one NUC better than the other? Journal of Hepatology 2019;71:453-5. [DOI: 10.1016/j.jhep.2019.05.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
602 Patil AP, Simon EG, Dutta AK, Joseph AJ, Kurien RT, Chowdhury SD. Prevalence of serological markers of hepatitis B in inflammatory bowel disease - Experience from a tertiary care centre in South India. Trop Doct 2021;51:326-31. [PMID: 34018886 DOI: 10.1177/00494755211015571] [Reference Citation Analysis]
603 Cerva C, Salpini R, Alkhatib M, Malagnino V, Piermatteo L, Battisti A, Bertoli A, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Ferrari L, Laura C, Teti E, Cantonetti M, Arcese W, Ceccherini-silberstein F, Perno C, Andreoni M, Svicher V, Sarmati L. Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines 2022;10:443. [DOI: 10.3390/biomedicines10020443] [Reference Citation Analysis]
604 Lawandi A, Cheng MP, Lee TC. Hepatitis B testing practices at a tertiary care centre and their associated costs: A retrospective analysis. PLoS One 2019;14:e0219347. [PMID: 31283801 DOI: 10.1371/journal.pone.0219347] [Reference Citation Analysis]
605 Mayran C, Foulongne V, Van de Perre P, Fournier-wirth C, Molès J, Cantaloube J. Rapid Diagnostic Test for Hepatitis B Virus Viral Load Based on Recombinase Polymerase Amplification Combined with a Lateral Flow Read-Out. Diagnostics 2022;12:621. [DOI: 10.3390/diagnostics12030621] [Reference Citation Analysis]
606 Revill PA, Tu T, Netter HJ, Yuen LKW, Locarnini SA, Littlejohn M. The evolution and clinical impact of hepatitis B virus genome diversity. Nat Rev Gastroenterol Hepatol 2020;17:618-34. [DOI: 10.1038/s41575-020-0296-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 30.0] [Reference Citation Analysis]
607 Cheung CKM, Law MF, Chao DC, Wong SH, Ho R, Chao ACW, Lai JWY, Chan TYT, Tam MTK, Lau SLF, Tam THC. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis. J Dig Dis 2020;21:160-9. [PMID: 32040243 DOI: 10.1111/1751-2980.12848] [Reference Citation Analysis]
608 Liu N, Yang N, Ma W, Yang S, Hu C, Li J, Zhao Y, Xu G, He Y. Efficacy of Antiviral Treatment in Liver Biopsy-Proven Immune-Tolerant Chronic Hepatitis B Patients: A Retrospective Cohort Study. Front Med (Lausanne) 2021;8:655530. [PMID: 33898489 DOI: 10.3389/fmed.2021.655530] [Reference Citation Analysis]
609 Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez-gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Idilman R, Esteban R, Janssen HL, Berg T, Lampertico P. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. Journal of Hepatology 2020;72:1088-96. [DOI: 10.1016/j.jhep.2020.01.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 17.0] [Reference Citation Analysis]
610 Alghamdi S, Fleckenstein J. Liver Disease in Pregnancy and Transplant. Curr Gastroenterol Rep 2019;21:43. [PMID: 31346820 DOI: 10.1007/s11894-019-0711-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
611 Harris AM, Millman AJ, Lora M, Osinubi A, Lom J, Miller LS. Hepatitis B testing, care linkage, and vaccination coverage within a registry of hepatitis C infected patients. Vaccine 2019;37:2188-93. [PMID: 30902481 DOI: 10.1016/j.vaccine.2019.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
612 Han Z, Hou H. Editorial: tenofovir disoproxil fumarate and prevention of mother-to-child transmission of hepatitis B virus. Aliment Pharmacol Ther 2019;50:707-8. [PMID: 31456302 DOI: 10.1111/apt.15383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
613 Shih C, Wu SY, Chou SF, Yuan TT. Virion Secretion of Hepatitis B Virus Naturally Occurring Core Antigen Variants. Cells 2020;10:E43. [PMID: 33396864 DOI: 10.3390/cells10010043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
614 Ricciotti E, Wangensteen KJ, FitzGerald GA. Aspirin in Hepatocellular Carcinoma. Cancer Res 2021;81:3751-61. [PMID: 33893087 DOI: 10.1158/0008-5472.CAN-21-0758] [Reference Citation Analysis]
615 Likhitsup A, Lok AS. Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials. Clin Liver Dis. 2019;23:401-416. [PMID: 31266616 DOI: 10.1016/j.cld.2019.04.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
616 Berke JM, Dehertogh P, Vergauwen K, Mostmans W, Vandyck K, Raboisson P, Pauwels F. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379. Antimicrob Agents Chemother. 2020;64:e02439-19. [PMID: 32094138 DOI: 10.1128/aac.02439-19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
617 Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Erratum to: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2021:ciab801. [PMID: 34878522 DOI: 10.1093/cid/ciab801] [Reference Citation Analysis]
618 Wu LL, Li XY, Deng H, Xie DY, Gu YR, Bi YH, Huang YH, Gao ZL. Transforming growth factor-β: An early predictor of a functional cure in chronic hepatitis B treated with interferon. Virus Res 2021;309:198657. [PMID: 34919970 DOI: 10.1016/j.virusres.2021.198657] [Reference Citation Analysis]
619 Wang L, Zhao J, Liu J, Zhen C, Zhang M, Dong Y, Gan Y, Xu Z, Li Y, Zhu S, Wang FS. Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B. J Viral Hepat 2021;28:1554-62. [PMID: 34448324 DOI: 10.1111/jvh.13598] [Reference Citation Analysis]
620 Tapper EB, Ufere NN, Huang DQ, Loomba R. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther 2022;55:1099-115. [PMID: 35235219 DOI: 10.1111/apt.16831] [Reference Citation Analysis]
621 Zhang X, Jie Y, Wan Z, Lin S, Li Y, Lin M, Wu S, Wu X, Shi M, Xiao H, Cao M, Gong J, Chi X. Prognostic Value of Inflammatory Indicators in Chronic Hepatitis B Patients With Significant Liver Fibrosis: A Multicenter Study in China. Front Pharmacol 2021;12:653751. [PMID: 34858162 DOI: 10.3389/fphar.2021.653751] [Reference Citation Analysis]
622 Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Tak WY, Park JY, Kweon YO, Kim DY, Ahn SH, Jang SY, Park SY, Kim SU. Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00604-2. [PMID: 34091048 DOI: 10.1016/j.cgh.2021.06.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
623 Lee WM, King WC, Janssen HLA, Ghany MG, Fontana RJ, Fried M, Sterling RK, Feld JJ, Wang J, Mogul DB, Cooper SL, Bisceglie AMD; Hepatitis B Research Network (HBRN). Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. J Viral Hepat 2021. [PMID: 34355475 DOI: 10.1111/jvh.13591] [Reference Citation Analysis]
624 Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18:827-844. [PMID: 31455905 DOI: 10.1038/s41573-019-0037-0] [Cited by in Crossref: 118] [Cited by in F6Publishing: 130] [Article Influence: 39.3] [Reference Citation Analysis]
625 Dionne-Odom J, Njei B, Tita ATN. Elimination of Vertical Transmission of Hepatitis B in Africa: A Review of Available Tools and New Opportunities. Clin Ther 2018;40:1255-67. [PMID: 29983265 DOI: 10.1016/j.clinthera.2018.05.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
626 Nicastro E, Norsa L, Di Giorgio A, Indolfi G, D'Antiga L. Breakthroughs and challenges in the management of pediatric viral hepatitis. World J Gastroenterol 2021; 27(20): 2474-2494 [PMID: 34092970 DOI: 10.3748/wjg.v27.i20.2474] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
627 Asselah T, Loureiro D, Boyer N, Mansouri A. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. The Lancet Gastroenterology & Hepatology 2019;4:883-92. [DOI: 10.1016/s2468-1253(19)30190-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 15.7] [Reference Citation Analysis]
628 Chen HS, Wu JF, Su TH, Chen HL, Hsu HY, Xia NS, Chen PJ, Chang MH. Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Children With a Normal Alanine Aminotransferase Level. Hepatology 2019;70:1903-12. [PMID: 31121067 DOI: 10.1002/hep.30788] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
629 Yuan C, Peng J, Xia R, He J, Qiu T, Yao Y. Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy. Front Microbiol 2022;13:865124. [DOI: 10.3389/fmicb.2022.865124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
630 Álvarez-López P, Riveiro-Barciela M, Oleas-Vega D, Flores-Cortes C, Román A, Perelló M, Berastegui C, Castells L, Esteban R, Buti M. Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients. Medicine (Baltimore) 2020;99:e19407. [PMID: 32118794 DOI: 10.1097/MD.0000000000019407] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
631 Mak LY, Seto WK, Fung J, Yuen MF. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int 2020;14:35-46. [PMID: 31745711 DOI: 10.1007/s12072-019-09998-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
632 El-Nabi SH, El-Garawani I, Ismail F, Abdelsameea E. Anti-HBc and hepatitis B virus DNA among HBsAg-negative blood donors from the main central blood bank units in Eastern Libya. Transfus Med 2020;30:401-5. [PMID: 32894893 DOI: 10.1111/tme.12711] [Reference Citation Analysis]
633 Lee AR, Cho JY, Kim JC, Dezhbord M, Choo SY, Ahn CH, Kim NY, Shin JJ, Park S, Park ES, Won J, Kim DS, Lee JH, Kim KH. Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes. Int J Mol Sci 2021;22:1606. [PMID: 33562603 DOI: 10.3390/ijms22041606] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
634 Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT;  IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
635 Lin Z, Zhang X, Zhou Y, Chen C, He LN, Li H, Wang Y, Chen T, Hong S, Zhang L. Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus. Cancer Immunol Immunother 2021. [PMID: 34647153 DOI: 10.1007/s00262-021-03082-4] [Reference Citation Analysis]
636 Chen Q, Liu J, He Y, Yang L, Luo H, Wang Y, Zhang X, Li N. Prevalence of HBsAg among reproductive age couples in Chongqing: A population-based, cross-sectional study. PLoS One 2021;16:e0260028. [PMID: 34780552 DOI: 10.1371/journal.pone.0260028] [Reference Citation Analysis]
637 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
638 Lee HW, Park SY, Lee YR, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. Am J Gastroenterol 2021. [PMID: 34506308 DOI: 10.14309/ajg.0000000000001497] [Reference Citation Analysis]
639 Li Z, Xie B, Yi N, Cai H, Yi W, Gao X. Efficacy and safety of tenofovir disoproxil fumarate or telbivudine used throughout pregnancy for the prevention of mother-to-child transmission of hepatitis B virus: A cohort study. Eur J Obstet Gynecol Reprod Biol 2022;276:102-6. [PMID: 35853269 DOI: 10.1016/j.ejogrb.2022.07.009] [Reference Citation Analysis]
640 Marlet J, Lier C, Roch E, Maugey M, Moreau A, Combe B, Lefeuvre S, d'Alteroche L, Barbereau D, Causse X, Bastides F, Bachelier MN, Brand D, Gaudy-Graffin C. Revisiting HBV resistance to entecavir with a phenotypic approach. Antiviral Res 2020;181:104869. [PMID: 32735901 DOI: 10.1016/j.antiviral.2020.104869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
641 Kohsar M, Landahl J, Neumann-Haefelin C, Schulze Zur Wiesch J. Human hepatitis D virus-specific T cell epitopes. JHEP Rep 2021;3:100294. [PMID: 34308324 DOI: 10.1016/j.jhepr.2021.100294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
642 Li Q, Zhou Y, Huang C, Li W, Chen L. A novel diagnostic algorithm to predict significant liver inflammation in chronic hepatitis B virus infection patients with detectable HBV DNA and persistently normal alanine transaminase. Sci Rep 2018;8:15449. [PMID: 30337643 DOI: 10.1038/s41598-018-33412-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
643 Nastasio S, Jonas MM. Effect of Universal Infant Hepatitis B Virus Immunization on Mother-to-Child Hepatitis B Virus Transmission. J Infect Dis 2019;220:1089-90. [PMID: 30576508 DOI: 10.1093/infdis/jiy707] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
644 Zeng QL, Yu ZJ, Shang J, Xu GH, Sun CY, Liu N, Li CX, Lv J, Liu YM, Liang HX, Li ZQ, Pan YJ, Hu QY, Li W, Zhang DW, Wang FS. Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels. Open Forum Infect Dis 2020;7:ofaa208. [PMID: 32626791 DOI: 10.1093/ofid/ofaa208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
645 Asín-Prieto E, Parra-Guillen ZP, Gómez Mantilla JD, Vandenbossche J, Stuyckens K, de Trixhe XW, Perez-Ruixo JJ, Troconiz IF. A quantitative systems pharmacology model for acute viral hepatitis B. Comput Struct Biotechnol J 2021;19:4997-5007. [PMID: 34589180 DOI: 10.1016/j.csbj.2021.08.052] [Reference Citation Analysis]
646 Garbuzenko DV. [The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection]. Vopr Virusol 2021;66:331-9. [PMID: 34738448 DOI: 10.36233/0507-4088-70] [Reference Citation Analysis]
647 Koffas A, Mak L, Gill US, Kennedy PTF. Early Treatment Consideration in Patients with Hepatitis B ‘e’ Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift? Viruses 2022;14:900. [DOI: 10.3390/v14050900] [Reference Citation Analysis]
648 Chitnis AS, Cheung R, Gish RG, Wong RJ. Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States. J Immigr Minor Health 2021. [PMID: 34160726 DOI: 10.1007/s10903-021-01231-6] [Reference Citation Analysis]
649 Suresh M, Menne S. Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer. World J Gastrointest Oncol 2021; 13(6): 509-535 [PMID: 34163570 DOI: 10.4251/wjgo.v13.i6.509] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
650 Zhang ZQ, Shi BS, Lu W, Liu DP, Huang D, Feng YL. Quantitative HBcrAg and HBcAb versus HBsAg and HBV DNA in predicting liver fibrosis levels of chronic hepatitis B patients. Gastroenterol Hepatol 2020;43:526-36. [PMID: 32921478 DOI: 10.1016/j.gastrohep.2020.03.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
651 Russo FP, Zanetto A, Pinto E, Battistella S, Penzo B, Burra P, Farinati F. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Int J Mol Sci 2022;23:500. [PMID: 35008926 DOI: 10.3390/ijms23010500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
652 Huang TH, Lin MT, Wang JH, Chang KC, Yen YH, Kuo FY, Huang CC, Hsiao CC, Chiu SY, Lu SN, Wang CC, Hu TH. Clinical and novel application of FibroScan, FIB-4 and aspartate aminotransferase-to-platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction. Int J Clin Pract 2021;75:e13945. [PMID: 33338308 DOI: 10.1111/ijcp.13945] [Reference Citation Analysis]
653 Delli Pizzi A, Mastrodicasa D, Cianci R, Serafini FL, Mincuzzi E, Di Fabio F, Giammarino A, Mannetta G, Basilico R, Caulo M. Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. Can Assoc Radiol J 2020;:846537120923982. [PMID: 32436394 DOI: 10.1177/0846537120923982] [Reference Citation Analysis]
654 Bonacci M, Forns X, Lens S. The HBeAg-Negative "Gray Zone" Phase: A Frequent Condition With Different Outcomes in Western and Asian Patients? Clin Gastroenterol Hepatol 2020;18:263-4. [PMID: 31858983 DOI: 10.1016/j.cgh.2019.05.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
655 Hur MH, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6009. [PMID: 34885118 DOI: 10.3390/cancers13236009] [Reference Citation Analysis]
656 Li Y, Xia Y, Cheng X, Kleiner DE, Hewitt SM, Sproch J, Li T, Zhuang H, Liang TJ. Hepatitis B Surface Antigen Activates Unfolded Protein Response in Forming Ground Glass Hepatocytes of Chronic Hepatitis B. Viruses. 2019;11. [PMID: 31027244 DOI: 10.3390/v11040386] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
657 Wong GL, Wong VW, Hui VW, Yip TC, Tse YK, Liang LY, Lui RN, Mok TS, Chan HL, Chan SL. Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection.Am J Gastroenterol. 2021;116:1274-1283. [PMID: 33560651 DOI: 10.14309/ajg.0000000000001142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
658 Gane E, Yuen MF, Kakuda TN, Ogawa T, Takahashi Y, Goeyvaerts N, Lonjon-Domanec I, Vaughan T, Schluep T, Hamilton J, Njumbe Ediage E, Hillewaert V, Snoeys J, Lenz O, Talloen W, Biermer M. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B. Antivir Ther 2022;27:13596535221093856. [PMID: 35695169 DOI: 10.1177/13596535221093856] [Reference Citation Analysis]
659 Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology. Clin Liver Dis 2019;23:487-92. [PMID: 31266622 DOI: 10.1016/j.cld.2019.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
660 Han LY, Yang JR, Zhao ZH, Gao S, Fan YC, Wang K. RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma. Pathol Res Pract 2020;216:153147. [PMID: 32853963 DOI: 10.1016/j.prp.2020.153147] [Reference Citation Analysis]
661 Liaw YF, Chien RN. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation". Kaohsiung J Med Sci 2022. [PMID: 35262284 DOI: 10.1002/kjm2.12518] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
662 Alqahtani SA, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. Cells 2021;10:3091. [PMID: 34831314 DOI: 10.3390/cells10113091] [Reference Citation Analysis]
663 Calabrese C. Vaccinations in Patients with Rheumatic Disease: Consider Disease and Therapy. Rheum Dis Clin North Am 2022;48:397-409. [PMID: 35400367 DOI: 10.1016/j.rdc.2022.02.001] [Reference Citation Analysis]
664 Cryer AM, Imperial JC. Hepatitis B in Pregnant Women and their Infants. Clin Liver Dis 2019;23:451-62. [PMID: 31266619 DOI: 10.1016/j.cld.2019.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
665 Yu X, Xin L, Rongyong M, Aibing W, Jianzhong C. Clinical efficacy and safety of TCM prescriptions combined with nucleoside (acid) analogues in treating chronic hepatitis B: a meta-analysis. Digital Chinese Medicine 2021;4:170-9. [DOI: 10.1016/j.dcmed.2021.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
666 Chang SH. Prevention of HBV Recurrence After Liver Transplant: Long-Term Results. Transplant Proc 2021;53:1707-10. [PMID: 33994187 DOI: 10.1016/j.transproceed.2021.04.006] [Reference Citation Analysis]
667 Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021;80:1255-65. [PMID: 34493491 DOI: 10.1136/annrheumdis-2021-221244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
668 Yamai T, Hikita H, Fukuoka M, Fukutomi K, Murai K, Nakabori T, Yamada R, Miyakawa K, Watashi K, Ryo A, Kodama T, Sakamori R, Tatsumi T, Takehara T. SIRT1 enhances hepatitis virus B transcription independent of hepatic autophagy. Biochem Biophys Res Commun 2020;527:64-70. [PMID: 32446392 DOI: 10.1016/j.bbrc.2020.04.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
669 Jeong S, Cho Y, Park SM, Kim W. Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:e77-86. [PMID: 33883516 DOI: 10.1097/MCG.0000000000001548] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
670 Qi W, Shen J, Dai J, Wu Y, Zhang Y, Leng S, Gao F, Ran S, Peng W, Zhang X, Wen T, Li C. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study. Cancer Med 2021. [PMID: 34643050 DOI: 10.1002/cam4.4348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
671 Shan S, Jia J. Prevention of Mother-to-Child Transmission of Hepatitis B Virus in the Western Pacific Region. Clin Liver Dis (Hoboken) 2021;18:18-21. [PMID: 34484699 DOI: 10.1002/cld.1096] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
672 Tseng T, Liu C, Hsu C, Hong C, Su T, Yang W, Chen C, Yang H, Huang Y, Fang-tzu Kuo S, Liu C, Chen P, Chen D, Kao J. High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. Gastroenterology 2019;157:1518-1529.e3. [DOI: 10.1053/j.gastro.2019.08.028] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
673 Roth D, Bloom RD, Molnar MZ, Reese PP, Sawinski D, Sise ME, Terrault NA. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. Am J Kidney Dis 2020;75:665-83. [PMID: 32279907 DOI: 10.1053/j.ajkd.2019.12.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
674 Oh H, Lee HY, Kim J, Kim YJ. Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail. Cancers (Basel) 2022;14:2617. [PMID: 35681596 DOI: 10.3390/cancers14112617] [Reference Citation Analysis]
675 Wangensteen KJ, Chang KM. Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:27-37. [PMID: 32737895 DOI: 10.1002/hep.31481] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
676 Sedano R, Castro L, Venegas M, Miranda J, Hurtado C, Poniachik J, Brahm J. Liver transplantation in acute liver failure due to Hepatitis B. Two clinical cases. Ann Hepatol 2021;21:100107. [PMID: 31623992 DOI: 10.1016/j.aohep.2019.06.012] [Reference Citation Analysis]
677 Li J, Wu Z, Wang GQ, Zhao H. Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients. Chin Med J (Engl) 2021;134:1160-7. [PMID: 33734135 DOI: 10.1097/CM9.0000000000001418] [Reference Citation Analysis]
678 Stasi C, Tiengo G, Sadalla S, Zignego AL. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. J Clin Med 2021;10:2564. [PMID: 34200522 DOI: 10.3390/jcm10122564] [Reference Citation Analysis]
679 Hou J, Ning Q, Duan Z, Chen Y, Xie Q, Wang FS, Zhang L, Wu S, Tang H, Li J, Lin F, Yang Y, Gong G, Flaherty JF, Gaggar A, Mo S, Cheng C, Camus G, Chen C, Huang Y, Jia J, Zhang M; GS-US-320-0110 and GS-US-320-0108 China Investigators. 3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China. J Clin Transl Hepatol 2021;9:324-34. [PMID: 34221918 DOI: 10.14218/JCTH.2020.00145] [Reference Citation Analysis]
680 Chan HLY. Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. J Gastroenterol Hepatol 2019;34:501-6. [PMID: 30402981 DOI: 10.1111/jgh.14534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
681 Sagnelli C, Sica A, Creta M, Borsetti A, Ciccozzi M, Sagnelli E. Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. Pathogens 2022;11:567. [DOI: 10.3390/pathogens11050567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
682 Lee JS, Lee HA, Jeon MY, Lim TS, Kim BK, Park JY, Kim DY, Ahn SH, Um SH, Han K, Seo YS, Kim SU. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. European Journal of Gastroenterology & Hepatology 2020;32:739-47. [DOI: 10.1097/meg.0000000000001585] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
683 Hao SR, Zhang SY, Lian JS, Jin X, Ye CY, Cai H, Zhang XL, Hu JH, Zheng L, Zhang YM, Jia HY, Yu GD, Wang XY, Gu JQ, Lu YF, Yu XP, Yu L, Xiang DR, Ye CY, Jin CL, Qiu YQ, Li LJ, Sheng JF, Liang TB, Yang YD. Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study. Am J Gastroenterol 2020;115:1075-83. [PMID: 32618658 DOI: 10.14309/ajg.0000000000000717] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
684 Liu WC, Wu IC, Chiu YC, Tseng KC, Chen CY, Chiu HC, Cheng PN, Chang TT. Genotyping of immune-related loci associated with delayed HBeAg seroconversion in immune-active chronic hepatitis B patients. Antiviral Res 2020;176:104719. [PMID: 32004619 DOI: 10.1016/j.antiviral.2020.104719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
685 Chevaliez S, Rodriguez C, Poiteau L, Soulier A, Donati F, Darty-Mercier M, Pioche C, Leroy V, Brodard V, Zoulim F, Brouard C, Larsen C, Semaille C, Roudot-Thoraval F, Pawlotsky JM; Hepatology Reference Centers Laboratories Network for Chronic Hepatitis B Surveillance. Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues. J Viral Hepat 2019;26:278-86. [PMID: 30339311 DOI: 10.1111/jvh.13025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
686 Gu L, Yao Q, Shen Z, He Y, Ng DM, Yang T, Chen B, Chen P, Mao F, Yu Q. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2020;35:1467-1476. [PMID: 32180249 DOI: 10.1111/jgh.15036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
687 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yang Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver. 2019;. [PMID: 31158948 DOI: 10.5009/gnl18546.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
688 Chen YC, Hsu CW, Chien RN, Tai DI. One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study. Medicine (Baltimore) 2022;101:e29269. [PMID: 35758355 DOI: 10.1097/MD.0000000000029269] [Reference Citation Analysis]
689 Cheung KW, Lao TT. Hepatitis B - Vertical transmission and the prevention of mother-to-child transmission. Best Pract Res Clin Obstet Gynaecol 2020;68:78-88. [PMID: 32249130 DOI: 10.1016/j.bpobgyn.2020.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
690 Durham SH, Milam A, Waer D, Chahine EB. Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis. Ann Pharmacother 2022;:10600280221102532. [PMID: 35778802 DOI: 10.1177/10600280221102532] [Reference Citation Analysis]
691 Yoon EL. [Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients]. Korean J Gastroenterol 2019;74:258-66. [PMID: 31765554 DOI: 10.4166/kjg.2019.74.5.258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
692 Peng CY. Editorial: a baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients-same score, different outcomes. Aliment Pharmacol Ther 2018;48:875-6. [PMID: 30281835 DOI: 10.1111/apt.14921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
693 Wang Y, Zhang J, Jin Y, Xiao X, Zhang Q. Kushenin combined with entecavir for chronic hepatitis B: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e18898. [PMID: 32000393 DOI: 10.1097/MD.0000000000018898] [Reference Citation Analysis]
694 Quan M, Liu X, Liu C, Li W, Xing H, Pan JS. Antiviral Therapy for Prevention of Perinatal Hepatitis B Virus Transmission Reduces the Incidence of Postpartum Hepatitis Flare. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/7046955] [Reference Citation Analysis]
695 Hsu YC, Nguyen MH, Mo LR, Wu MS, Yang TH, Chen CC, Tseng CH, Tai CM, Wu CY, Lin JT, Tanaka Y, Chang CY. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther. 2019;49:107-115. [PMID: 30450681 DOI: 10.1111/apt.15058] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 12.5] [Reference Citation Analysis]
696 Lee YS, Bang SM, Lee YS. Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B. J Clin Med 2021;10:2320. [PMID: 34073357 DOI: 10.3390/jcm10112320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
697 Liu K, Wong VWS, Liang LY, Lui GCY, Chan HLY, Wong GLH. Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone. Liver Int 2019;39:494-502. [PMID: 30417579 DOI: 10.1111/liv.14001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
698 Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J 2021;18:114. [PMID: 34082765 DOI: 10.1186/s12985-021-01589-x] [Reference Citation Analysis]
699 Wang K, Lu X, Zhou H, Gao Y, Zheng J, Tong M, Wu C, Liu C, Huang L, Jiang T, Meng F, Lu Y, Ai H, Xie XY, Yin LP, Liang P, Tian J, Zheng R. Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study. Gut 2019;68:729-41. [PMID: 29730602 DOI: 10.1136/gutjnl-2018-316204] [Cited by in Crossref: 191] [Cited by in F6Publishing: 155] [Article Influence: 63.7] [Reference Citation Analysis]
700 Mak LY, Wong DK, Pollicino T, Raimondo G, Hollinger FB, Yuen MF. Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance. J Hepatol. 2020;73:952-964. [PMID: 32504662 DOI: 10.1016/j.jhep.2020.05.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
701 Wang CH, Chang KK, Lin RC, Kuo MJ, Yang CC, Tseng YT. Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study. Medicine (Baltimore) 2020;99:e19907. [PMID: 32358357 DOI: 10.1097/MD.0000000000019907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
702 Zhou Q, Zhang Q, Wang K, Huang T, Deng S, Wang Y, Cheng C. Anti-rheumatic Drug-induced Hepatitis B Virus Reactivation and Preventive Strategies for Hepatocellular Carcinoma. Pharmacol Res 2022;:106181. [PMID: 35301112 DOI: 10.1016/j.phrs.2022.106181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
703 Tsuji Y, Namisaki T, Kaji K, Takaya H, Nakanishi K, Sato S, Saikawa S, Sawada Y, Kitagawa K, Shimozato N, Kawaratani H, Moriya K, Noguchi R, Akahane T, Mitoro A, Yoshiji H. Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B. Exp Ther Med 2020;20:985-95. [PMID: 32765655 DOI: 10.3892/etm.2020.8798] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
704 Yang J, Wang J, Li H, Gao S, Fan Y, Wang K. IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Front Oncol 2022;12:746643. [DOI: 10.3389/fonc.2022.746643] [Reference Citation Analysis]
705 Choi J, Kim GA, Han S, Lim YS. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Am J Gastroenterol 2020;115:406-14. [PMID: 31895708 DOI: 10.14309/ajg.0000000000000490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
706 Fragkou PC, Moschopoulos CD, Karofylakis E, Kelesidis T, Tsiodras S. Update in Viral Infections in the Intensive Care Unit. Front Med (Lausanne) 2021;8:575580. [PMID: 33708775 DOI: 10.3389/fmed.2021.575580] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
707 Shah AS, Civelli VF, Bali V, Johnson RH, Heidari A. A Case of S-Variant Hepatitis B Virus: An Immune System Escape Artist. J Investig Med High Impact Case Rep 2021;9:23247096211045450. [PMID: 34521227 DOI: 10.1177/23247096211045450] [Reference Citation Analysis]
708 Ou Q, Guo J, Zeng Y, Chen H. Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection. J Viral Hepat 2020;27:224-32. [PMID: 31954089 DOI: 10.1111/jvh.13260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
709 Kumar S, Ramachandran TM. Immunotolerant Chronic Hepatitis B Infection: When Do I Treat? J Clin Exp Hepatol 2019;9:277-9. [PMID: 31024211 DOI: 10.1016/j.jceh.2018.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
710 Aslam A, Ishtiaq R, Lau DTY. Timely Administration of Birth Dose Hepatitis B Virus Vaccine May Break the Chain of Perinatal Transmission. Hepatology 2019;69:2284-6. [PMID: 30372542 DOI: 10.1002/hep.30332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
711 Wu CS, Zhao Q, Zhang J, Wang JW, Qian Y, Fan YC, Wang K. Methylation status of the stimulator of interferon genes promoter in patients with chronic hepatitis B. Medicine (Baltimore) 2018;97:e13904. [PMID: 30593207 DOI: 10.1097/MD.0000000000013904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
712 Lu M, Shih Y, Hsieh T, Lin J. Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis. Journal of the Formosan Medical Association 2020;119:886-7. [DOI: 10.1016/j.jfma.2019.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
713 Maiocchi L, Ferraioli G. A model to predict liver damage in patients with HBeAg-positive chronic HBV infection. EBioMedicine 2021;68:103422. [PMID: 34091417 DOI: 10.1016/j.ebiom.2021.103422] [Reference Citation Analysis]
714 Gupta E, Khodare A, Rani N, Singh G, Aggarwal K, Sharma M. Performance evaluation of Xpert HBV viral load (VL) assay: Point-of-care molecular test to strengthen and decentralize management of chronic hepatitis B (CHB) infection. J Virol Methods 2021;290:114063. [PMID: 33453301 DOI: 10.1016/j.jviromet.2021.114063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
715 Harputluoglu M, Carr BI. Hepatitis B Before and After Hepatocellular Carcinoma. J Gastrointest Cancer 2021. [PMID: 34762265 DOI: 10.1007/s12029-021-00745-4] [Reference Citation Analysis]
716 Lim YS, Ahn SH, Shim JJ, Razavi H, Razavi-Shearer D, Sinn DH. Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis. Aliment Pharmacol Ther 2022. [PMID: 35614532 DOI: 10.1111/apt.17052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
717 Ninomiya M, Inoue J, Krueger EW, Chen J, Cao H, Masamune A, McNiven MA. The Exosome-Associated Tetraspanin CD63 Contributes to the Efficient Assembly and Infectivity of the Hepatitis B Virus. Hepatol Commun 2021;5:1238-51. [PMID: 34278172 DOI: 10.1002/hep4.1709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
718 Stroffolini T, Ciancio A, Furlan C, Vinci M, Niro GA, Russello M, Colloredo G, Morisco F, Coppola N, Babudieri S, Ferrigno L, Sagnelli C, Sagnelli E; Collaborating group. Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019. Eur J Clin Microbiol Infect Dis 2021;40:607-14. [PMID: 33029767 DOI: 10.1007/s10096-020-04065-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
719 Zhou X, Cai BB, Hou XQ, Kang XK, Xu XX, Wang WM. Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma. Aging (Albany NY) 2020;12:11878-92. [PMID: 32568098 DOI: 10.18632/aging.103360] [Reference Citation Analysis]
720 Liang LY, Wong VW, Toyoda H, Tse YK, Yip TC, Yuen BW, Tada T, Kumada T, Lee HW, Lui GC, Chan HL, Wong GL. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. J Gastroenterol 2020;55:899-908. [PMID: 32556643 DOI: 10.1007/s00535-020-01700-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
721 Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, Susilo A, Tanaka Y, Chan WK, Gane E, Ong-Go AK, Lim SG, Ahn SH, Yu ML, Piratvisuth T, Chan HL;  Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020;5:776-787. [PMID: 32585136 DOI: 10.1016/s2468-1253(20)30190-4] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 23.0] [Reference Citation Analysis]
722 Rybicka M, Woziwodzka A, Sznarkowska A, Romanowski T, Stalke P, Dręczewski M, Verrier ER, Baumert TF, Bielawski KP. Liver Cirrhosis in Chronic Hepatitis B Patients Is Associated with Genetic Variations in DNA Repair Pathway Genes. Cancers (Basel) 2020;12:E3295. [PMID: 33171788 DOI: 10.3390/cancers12113295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
723 Wang Y, Han SB. Hepatitis B Reactivation: A Review of Clinical Guidelines. J Clin Gastroenterol 2021;55:393-9. [PMID: 33828065 DOI: 10.1097/MCG.0000000000001520] [Reference Citation Analysis]
724 Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol 2020;13:493-503. [PMID: 32394765 DOI: 10.1080/17512433.2020.1767590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
725 . Point-of-care test to detect hepatitis B virus DNA: Is it useful? Asian Biomedicine 2019;12:199-200. [DOI: 10.1515/abm-2019-0020] [Reference Citation Analysis]
726 Chen W, Zhang Q, Li S, Liang R, Liang H, Yu Y, Qiu C, Lv J, Zhang W. Acute-on-Chronic Liver Failure Precipitated by Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a Patient with Hepatitis B Virus-Related Cirrhosis: A Case Report. Infectious Diseases & Immunity 2021;1:169-73. [DOI: 10.1097/id9.0000000000000023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
727 Aby ES, Lake JR, Vaughn BP. The Impact of Biologics for the Management of Inflammatory Bowel Disease on Liver Enzymes. Clin Liver Dis (Hoboken) 2020;16:212-7. [PMID: 33318791 DOI: 10.1002/cld.1005] [Reference Citation Analysis]
728 Farag MS, Fung S, Tam E, Doucette K, Wong A, Ramji A, Conway B, Cooper C, Tsoi K, Wong P, Sebastiani G, Brahmania M, Haylock-Jacobs S, Coffin CS, Hansen BE, Janssen HLA. Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. J Viral Hepat 2021;28:942-50. [PMID: 33749086 DOI: 10.1111/jvh.13500] [Reference Citation Analysis]
729 Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol. 2021;74:1200-1211. [PMID: 33484770 DOI: 10.1016/j.jhep.2021.01.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
730 Peng CY. Editorial: identifying candidates for pegylated interferon add-on to entecavir therapy in patients with HBeAg-positive chronic hepatitis B. Aliment Pharmacol Ther 2019;49:609-10. [PMID: 30746775 DOI: 10.1111/apt.15136] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
731 Lim TS, Lee HW, Lee JI, Kim IH, Lee CH, Jang BK, Chung WJ, Yim HJ, Suh SJ, Seo YS, Lee HA, Yu JH, Lee J, Kim SG, Kim YS, Park SY, Tak WY, Kim SS, Cheong JY, Jeong SW, Jang JY, Rou WS, Lee BS, Kim SU; The Korean Transient Elastography Study Group. Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. J Viral Hepat 2020;27:1052-60. [DOI: 10.1111/jvh.13316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
732 Li N, Fan X, Wang X, Deng H, Zhang K, Zhang X, Han Q, Lv Y, Liu Z. PRDM1 rs1010273 polymorphism is associated with overall survival of patients with hepatitis B virus-related hepatocellular carcinoma. Immunol Lett 2019;213:39-45. [PMID: 31376415 DOI: 10.1016/j.imlet.2019.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
733 Bhattacharya D, Guo R, Tseng CH, Emel L, Sun R, Chiu SH, Stranix-Chibanda L, Chipato T, Mohtashemi NZ, Kintu K, Manji KP, Moodley D, Thio CL, Maldonado Y, Currier JS. Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV. Pediatr Infect Dis J 2021;40:e56-61. [PMID: 33181788 DOI: 10.1097/INF.0000000000002980] [Reference Citation Analysis]
734 Shankaraiah RC, Gramantieri L, Fornari F, Sabbioni S, Callegari E, Negrini M. Animal Models of Hepatocellular Carcinoma Prevention. Cancers (Basel) 2019;11:E1792. [PMID: 31739536 DOI: 10.3390/cancers11111792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
735 Kawashima K, Isogawa M, Onishi M, Baudi I, Saito S, Nakajima A, Fujita T, Tanaka Y. Restoration of type I interferon signaling in intrahepatically primed CD8+ T cells promotes functional differentiation. JCI Insight 2021;6:145761. [PMID: 33400688 DOI: 10.1172/jci.insight.145761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
736 Chi Z, Zhao W, Li JW, Liu H, Shao C, Zhao H, Gui-Qiang W. Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy. Clin Res Hepatol Gastroenterol 2020;:101563. [PMID: 33272888 DOI: 10.1016/j.clinre.2020.10.008] [Reference Citation Analysis]
737 Langerová H, Lubyová B, Zábranský A, Hubálek M, Glendová K, Aillot L, Hodek J, Strunin D, Janovec V, Hirsch I, Weber J. Hepatitis B Core Protein Is Post-Translationally Modified through K29-Linked Ubiquitination. Cells 2020;9:E2547. [PMID: 33256078 DOI: 10.3390/cells9122547] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
738 Cailhol J, Lebon MC, Sherlaw W. Will my patients get their residence permit? A critical analysis of the ethical dilemmas involved in writing medical certificates for residence permits in France. BMC Med Ethics 2020;21:59. [PMID: 32660550 DOI: 10.1186/s12910-020-00500-7] [Reference Citation Analysis]
739 Lin YC, Chen YJ, Lee SW, Lee TY, Chen YH, Huang WN, Yang SS, Chen YM. Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy. J Clin Med 2021;10:3296. [PMID: 34362079 DOI: 10.3390/jcm10153296] [Reference Citation Analysis]
740 Varley CD, Winthrop KL. Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections). Curr Rheumatol Rep 2021;23:74. [PMID: 34269903 DOI: 10.1007/s11926-021-01037-3] [Reference Citation Analysis]
741 Nguyen MH, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh HN, Arai T, Fukunishi S, Ogawa E, Hsu YC, Maeda M, Dang H, Tseng CH, Takahashi H, Jun DW, Watanabe T, Chuma M, Nozaki A, Kawada N, Cheung R, Enomoto M, Takaguchi K, Toyoda H. Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. Am J Gastroenterol 2021;116:1264-73. [PMID: 34074829 DOI: 10.14309/ajg.0000000000001157] [Reference Citation Analysis]
742 Hashimoto A, Matsui T, Urata Y, Tohma S. Reactivation of hepatitis B (HB) in rheumatoid arthritis patients who are HB carriers: A multicenter, prospective, observational study in Japan. Hepatol Res 2019;49:1249-50. [PMID: 31173444 DOI: 10.1111/hepr.13384] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
743 Song JE, Lee CH, Kim BS. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. Korean J Intern Med. 2019;34:802-810. [PMID: 30959583 DOI: 10.3904/kjim.2019.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
744 McMahon BJ, Dusheiko G. Predicting treatment eligibility for hepatitis B in low income regions: Can treatment scores without HBV DNA testing serve the purpose? J Hepatol 2018;69:765-6. [PMID: 30007507 DOI: 10.1016/j.jhep.2018.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
745 Mysore KR, Leung DH. Hepatitis B and C. Clin Liver Dis. 2018;22:703-722. [PMID: 30266158 DOI: 10.1016/j.cld.2018.06.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
746 Gane E, Pastagia M, Schwertschlag U, De Creus A, Schwabe C, Vandenbossche J, Slaets L, Fevery B, Smyej I, Wu LS, Li R, Siddiqui S, Oey A, Musto C, Van Remoortere P. Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults. Antiviral Therapy 2021;26:58-68. [DOI: 10.1177/13596535211056581] [Reference Citation Analysis]
747 Yip TC, Gill M, Wong GL, Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol Int 2022. [PMID: 35235148 DOI: 10.1007/s12072-022-10306-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
748 Schaefer EAK. A Deep Ravine Rather Than a Shallow Gap: Many More Bridges Needed to Improve Care of Chronic Hepatitis B in the United States. Am J Gastroenterol 2021;116:1842-3. [PMID: 34187982 DOI: 10.14309/ajg.0000000000001364] [Reference Citation Analysis]
749 Belopolskaya M, Avrutin V, Kalinina O, Dmitriev A, Gusev D. Chronic hepatitis B in pregnant women: Current trends and approaches. World J Gastroenterol 2021; 27(23): 3279-3289 [PMID: 34163111 DOI: 10.3748/wjg.v27.i23.3279] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
750 Koffas A, Kennedy PT. Hepatitis B and D. Medicine 2019;47:746-51. [DOI: 10.1016/j.mpmed.2019.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
751 Yin X, Han G, Zhang H, Wang M, Zhang W, Gao Y, Zhong M, Wang X, Zhong X, Shen G, Yang C, Liu H, Liu Z, Chan PL, Bulterys M, Cui F, Zhuang H, Liu Z, Hou J. A Real-world Prospective Study of Mother-to-child Transmission of HBV in China Using a Mobile Health Application (Shield 01). J Clin Transl Hepatol 2020;8:1-8. [PMID: 32274339 DOI: 10.14218/JCTH.2019.00057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
752 Ibrahim SH, Jonas MM, Taylor SA, Gutierrez Sanchez LH, Wolf JL, Sundaram SS. Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant. Hepatology 2020;71:1474-85. [PMID: 31925801 DOI: 10.1002/hep.31109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
753 Mobini S, Chizari M, Mafakher L, Rismani E, Rismani E. Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus. Front Immunol 2020;11:2074. [PMID: 33042118 DOI: 10.3389/fimmu.2020.02074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
754 Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2020:ciaa1391. [PMID: 33225349 DOI: 10.1093/cid/ciaa1391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
755 Choi YH, Lee HW, Purdy MA. Natural antibody IgG levels are associated with HBeAg-positivity and seroconversion in chronic hepatitis B patients treated with entecavir. Sci Rep 2022;12:4382. [PMID: 35288624 DOI: 10.1038/s41598-022-08457-w] [Reference Citation Analysis]
756 Wong RJ, Khalili M. A Patient-Centered Hepatitis B Virus (HBV) Educational Intervention Improves HBV Care Among Underserved Safety-Net Populations. J Clin Gastroenterol 2020;54:642-7. [PMID: 31688365 DOI: 10.1097/MCG.0000000000001276] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
757 Kwon JH, Song MJ, Jang JW, Bae SH, Choi JY, Yoon SK, Kim HY, Kim CW, Song DS, Chang UI, Yang JM, You CR, Choi SW, Lee HL, Lee SW, Han NI, Nam SW, Kim SG, Kim YS, Kim SH, Lee BS, Lee TH, Cho EY. Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Chronic Hepatitis B in Korea. Dig Dis Sci 2019;64:2039-48. [PMID: 30725293 DOI: 10.1007/s10620-019-05489-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
758 Prasad D, Nguyen MH. Chronic hepatitis, osteoporosis, and men: under-recognised and underdiagnosed. The Lancet Diabetes & Endocrinology 2021;9:141. [DOI: 10.1016/s2213-8587(21)00020-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
759 Liu CH, Huang YJ, Yang SS, Chang CH, Yang SS, Sun HY, Liu CJ, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. Sci Rep 2018;8:13699. [PMID: 30209349 DOI: 10.1038/s41598-018-32060-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
760 Kim HS, Baatarkhuu O, Lee HW, Park JY, Kim DY, Ahn SH, Song K, Han KH, Kim BK, Kim SU. Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. Liver Int 2019;39:81-9. [PMID: 30280461 DOI: 10.1111/liv.13948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
761 Sun J, Zhao Y, Qin L, Li K, Zhao Y, Sun H, Zhang T, Zhang Y. Metabolomic Profiles for HBV Related Hepatocellular Carcinoma Including Alpha-Fetoproteins Positive and Negative Subtypes. Front Oncol 2019;9:1069. [PMID: 31681602 DOI: 10.3389/fonc.2019.01069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
762 Kim HL, Kim GA, Park JA, Kang HR, Lee EK, Lim YS. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. Gut 2021;70:2172-82. [PMID: 33239344 DOI: 10.1136/gutjnl-2020-321309] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
763 Yip TC, Lai JC, Wong GL. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same? J Gastroenterol 2020;55:1023-36. [PMID: 32974760 DOI: 10.1007/s00535-020-01726-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
764 Sonneveld MJ, Brouwer WP, Hansen BE, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Chien RN, Choi H, de Knegt RJ, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Man RA, Janssen HLA; SONIC-B Study Group. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. Aliment Pharmacol Ther 2020;52:1399-406. [PMID: 32886813 DOI: 10.1111/apt.16067] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
765 Hu Y, Ye YZ, Ye LJ, Wang XH, Yu H. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China. World J Pediatr 2019;15:595-600. [PMID: 31487005 DOI: 10.1007/s12519-019-00303-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
766 Liaw YF. Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat. Hepatology 2021;73:843-52. [PMID: 32810321 DOI: 10.1002/hep.31525] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
767 Lim YS. Quantification of Antibody to Hepatitis B Core Antigen to Predict Outcomes of Patients With HBV Infection. Clin Gastroenterol Hepatol 2019;17:39-40. [PMID: 30099105 DOI: 10.1016/j.cgh.2018.08.003] [Reference Citation Analysis]
768 Shiue SJ, Cheng CL, Shiue HS, Chen CN, Cheng SW, Wu LW, Jargalsaikhan G, Chan TS, Lin HY, Wu MS. Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile. Nutrients 2022;14:2790. [PMID: 35889747 DOI: 10.3390/nu14142790] [Reference Citation Analysis]
769 Kang N, Zhang J, Lin M, Chen X, Huang Z, Zhu Y, Liu Y, Zeng D. Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients. WJG 2020;26:3948-58. [DOI: 10.3748/wjg.v26.i27.3948] [Reference Citation Analysis]
770 Usai C, Gill US, Riddell AC, Asselah T, Kennedy PT. Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus. Aliment Pharmacol Ther 2022;55:978-93. [PMID: 35292991 DOI: 10.1111/apt.16807] [Reference Citation Analysis]
771 Sun T, Li R, Qiu Y, Shen S, Wang W. New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram. Int J Gen Med 2021;14:6149-65. [PMID: 34611429 DOI: 10.2147/IJGM.S335400] [Reference Citation Analysis]
772 Shang J, Liu H, Wen Q, M Ise R, Tu Y, Bai L, Tang H. Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy. Int J Infect Dis 2021;105:626-31. [PMID: 33722684 DOI: 10.1016/j.ijid.2021.03.023] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
773 Hu C, Song Y, Tang C, Li M, Liu J, Liu J, Liao M, Zhou F, Zhang YY, Zhou Y. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience. Clin Ther 2021;43:572-581.e3. [PMID: 33516527 DOI: 10.1016/j.clinthera.2020.12.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
774 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
775 Wang JW, Qian Y, Wu CS, Zhao NH, Fang Y, Yuan XD, Gao S, Fan YC, Wang K. Combined use of murine double minute-2 promoter methylation and serum AFP improves diagnostic efficiency in hepatitis B virus-related hepatocellular carcinoma. Int J Med Sci 2020;17:3190-9. [PMID: 33173438 DOI: 10.7150/ijms.47003] [Reference Citation Analysis]
776 Terrault NA, Brown RS Jr, Lok AS, Wong JB, Bzowej NH, Chang KM, Hwang JP, Jonas MM, McMahon BJ. Reply. Hepatology 2018;68:1658-60. [PMID: 30070717 DOI: 10.1002/hep.30137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
777 Maraolo AE, Gentile I, Buonomo AR, Pinchera B, Borgia G. Current evidence on the management of hepatiti